HRP20021000A2 - PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS - Google Patents
PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS Download PDFInfo
- Publication number
- HRP20021000A2 HRP20021000A2 HR20021000A HRP20021000A HRP20021000A2 HR P20021000 A2 HRP20021000 A2 HR P20021000A2 HR 20021000 A HR20021000 A HR 20021000A HR P20021000 A HRP20021000 A HR P20021000A HR P20021000 A2 HRP20021000 A2 HR P20021000A2
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- alkyl
- amino
- pyrrolo
- pyrimidin
- Prior art date
Links
- 229940125721 immunosuppressive agent Drugs 0.000 title description 2
- 239000003018 immunosuppressive agent Substances 0.000 title description 2
- 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 title description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 189
- 150000001875 compounds Chemical class 0.000 claims description 141
- -1 hydroxy, amino Chemical group 0.000 claims description 101
- 238000000034 method Methods 0.000 claims description 52
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 38
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 32
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 32
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 32
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims description 28
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 28
- 108010019421 Janus Kinase 3 Proteins 0.000 claims description 28
- 102000006500 Janus Kinase 3 Human genes 0.000 claims description 28
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 23
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 16
- 125000004442 acylamino group Chemical group 0.000 claims description 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 16
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 14
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 14
- 125000002252 acyl group Chemical group 0.000 claims description 14
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims description 14
- 229910052805 deuterium Inorganic materials 0.000 claims description 14
- 125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 claims description 12
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 10
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 9
- 241000282412 Homo Species 0.000 claims description 8
- 102000001253 Protein Kinase Human genes 0.000 claims description 8
- 125000004423 acyloxy group Chemical group 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 108060006633 protein kinase Proteins 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 7
- 201000008937 atopic dermatitis Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 7
- 206010025135 lupus erythematosus Diseases 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- RDGVREXPTVNIOZ-UHFFFAOYSA-N (3-hydroxypyrrolidin-1-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N1CCC(O)C1 RDGVREXPTVNIOZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 6
- HJWUCTNLSFICSW-UHFFFAOYSA-N 2-[2-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]amino]-1,3-thiazol-4-yl]acetic acid Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=NC(CC(O)=O)=CS1 HJWUCTNLSFICSW-UHFFFAOYSA-N 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 210000000987 immune system Anatomy 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 4
- KNRLJPBXCVZFKC-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-(tetrazol-1-yl)ethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CN1C=NN=N1 KNRLJPBXCVZFKC-UHFFFAOYSA-N 0.000 claims description 4
- YXPJSLNLGWWFQK-UHFFFAOYSA-N 4-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]benzenesulfonamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=C(S(N)(=O)=O)C=C1 YXPJSLNLGWWFQK-UHFFFAOYSA-N 0.000 claims description 4
- 208000024799 Thyroid disease Diseases 0.000 claims description 4
- 125000005157 alkyl carboxy group Chemical group 0.000 claims description 4
- 125000001769 aryl amino group Chemical group 0.000 claims description 4
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 4
- 125000005110 aryl thio group Chemical group 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 102200031660 rs730880032 Human genes 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- JTRGLKTYLIFFTR-UHFFFAOYSA-N 2-[4-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]amino]phenyl]acetic acid Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(CC(O)=O)C=C1 JTRGLKTYLIFFTR-UHFFFAOYSA-N 0.000 claims description 3
- JAUIMPSXWZMZOR-UHFFFAOYSA-N 2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-1,3-thiazol-5-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=NC=C(N)S1 JAUIMPSXWZMZOR-UHFFFAOYSA-N 0.000 claims description 3
- WCEMRCSQVJUUEL-UHFFFAOYSA-N 2-cyclopropyl-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CC1CC1 WCEMRCSQVJUUEL-UHFFFAOYSA-N 0.000 claims description 3
- XLWYJSMYNALODL-UHFFFAOYSA-N 3-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]cyclopentan-1-one Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCC(=O)C1 XLWYJSMYNALODL-UHFFFAOYSA-N 0.000 claims description 3
- XZXYNRDSRVDEFY-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(3-methyl-1,2-thiazol-5-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC(C)=NS1 XZXYNRDSRVDEFY-UHFFFAOYSA-N 0.000 claims description 3
- JNDULUJHHAKHFI-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(4-methylsulfonylphenyl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 JNDULUJHHAKHFI-UHFFFAOYSA-N 0.000 claims description 3
- BAMSJXFWGUSAPN-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(4-nitrophenyl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C([N+]([O-])=O)C=C1 BAMSJXFWGUSAPN-UHFFFAOYSA-N 0.000 claims description 3
- MNZUYWZVJCMTLM-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(4-sulfamoylphenyl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(S(N)(=O)=O)C=C1 MNZUYWZVJCMTLM-UHFFFAOYSA-N 0.000 claims description 3
- KSZRXZRZFBENAS-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-[4-(methylsulfamoyl)phenyl]piperidine-1-carboxamide Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1NC(=O)N1CC(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CC1 KSZRXZRZFBENAS-UHFFFAOYSA-N 0.000 claims description 3
- NHFAFANWNRBBTO-UHFFFAOYSA-N 5-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-oxoethyl]-1,3-thiazolidine-2,4-dione Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CC1SC(=O)NC1=O NHFAFANWNRBBTO-UHFFFAOYSA-N 0.000 claims description 3
- LSGKKCWYBMNKRE-UHFFFAOYSA-N 6-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]pyridine-3-carbonitrile Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=CC=C(C#N)C=N1 LSGKKCWYBMNKRE-UHFFFAOYSA-N 0.000 claims description 3
- IGNOXKOLEZVMMV-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(oxolan-3-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCOC1 IGNOXKOLEZVMMV-UHFFFAOYSA-N 0.000 claims description 3
- RONMOMUOZGIDET-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-pyrrolidin-1-ylmethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N1CCCC1 RONMOMUOZGIDET-UHFFFAOYSA-N 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- IKJVHXOXTUJMHW-UHFFFAOYSA-N cyclopentyl-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCCC1 IKJVHXOXTUJMHW-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000004494 ethyl ester group Chemical group 0.000 claims description 3
- VEMGCXQTHHJHSV-UHFFFAOYSA-N n-(4-cyanophenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(C#N)C=C1 VEMGCXQTHHJHSV-UHFFFAOYSA-N 0.000 claims description 3
- PJIDNSQIATYRAD-UHFFFAOYSA-N n-(6-cyanopyridin-3-yl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(C#N)N=C1 PJIDNSQIATYRAD-UHFFFAOYSA-N 0.000 claims description 3
- OHYJNSIOYVRHEF-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(5-nitro-1,3-thiazol-2-yl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=NC=C([N+]([O-])=O)S1 OHYJNSIOYVRHEF-UHFFFAOYSA-N 0.000 claims description 3
- WYAWBXYGRGZLTM-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(5-nitropyridin-2-yl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=CC=C([N+]([O-])=O)C=N1 WYAWBXYGRGZLTM-UHFFFAOYSA-N 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 claims description 2
- BXLOTZYFEBJGFO-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(1,2-oxazol-3-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC=1C=CON=1 BXLOTZYFEBJGFO-UHFFFAOYSA-N 0.000 claims description 2
- TXZVMZALSHPMNV-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(1,3-thiazol-2-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=NC=CS1 TXZVMZALSHPMNV-UHFFFAOYSA-N 0.000 claims description 2
- HIOUMGNWXIKDEL-UHFFFAOYSA-N 4-methyl-n-(3-methyl-1,2-oxazol-4-yl)-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CON=C1C HIOUMGNWXIKDEL-UHFFFAOYSA-N 0.000 claims description 2
- BIZBPVFLUUDEQH-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(1,3-thiazolidin-3-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N1CCSC1 BIZBPVFLUUDEQH-UHFFFAOYSA-N 0.000 claims description 2
- 229920001577 copolymer Chemical group 0.000 claims description 2
- LRIZCRLAGSEHSM-UHFFFAOYSA-N n,n,4-trimethyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound CC1CCN(C(=O)N(C)C)CC1N(C)C1=NC=NC2=C1C=CN2 LRIZCRLAGSEHSM-UHFFFAOYSA-N 0.000 claims description 2
- YDALXWLQBQYZST-UHFFFAOYSA-N n-benzyl-n,4-dimethyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N(C)CC1=CC=CC=C1 YDALXWLQBQYZST-UHFFFAOYSA-N 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 239000000203 mixture Substances 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 10
- 108010036949 Cyclosporine Proteins 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000002585 base Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 125000004404 heteroalkyl group Chemical group 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 5
- 150000001447 alkali salts Chemical class 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- KEFMRZKKLKQKBB-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(6-methylsulfonylpyridin-3-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(S(C)(=O)=O)N=C1 KEFMRZKKLKQKBB-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 229930105110 Cyclosporin A Natural products 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 4
- 239000012039 electrophile Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- UMWNXPTXDOVDFE-UHFFFAOYSA-N n-(1-benzyl-4-methylpiperidin-3-yl)-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CC=C1 UMWNXPTXDOVDFE-UHFFFAOYSA-N 0.000 description 4
- GCEUCNYSHSTDDL-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(1-phenylethyl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1CC(C)C(N(C)C=2C=3C=CNC=3N=CN=2)CN1C(C)C1=CC=CC=C1 GCEUCNYSHSTDDL-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 150000007514 bases Chemical class 0.000 description 3
- 229940077388 benzenesulfonate Drugs 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 3
- 229940073608 benzyl chloride Drugs 0.000 description 3
- MOOAHMCRPCTRLV-UHFFFAOYSA-N boron sodium Chemical compound [B].[Na] MOOAHMCRPCTRLV-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N gamma-methylpyridine Natural products CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- MKWSPUVYRGWYGY-UHFFFAOYSA-N n-[1-[(2-fluorophenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CC=C1F MKWSPUVYRGWYGY-UHFFFAOYSA-N 0.000 description 3
- 229940063121 neoral Drugs 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 3
- 239000003880 polar aprotic solvent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229940063122 sandimmune Drugs 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- MMXJPJIKZFXULY-UHFFFAOYSA-N 2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylbenzonitrile Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=CC=C1C#N MMXJPJIKZFXULY-UHFFFAOYSA-N 0.000 description 2
- MXXGGSPJLJXFSH-UHFFFAOYSA-N 2-imidazol-1-yl-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CN1C=CN=C1 MXXGGSPJLJXFSH-UHFFFAOYSA-N 0.000 description 2
- KXZOTFGMNBPYTP-UHFFFAOYSA-N 4-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylbenzenesulfonyl fluoride Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=C(S(F)(=O)=O)C=C1 KXZOTFGMNBPYTP-UHFFFAOYSA-N 0.000 description 2
- XMAVNULAQUBQMQ-UHFFFAOYSA-N 4-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylbenzoic acid Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=C(C(O)=O)C=C1 XMAVNULAQUBQMQ-UHFFFAOYSA-N 0.000 description 2
- BKPKARLNQYNFRC-UHFFFAOYSA-N 4-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylbenzonitrile Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=C(C#N)C=C1 BKPKARLNQYNFRC-UHFFFAOYSA-N 0.000 description 2
- BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 2
- JHQOCEWOJAFCTJ-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylic acid Chemical compound CC1CCN(C(O)=O)CC1N(C)C1=NC=NC2=C1C=CN2 JHQOCEWOJAFCTJ-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 150000001503 aryl iodides Chemical class 0.000 description 2
- 229940092117 atgam Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229960002806 daclizumab Drugs 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 229940073062 imuran Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- GHXZPUGJZVBLGC-UHFFFAOYSA-N iodoethene Chemical compound IC=C GHXZPUGJZVBLGC-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
- 229960000681 leflunomide Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229940014456 mycophenolate Drugs 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- VUAQEMYSGWNUMD-UHFFFAOYSA-N n-(2-cyanoethyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound CC1CCN(C(=O)NCCC#N)CC1N(C)C1=NC=NC2=C1C=CN2 VUAQEMYSGWNUMD-UHFFFAOYSA-N 0.000 description 2
- BGYQOFXRCCLHGH-UHFFFAOYSA-N n-[1-(2,4-difluorophenyl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=C(F)C=C1F BGYQOFXRCCLHGH-UHFFFAOYSA-N 0.000 description 2
- CAHBCGJMNWWIHK-UHFFFAOYSA-N n-[1-(2,6-difluorophenyl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=C(F)C=CC=C1F CAHBCGJMNWWIHK-UHFFFAOYSA-N 0.000 description 2
- MDWUMNUEIRPBGS-UHFFFAOYSA-N n-[1-(3,5-dichlorophenyl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC(Cl)=CC(Cl)=C1 MDWUMNUEIRPBGS-UHFFFAOYSA-N 0.000 description 2
- KREZOGIZJJUJJZ-UHFFFAOYSA-N n-[1-(4-chlorophenyl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=C(Cl)C=C1 KREZOGIZJJUJJZ-UHFFFAOYSA-N 0.000 description 2
- FPRHYPXOQJQGQC-UHFFFAOYSA-N n-[1-(4-fluorophenyl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=C(F)C=C1 FPRHYPXOQJQGQC-UHFFFAOYSA-N 0.000 description 2
- GLURSCMXAMMXQN-UHFFFAOYSA-N n-[1-(4-methoxyphenyl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1CC(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CC1 GLURSCMXAMMXQN-UHFFFAOYSA-N 0.000 description 2
- ROWZXPPVVPNTCH-UHFFFAOYSA-N n-[1-(4-tert-butylphenyl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 ROWZXPPVVPNTCH-UHFFFAOYSA-N 0.000 description 2
- MFTWMFCKCRVSPQ-UHFFFAOYSA-N n-[1-(6-chloropyridin-3-yl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=C(Cl)N=C1 MFTWMFCKCRVSPQ-UHFFFAOYSA-N 0.000 description 2
- HLLYJLHURBDKCW-UHFFFAOYSA-N n-[1-[(3,5-difluorophenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC(F)=CC(F)=C1 HLLYJLHURBDKCW-UHFFFAOYSA-N 0.000 description 2
- FUUJGALXOPJPPY-UHFFFAOYSA-N n-[1-[(3-chlorophenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CC(Cl)=C1 FUUJGALXOPJPPY-UHFFFAOYSA-N 0.000 description 2
- BBBOVXVBUYZWSD-UHFFFAOYSA-N n-[1-[3,5-bis(trifluoromethyl)phenyl]sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BBBOVXVBUYZWSD-UHFFFAOYSA-N 0.000 description 2
- XRIARWQZLGCQDM-UHFFFAOYSA-N n-methyl-n-(4-methylpiperidin-3-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CC1CCNCC1N(C)C1=NC=NC2=C1C=CN2 XRIARWQZLGCQDM-UHFFFAOYSA-N 0.000 description 2
- IQGBQQYFBCFKHW-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(2,2,2-trifluoroethylsulfonyl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CC1CCN(S(=O)(=O)CC(F)(F)F)CC1N(C)C1=NC=NC2=C1C=CN2 IQGBQQYFBCFKHW-UHFFFAOYSA-N 0.000 description 2
- IGTBMXYYACQAJI-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(6-nitro-1,3-benzoxazol-2-yl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=C([N+]([O-])=O)C=C2OC(N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=NC2=C1 IGTBMXYYACQAJI-UHFFFAOYSA-N 0.000 description 2
- YFDJCUNWPCDTMB-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-[2-(trifluoromethyl)phenyl]sulfonylpiperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=CC=C1C(F)(F)F YFDJCUNWPCDTMB-UHFFFAOYSA-N 0.000 description 2
- KBNNITHCTOEGAP-UHFFFAOYSA-N n-tert-butyl-4-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]benzenesulfonamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=C(S(=O)(=O)NC(C)(C)C)C=C1 KBNNITHCTOEGAP-UHFFFAOYSA-N 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000003011 styrenyl group Chemical class [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- BJVKTRODDXZYQJ-UHFFFAOYSA-N tert-butyl 2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCCN1C(=O)OC(C)(C)C BJVKTRODDXZYQJ-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- MEAVBNFGUHYRTG-UHFFFAOYSA-N (1,5-dimethylpyrazol-3-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C=1C=C(C)N(C)N=1 MEAVBNFGUHYRTG-UHFFFAOYSA-N 0.000 description 1
- NNUGOPRDIQAKOA-UHFFFAOYSA-N (2-chlorophenyl)methyl 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylate Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)OCC1=CC=CC=C1Cl NNUGOPRDIQAKOA-UHFFFAOYSA-N 0.000 description 1
- IHGIRIVIZPHMKN-UHFFFAOYSA-N (2-fluorophenyl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1=CC=CC=C1F IHGIRIVIZPHMKN-UHFFFAOYSA-N 0.000 description 1
- DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 description 1
- NDQQRRVKUBPTHQ-QBIQUQHTSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NDQQRRVKUBPTHQ-QBIQUQHTSA-N 0.000 description 1
- IQTLZOZLURQFLT-UHFFFAOYSA-N (3,4-dihydroxypyrrolidin-1-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N1CC(O)C(O)C1 IQTLZOZLURQFLT-UHFFFAOYSA-N 0.000 description 1
- PKKUWUMMZPLYAB-UHFFFAOYSA-N (3-fluorophenyl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1=CC=CC(F)=C1 PKKUWUMMZPLYAB-UHFFFAOYSA-N 0.000 description 1
- YQFCATXTMSPGIX-UHFFFAOYSA-N (3-hydroxycyclopentyl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCC(O)C1 YQFCATXTMSPGIX-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- APRNMRMUPPONOZ-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone;hydrochloride Chemical compound Cl.C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N1CCC(N)CC1 APRNMRMUPPONOZ-UHFFFAOYSA-N 0.000 description 1
- GHCBTAVVWSPDJJ-UHFFFAOYSA-N (4-fluorophenyl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1=CC=C(F)C=C1 GHCBTAVVWSPDJJ-UHFFFAOYSA-N 0.000 description 1
- CTLXCGHVHAGPKV-UHFFFAOYSA-N (4-hydroxypiperidin-1-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N1CCC(O)CC1 CTLXCGHVHAGPKV-UHFFFAOYSA-N 0.000 description 1
- FOQWAMSIDZJEFW-UHFFFAOYSA-N (5,7-dichloro-1h-indol-2-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound ClC1=CC(Cl)=C2NC(C(=O)N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=CC2=C1 FOQWAMSIDZJEFW-UHFFFAOYSA-N 0.000 description 1
- XMXLKEXVFYCIBY-UHFFFAOYSA-N (5-chloro-1-benzofuran-2-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound ClC1=CC=C2OC(C(=O)N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=CC2=C1 XMXLKEXVFYCIBY-UHFFFAOYSA-N 0.000 description 1
- IYAFKKGFYHLLJK-UHFFFAOYSA-N (5-chloro-2,3-dihydro-1-benzofuran-2-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C2=CC(Cl)=CC=C2OC1C(=O)N1CCC(C)C(N(C)C=2C=3C=CNC=3N=CN=2)C1 IYAFKKGFYHLLJK-UHFFFAOYSA-N 0.000 description 1
- QPWBKRGHRNNUSM-UHFFFAOYSA-N (5-fluoro-1h-indol-2-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound FC1=CC=C2NC(C(=O)N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=CC2=C1 QPWBKRGHRNNUSM-UHFFFAOYSA-N 0.000 description 1
- FFVIFWOAGYOEOW-UHFFFAOYSA-N (5-methoxy-3-methyl-1-benzofuran-2-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound CC=1C2=CC(OC)=CC=C2OC=1C(=O)N(C1)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 FFVIFWOAGYOEOW-UHFFFAOYSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- YCWQXMWZZNXJNC-UHFFFAOYSA-N 1-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]-1-benzofuran-5-yl]ethanone Chemical compound CC(=O)C1=CC=C2OC(C(=O)N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=CC2=C1 YCWQXMWZZNXJNC-UHFFFAOYSA-N 0.000 description 1
- XKIJFZMZBNZZGJ-UHFFFAOYSA-N 1-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]pyrrolidin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCCN1C(C)=O XKIJFZMZBNZZGJ-UHFFFAOYSA-N 0.000 description 1
- NFEWCNUVUHEPPS-UHFFFAOYSA-N 1-[3-methyl-2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]-1h-indol-5-yl]ethanone Chemical compound N1C2=CC=C(C(C)=O)C=C2C(C)=C1C(=O)N1CCC(C)C(N(C)C=2C=3C=CNC=3N=CN=2)C1 NFEWCNUVUHEPPS-UHFFFAOYSA-N 0.000 description 1
- BFIJFTSOTVEXRP-UHFFFAOYSA-N 1-[4-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]piperidin-1-yl]ethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCN(C(C)=O)CC1 BFIJFTSOTVEXRP-UHFFFAOYSA-N 0.000 description 1
- BXZWMPROQVAXHA-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-(1,3-thiazolidin-3-ylsulfonyl)ethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CS(=O)(=O)N1CCSC1 BXZWMPROQVAXHA-UHFFFAOYSA-N 0.000 description 1
- LFZCTGZBVFSCRQ-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-(4-methylphenyl)sulfonylethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CS(=O)(=O)C1=CC=C(C)C=C1 LFZCTGZBVFSCRQ-UHFFFAOYSA-N 0.000 description 1
- BUNOUGVLAYVGAE-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-methylsulfonylethanone Chemical compound CC1CCN(C(=O)CS(C)(=O)=O)CC1N(C)C1=NC=NC2=C1C=CN2 BUNOUGVLAYVGAE-UHFFFAOYSA-N 0.000 description 1
- IVBUYSHJEHLIMK-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-morpholin-4-ylethane-1,2-dione Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C(=O)N1CCOCC1 IVBUYSHJEHLIMK-UHFFFAOYSA-N 0.000 description 1
- ZJFXSXNPKWZYTQ-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-phenoxyethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)COC1=CC=CC=C1 ZJFXSXNPKWZYTQ-UHFFFAOYSA-N 0.000 description 1
- BYCJYXUXZAOMRI-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-phenylethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CC1=CC=CC=C1 BYCJYXUXZAOMRI-UHFFFAOYSA-N 0.000 description 1
- BLXPTDGSXNVOKB-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-pyrazol-1-ylethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CN1C=CC=N1 BLXPTDGSXNVOKB-UHFFFAOYSA-N 0.000 description 1
- KBBNQXKKBALYNH-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-pyrrolidin-1-ylethane-1,2-dione Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C(=O)N1CCCC1 KBBNQXKKBALYNH-UHFFFAOYSA-N 0.000 description 1
- YBLLNNSAWUBEKR-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-nitropropan-1-one Chemical compound CC1CCN(C(=O)CC[N+]([O-])=O)CC1N(C)C1=NC=NC2=C1C=CN2 YBLLNNSAWUBEKR-UHFFFAOYSA-N 0.000 description 1
- HEWZKTNWCFYMLF-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]propan-2-one Chemical compound CC1CCN(CC(C)=O)CC1N(C)C1=NC=NC2=C1C=CN2 HEWZKTNWCFYMLF-UHFFFAOYSA-N 0.000 description 1
- RBROMUQSJAPIRW-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]propane-1,2-dione Chemical compound CC1CCN(C(=O)C(C)=O)CC1N(C)C1=NC=NC2=C1C=CN2 RBROMUQSJAPIRW-UHFFFAOYSA-N 0.000 description 1
- XESQWPJSAAPPTR-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]piperidine-4-carboxamide;hydrochloride Chemical compound Cl.C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N1CCC(C(N)=O)CC1 XESQWPJSAAPPTR-UHFFFAOYSA-N 0.000 description 1
- CKODHKNZMAPUTK-UHFFFAOYSA-N 1-benzyl-3-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]pyrrolidin-2-one Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C(C1=O)CCN1CC1=CC=CC=C1 CKODHKNZMAPUTK-UHFFFAOYSA-N 0.000 description 1
- MKIZSVUTUWPHMD-UHFFFAOYSA-N 1-benzyl-4-methyl-3,6-dihydro-2h-pyridine Chemical compound C1CC(C)=CCN1CC1=CC=CC=C1 MKIZSVUTUWPHMD-UHFFFAOYSA-N 0.000 description 1
- QRGQXVUZVXXWAG-UHFFFAOYSA-N 1-benzyl-4-methylpiperidin-3-ol Chemical compound C1C(O)C(C)CCN1CC1=CC=CC=C1 QRGQXVUZVXXWAG-UHFFFAOYSA-N 0.000 description 1
- IXZHVWWLFJWBQN-UHFFFAOYSA-N 1-benzyl-4-methylpiperidin-3-ol;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C1C(O)C(C)CCN1CC1=CC=CC=C1 IXZHVWWLFJWBQN-UHFFFAOYSA-N 0.000 description 1
- BSBVJNUGGBQEPO-UHFFFAOYSA-N 1-benzyl-4-methylpiperidin-3-one Chemical compound C1C(=O)C(C)CCN1CC1=CC=CC=C1 BSBVJNUGGBQEPO-UHFFFAOYSA-N 0.000 description 1
- LJHMBIINLKLHSI-UHFFFAOYSA-M 1-benzyl-4-methylpyridin-1-ium;chloride Chemical compound [Cl-].C1=CC(C)=CC=[N+]1CC1=CC=CC=C1 LJHMBIINLKLHSI-UHFFFAOYSA-M 0.000 description 1
- NVKDDQBZODSEIN-UHFFFAOYSA-N 1-benzyl-n,4-dimethylpiperidin-3-amine Chemical compound C1CC(C)C(NC)CN1CC1=CC=CC=C1 NVKDDQBZODSEIN-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- NIUHHXFPHLGXJZ-UHFFFAOYSA-N 1-methyl-4-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]pyrrolidin-2-one Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CN(C)C(=O)C1 NIUHHXFPHLGXJZ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HGMQPYNIMJVSEK-UHFFFAOYSA-N 1h-indol-2-yl-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1=CC=C2NC(C(=O)N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=CC2=C1 HGMQPYNIMJVSEK-UHFFFAOYSA-N 0.000 description 1
- LIRGFMZWLNEASY-UHFFFAOYSA-N 2,2,2-trichloroethyl 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylate Chemical compound CC1CCN(C(=O)OCC(Cl)(Cl)Cl)CC1N(C)C1=NC=NC2=C1C=CN2 LIRGFMZWLNEASY-UHFFFAOYSA-N 0.000 description 1
- NWSXTGLTZBLHEF-UHFFFAOYSA-N 2,2-dimethyl-5-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-oxoethyl]-1,3-dioxolan-4-one Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CC1OC(C)(C)OC1=O NWSXTGLTZBLHEF-UHFFFAOYSA-N 0.000 description 1
- KAKIPOYENBQNRH-UHFFFAOYSA-N 2,2-dimethylpropyl 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylate Chemical compound CC1CCN(C(=O)OCC(C)(C)C)CC1N(C)C1=NC=NC2=C1C=CN2 KAKIPOYENBQNRH-UHFFFAOYSA-N 0.000 description 1
- UQQDPUBXMGENLT-UHFFFAOYSA-N 2,4-difluoro-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]benzamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1=CC=C(F)C=C1F UQQDPUBXMGENLT-UHFFFAOYSA-N 0.000 description 1
- OCXRXVUQEDJXAR-UHFFFAOYSA-N 2-(2-chlorophenoxy)-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)COC1=CC=CC=C1Cl OCXRXVUQEDJXAR-UHFFFAOYSA-N 0.000 description 1
- GKMXCQXCLPRYEM-UHFFFAOYSA-N 2-(3-chlorophenoxy)-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)COC1=CC=CC(Cl)=C1 GKMXCQXCLPRYEM-UHFFFAOYSA-N 0.000 description 1
- ORTAKGYHUCSVSP-UHFFFAOYSA-N 2-(4-fluorophenoxy)-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)COC1=CC=C(F)C=C1 ORTAKGYHUCSVSP-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- AOEXMJZVERDQQZ-UHFFFAOYSA-N 2-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCS(=O)(=O)N1CCC(C)C(N(C)C=2C=3C=CNC=3N=CN=2)C1 AOEXMJZVERDQQZ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ZPVYAUZMMIHOKY-UHFFFAOYSA-N 2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]acetonitrile Chemical compound CC1CCN(CC#N)CC1N(C)C1=NC=NC2=C1C=CN2 ZPVYAUZMMIHOKY-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- YXBCFGXEZKKAJD-UHFFFAOYSA-N 2-cyclopentyl-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CC1CCCC1 YXBCFGXEZKKAJD-UHFFFAOYSA-N 0.000 description 1
- XOFDIBJJAMYNPO-UHFFFAOYSA-N 2-cyclopropyl-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CC1CC1 XOFDIBJJAMYNPO-UHFFFAOYSA-N 0.000 description 1
- GXXUQZCYUJMQGD-UHFFFAOYSA-N 2-cyclopropyl-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]acetamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)CC1CC1 GXXUQZCYUJMQGD-UHFFFAOYSA-N 0.000 description 1
- YSZSWVSNVMKHCJ-UHFFFAOYSA-N 2-fluoro-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]benzamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1=CC=CC=C1F YSZSWVSNVMKHCJ-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- JQHGMIPHNKBUHP-UHFFFAOYSA-N 3-(4-chlorophenoxy)-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]propan-1-one Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CCOC1=CC=C(Cl)C=C1 JQHGMIPHNKBUHP-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- FCFYERCABJTGIY-UHFFFAOYSA-N 3-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylbenzenesulfonyl fluoride Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=CC(S(F)(=O)=O)=C1 FCFYERCABJTGIY-UHFFFAOYSA-N 0.000 description 1
- FXGUQUCAGSISKB-UHFFFAOYSA-N 3-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]cyclohexan-1-one Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCCC(=O)C1 FXGUQUCAGSISKB-UHFFFAOYSA-N 0.000 description 1
- SZEYBHNUNGAPOQ-UHFFFAOYSA-N 3-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]benzoic acid Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CC(C(O)=O)=C1 SZEYBHNUNGAPOQ-UHFFFAOYSA-N 0.000 description 1
- BJVVAQQNYISPQY-UHFFFAOYSA-N 3-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]benzonitrile Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CC(C#N)=C1 BJVVAQQNYISPQY-UHFFFAOYSA-N 0.000 description 1
- JOLJKBDRCLFYGN-UHFFFAOYSA-N 3-amino-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]propan-1-one Chemical compound CC1CCN(C(=O)CCN)CC1N(C)C1=NC=NC2=C1C=CN2 JOLJKBDRCLFYGN-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- UJRQBRQCRJAING-UHFFFAOYSA-N 3-chloro-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]benzamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1=CC=CC(Cl)=C1 UJRQBRQCRJAING-UHFFFAOYSA-N 0.000 description 1
- IMWCUOSIKDUHCK-UHFFFAOYSA-N 3-fluoro-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]benzamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1=CC=CC(F)=C1 IMWCUOSIKDUHCK-UHFFFAOYSA-N 0.000 description 1
- NUGKVVXANREPOX-UHFFFAOYSA-N 3-hydroxy-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]propan-1-one Chemical compound CC1CCN(C(=O)CCO)CC1N(C)C1=NC=NC2=C1C=CN2 NUGKVVXANREPOX-UHFFFAOYSA-N 0.000 description 1
- SJTDTLGBWDAFDJ-UHFFFAOYSA-N 3-methoxy-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]benzamide Chemical compound COC1=CC=CC(C(=O)NCCS(=O)(=O)N2CC(C(C)CC2)N(C)C=2C=3C=CNC=3N=CN=2)=C1 SJTDTLGBWDAFDJ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- VKBWDXQRWNGFDC-UHFFFAOYSA-N 4-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]-1,3-thiazolidin-2-one Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CSC(=O)N1 VKBWDXQRWNGFDC-UHFFFAOYSA-N 0.000 description 1
- OBFJCFNQFDYZHU-UHFFFAOYSA-N 4-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]cyclohexan-1-one Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCC(=O)CC1 OBFJCFNQFDYZHU-UHFFFAOYSA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- DAGNWGTYQUFJPI-UHFFFAOYSA-N 4-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]benzoic acid Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=C(C(O)=O)C=C1 DAGNWGTYQUFJPI-UHFFFAOYSA-N 0.000 description 1
- LNXDPZZVXXRBJV-UHFFFAOYSA-N 4-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]benzonitrile Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=C(C#N)C=C1 LNXDPZZVXXRBJV-UHFFFAOYSA-N 0.000 description 1
- QSYVVXZSXXOBGK-UHFFFAOYSA-N 4-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]amino]benzoic acid Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(C(O)=O)C=C1 QSYVVXZSXXOBGK-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- FTYXRILYMGQZIW-UHFFFAOYSA-N 4-chloro-5-nitro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=NC(Cl)=C2C([N+](=O)[O-])=CNC2=N1 FTYXRILYMGQZIW-UHFFFAOYSA-N 0.000 description 1
- KAUCHHKKEDFVMC-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidin-5-amine Chemical compound N1C=NC(Cl)=C2C(N)=CN=C21 KAUCHHKKEDFVMC-UHFFFAOYSA-N 0.000 description 1
- GVLJTCVFFUOICL-UHFFFAOYSA-N 4-chloro-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]benzamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1=CC=C(Cl)C=C1 GVLJTCVFFUOICL-UHFFFAOYSA-N 0.000 description 1
- VUYIJEVHEZNMOM-UHFFFAOYSA-N 4-fluoro-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]benzamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1=CC=C(F)C=C1 VUYIJEVHEZNMOM-UHFFFAOYSA-N 0.000 description 1
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 1
- YUOWAWBQTJNFPV-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(3-nitrophenyl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=CC([N+]([O-])=O)=C1 YUOWAWBQTJNFPV-UHFFFAOYSA-N 0.000 description 1
- WQXRYEVRJRVDSK-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(4-methyl-1,3-thiazol-2-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=NC(C)=CS1 WQXRYEVRJRVDSK-UHFFFAOYSA-N 0.000 description 1
- CERCNXOIJVTNOI-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(4-phenylphenyl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC(C=C1)=CC=C1C1=CC=CC=C1 CERCNXOIJVTNOI-UHFFFAOYSA-N 0.000 description 1
- VXPQMXUSNXGCGC-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(5-methyl-1,3-thiazol-2-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=NC=C(C)S1 VXPQMXUSNXGCGC-UHFFFAOYSA-N 0.000 description 1
- NLTMMUCSEQZBHA-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(5-nitropyridin-2-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C([N+]([O-])=O)C=N1 NLTMMUCSEQZBHA-UHFFFAOYSA-N 0.000 description 1
- NUMGKGIDXWEMIS-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(6-sulfamoylpyridin-3-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(S(N)(=O)=O)N=C1 NUMGKGIDXWEMIS-UHFFFAOYSA-N 0.000 description 1
- OQZBUDHKBPGIAY-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-[4-(trifluoromethyl)phenyl]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(C(F)(F)F)C=C1 OQZBUDHKBPGIAY-UHFFFAOYSA-N 0.000 description 1
- MSPMHPJXWCDMMS-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-[5-(trifluoromethyl)pyridin-2-yl]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(C(F)(F)F)C=N1 MSPMHPJXWCDMMS-UHFFFAOYSA-N 0.000 description 1
- LGTDVXIMKXISMG-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-phenylpiperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=CC=C1 LGTDVXIMKXISMG-UHFFFAOYSA-N 0.000 description 1
- GWTZQKAICWLKBY-UHFFFAOYSA-N 4-methyl-n-(3-methyl-1,2-oxazol-5-yl)-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC(C)=NO1 GWTZQKAICWLKBY-UHFFFAOYSA-N 0.000 description 1
- AXECWBLWTKUNKI-UHFFFAOYSA-N 4-methyl-n-(5-methyl-1,2-oxazol-3-yl)-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC=1C=C(C)ON=1 AXECWBLWTKUNKI-UHFFFAOYSA-N 0.000 description 1
- QOQLNRWVRJXYBY-UHFFFAOYSA-N 4-methyl-n-(6-methylpyridin-2-yl)-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=CC(C)=N1 QOQLNRWVRJXYBY-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- UNQYAAAWKOOBFQ-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-8-[4-chloro-3-(trifluoromethoxy)phenoxy]-1-(3-hydroxypropyl)-3-methylpurine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCCO)C(=O)N(C)C=2N=C1OC1=CC=C(Cl)C(OC(F)(F)F)=C1 UNQYAAAWKOOBFQ-UHFFFAOYSA-N 0.000 description 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical group N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical class NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OVGSNVUVHVUHKX-UHFFFAOYSA-N Cl.C1=CC(S(=O)(=O)NC)=CC=C1NC(=O)N1CC(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CC1 Chemical compound Cl.C1=CC(S(=O)(=O)NC)=CC=C1NC(=O)N1CC(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CC1 OVGSNVUVHVUHKX-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Natural products OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000008986 Janus Human genes 0.000 description 1
- 108050000950 Janus Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000581002 Murex Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- FEYNFHSRETUBEM-UHFFFAOYSA-N N-[3-(1,1-difluoroethyl)phenyl]-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazole-4-carboxamide Chemical compound COc1ccc(cc1)N1N=C(C)C(C(=O)Nc2cccc(c2)C(C)(F)F)C1=O FEYNFHSRETUBEM-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 1
- 201000007146 X-linked severe combined immunodeficiency Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- FRNVQSITWLFBOC-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(1,2-thiazol-4-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C=1C=NSC=1 FRNVQSITWLFBOC-UHFFFAOYSA-N 0.000 description 1
- LAXXEWWSKAEXQA-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(1,3-thiazol-4-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1=CSC=N1 LAXXEWWSKAEXQA-UHFFFAOYSA-N 0.000 description 1
- RFXCMSIDTNASLB-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(2-methyl-1,3-thiazol-4-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1=CSC(C)=N1 RFXCMSIDTNASLB-UHFFFAOYSA-N 0.000 description 1
- OBNYTNLANQYAKG-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(4-methyl-1,2-thiazol-5-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C=1SN=CC=1C OBNYTNLANQYAKG-UHFFFAOYSA-N 0.000 description 1
- MKFLMVFCNAEJIB-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(5-methyl-1,2-oxazol-3-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C=1C=C(C)ON=1 MKFLMVFCNAEJIB-UHFFFAOYSA-N 0.000 description 1
- RUAQJYIYTBWUNM-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(5-methyl-1h-pyrazol-3-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C=1C=C(C)NN=1 RUAQJYIYTBWUNM-UHFFFAOYSA-N 0.000 description 1
- BUMQMCHZIVFESJ-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(5-methylthiophen-2-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1=CC=C(C)S1 BUMQMCHZIVFESJ-UHFFFAOYSA-N 0.000 description 1
- UHCGTWYKWVIEOO-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(5-nitro-1-benzofuran-2-yl)methanone Chemical compound [O-][N+](=O)C1=CC=C2OC(C(=O)N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=CC2=C1 UHCGTWYKWVIEOO-UHFFFAOYSA-N 0.000 description 1
- SOLFDRIEOMXKOP-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(oxolan-2-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCCO1 SOLFDRIEOMXKOP-UHFFFAOYSA-N 0.000 description 1
- AKYLWWKYKHNOQZ-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-morpholin-4-ylmethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N1CCOCC1 AKYLWWKYKHNOQZ-UHFFFAOYSA-N 0.000 description 1
- HWHZRORVDATTRP-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-phenylmethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1=CC=CC=C1 HWHZRORVDATTRP-UHFFFAOYSA-N 0.000 description 1
- QEOGTRNHPCFQLX-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-piperidin-1-ylmethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N1CCCCC1 QEOGTRNHPCFQLX-UHFFFAOYSA-N 0.000 description 1
- LRXSQANBZHZHCZ-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-pyridin-2-ylmethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1=CC=CC=N1 LRXSQANBZHZHCZ-UHFFFAOYSA-N 0.000 description 1
- HVJJPRASNOJXDK-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-pyrrolidin-2-ylmethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCCN1 HVJJPRASNOJXDK-UHFFFAOYSA-N 0.000 description 1
- CFQZFXWCFBDZIK-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-thiophen-3-ylmethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C=1C=CSC=1 CFQZFXWCFBDZIK-UHFFFAOYSA-N 0.000 description 1
- OFHZXPIDYDEZMU-UHFFFAOYSA-N [6-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]pyridin-3-yl]-morpholin-4-ylmethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(N=C1)=CC=C1C(=O)N1CCOCC1 OFHZXPIDYDEZMU-UHFFFAOYSA-N 0.000 description 1
- GZEMWMLTGAYLBT-UHFFFAOYSA-N [6-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]pyridin-3-yl]methanol Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=CC=C(CO)C=N1 GZEMWMLTGAYLBT-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- PHHXKYGBYYYQDX-UHFFFAOYSA-N azetidin-1-yl-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone;hydrochloride Chemical compound Cl.C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N1CCC1 PHHXKYGBYYYQDX-UHFFFAOYSA-N 0.000 description 1
- SXPLDGFSEXIUBZ-UHFFFAOYSA-N azetidin-3-yl-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CNC1 SXPLDGFSEXIUBZ-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- VEXPBNIZLGFIDN-UHFFFAOYSA-N benzyl 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylate Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)OCC1=CC=CC=C1 VEXPBNIZLGFIDN-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- CDLIGISCRYAUFG-UHFFFAOYSA-N benzyl n-methyl-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]carbamate Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCN(C)C(=O)OCC1=CC=CC=C1 CDLIGISCRYAUFG-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229940107810 cellcept Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- PTMBWDICPIENIA-UHFFFAOYSA-N cyclobutyl-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCC1 PTMBWDICPIENIA-UHFFFAOYSA-N 0.000 description 1
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- SCIVYQMCQDJIGQ-UHFFFAOYSA-N cyclopropyl-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CC1 SCIVYQMCQDJIGQ-UHFFFAOYSA-N 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- KFJVOMUBTRMMJQ-UHFFFAOYSA-N ethyl 4-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]amino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NC(=O)N1CC(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CC1 KFJVOMUBTRMMJQ-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ULFSTAKFWLVFFC-UHFFFAOYSA-N furan-2-yl-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1=CC=CO1 ULFSTAKFWLVFFC-UHFFFAOYSA-N 0.000 description 1
- JYEJANHTIHUXJA-UHFFFAOYSA-N furan-3-yl-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C=1C=COC=1 JYEJANHTIHUXJA-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 102000049912 human JAK3 Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- ZANBAWCCGAZGAI-UHFFFAOYSA-N methyl 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]pyrrolidine-2-carboxylate Chemical compound COC(=O)C1CCCN1C(=O)N1CC(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CC1 ZANBAWCCGAZGAI-UHFFFAOYSA-N 0.000 description 1
- OFCJBGWMMGEZCC-UHFFFAOYSA-N methyl 2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-1,3-benzoxazole-6-carboxylate Chemical compound O1C2=CC(C(=O)OC)=CC=C2N=C1N(C1)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 OFCJBGWMMGEZCC-UHFFFAOYSA-N 0.000 description 1
- ABEQAYKYAOYJKH-UHFFFAOYSA-N methyl 2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-oxoacetate Chemical compound C1N(C(=O)C(=O)OC)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 ABEQAYKYAOYJKH-UHFFFAOYSA-N 0.000 description 1
- MBBWHWXFWMYUEZ-UHFFFAOYSA-N methyl 3-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanoate Chemical compound C1N(C(=O)CC(=O)OC)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 MBBWHWXFWMYUEZ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- PWNBFGLPPQHBOG-UHFFFAOYSA-N n',n'-dimethyl-n-[6-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]pyrimidin-4-yl]ethane-1,2-diamine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=CC(NCCN(C)C)=NC=N1 PWNBFGLPPQHBOG-UHFFFAOYSA-N 0.000 description 1
- FJZHONHKCYKRQB-UHFFFAOYSA-N n,n-dimethyl-2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]acetamide Chemical compound CC1CCN(CC(=O)N(C)C)CC1N(C)C1=NC=NC2=C1C=CN2 FJZHONHKCYKRQB-UHFFFAOYSA-N 0.000 description 1
- WTAVUCSHHBXNAU-UHFFFAOYSA-N n-(2,4-difluorophenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(F)C=C1F WTAVUCSHHBXNAU-UHFFFAOYSA-N 0.000 description 1
- WCRSFPARSWZFGJ-UHFFFAOYSA-N n-(2-cyanoethyl)-n,4-dimethyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound CC1CCN(C(=O)N(C)CCC#N)CC1N(C)C1=NC=NC2=C1C=CN2 WCRSFPARSWZFGJ-UHFFFAOYSA-N 0.000 description 1
- CSSVJWJGZOFBGB-UHFFFAOYSA-N n-(3,4-difluorophenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(F)C(F)=C1 CSSVJWJGZOFBGB-UHFFFAOYSA-N 0.000 description 1
- KTVSFKVDVONQQP-UHFFFAOYSA-N n-(3-cyanophenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=CC(C#N)=C1 KTVSFKVDVONQQP-UHFFFAOYSA-N 0.000 description 1
- FSYPBFOBTUJGFG-UHFFFAOYSA-N n-(3-fluorophenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=CC(F)=C1 FSYPBFOBTUJGFG-UHFFFAOYSA-N 0.000 description 1
- LXKUADWXZVTYED-UHFFFAOYSA-N n-(3-methoxyphenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound COC1=CC=CC(NC(=O)N2CC(C(C)CC2)N(C)C=2C=3C=CNC=3N=CN=2)=C1 LXKUADWXZVTYED-UHFFFAOYSA-N 0.000 description 1
- UKRCCLOCZAYFDB-UHFFFAOYSA-N n-(4-carbamoylphenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(C(N)=O)C=C1 UKRCCLOCZAYFDB-UHFFFAOYSA-N 0.000 description 1
- PJPPECSJTSUKLO-UHFFFAOYSA-N n-(4-chlorophenyl)-2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]acetamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC(=O)NC1=CC=C(Cl)C=C1 PJPPECSJTSUKLO-UHFFFAOYSA-N 0.000 description 1
- HOMLLBRPTTUVDV-UHFFFAOYSA-N n-(4-chlorophenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(Cl)C=C1 HOMLLBRPTTUVDV-UHFFFAOYSA-N 0.000 description 1
- KUXDTNVHBXEUSG-UHFFFAOYSA-N n-(4-cyanophenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexane-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCC1C(=O)NC1=CC=C(C#N)C=C1 KUXDTNVHBXEUSG-UHFFFAOYSA-N 0.000 description 1
- FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 1
- WEUCBDWSLVVWDC-UHFFFAOYSA-N n-(4-fluorophenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(F)C=C1 WEUCBDWSLVVWDC-UHFFFAOYSA-N 0.000 description 1
- UQXXIMBBVYSFNY-UHFFFAOYSA-N n-(4-methoxyphenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)N1CC(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CC1 UQXXIMBBVYSFNY-UHFFFAOYSA-N 0.000 description 1
- OEYQMFLXKYNHHX-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(Cl)C=N1 OEYQMFLXKYNHHX-UHFFFAOYSA-N 0.000 description 1
- VRYPRPWUASLBKW-UHFFFAOYSA-N n-(6-acetamidopyridin-3-yl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(NC(C)=O)N=C1 VRYPRPWUASLBKW-UHFFFAOYSA-N 0.000 description 1
- DARQGOIBFWYTDR-UHFFFAOYSA-N n-(6-chloropyridin-3-yl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(Cl)N=C1 DARQGOIBFWYTDR-UHFFFAOYSA-N 0.000 description 1
- NIBJZAILJOWIQQ-UHFFFAOYSA-N n-[1-(1,3-benzoxazol-2-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC=C2OC(N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=NC2=C1 NIBJZAILJOWIQQ-UHFFFAOYSA-N 0.000 description 1
- VADLXRPQOFCWQX-UHFFFAOYSA-N n-[1-(1h-imidazol-2-ylmethyl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=NC=CN1 VADLXRPQOFCWQX-UHFFFAOYSA-N 0.000 description 1
- JITFZYYWBKUOOK-UHFFFAOYSA-N n-[1-(2-chloropyrimidin-4-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=CC=NC(Cl)=N1 JITFZYYWBKUOOK-UHFFFAOYSA-N 0.000 description 1
- UAONIQCOJSBENP-UHFFFAOYSA-N n-[1-(3-fluorophenyl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=CC(F)=C1 UAONIQCOJSBENP-UHFFFAOYSA-N 0.000 description 1
- XVEOPYFRZSNYRS-UHFFFAOYSA-N n-[1-(4-chloropyrimidin-2-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=NC=CC(Cl)=N1 XVEOPYFRZSNYRS-UHFFFAOYSA-N 0.000 description 1
- BZUPLPCFCWNQJZ-UHFFFAOYSA-N n-[1-(5,7-dichloro-1,3-benzoxazol-2-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound ClC1=CC(Cl)=C2OC(N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=NC2=C1 BZUPLPCFCWNQJZ-UHFFFAOYSA-N 0.000 description 1
- JIDOCDWDYSHWDP-UHFFFAOYSA-N n-[1-(5,7-dimethyl-1,3-benzoxazol-2-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CC1=CC(C)=C2OC(N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=NC2=C1 JIDOCDWDYSHWDP-UHFFFAOYSA-N 0.000 description 1
- SDTDZNFZCYBCMW-UHFFFAOYSA-N n-[1-(5-chloro-1,3-benzothiazol-2-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound ClC1=CC=C2SC(N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=NC2=C1 SDTDZNFZCYBCMW-UHFFFAOYSA-N 0.000 description 1
- HZQZOIOMQQURSQ-UHFFFAOYSA-N n-[1-(5-ethylsulfonyl-1,3-benzoxazol-2-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=CC(S(=O)(=O)CC)=CC=C2OC=1N(C1)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 HZQZOIOMQQURSQ-UHFFFAOYSA-N 0.000 description 1
- NKJRMXWUWIKAKK-UHFFFAOYSA-N n-[1-(6-chloropyrimidin-4-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=CC(Cl)=NC=N1 NKJRMXWUWIKAKK-UHFFFAOYSA-N 0.000 description 1
- KZLGBKRXQFQMGR-UHFFFAOYSA-N n-[1-(6-methoxy-1,3-benzoxazol-2-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound O1C2=CC(OC)=CC=C2N=C1N(C1)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 KZLGBKRXQFQMGR-UHFFFAOYSA-N 0.000 description 1
- XAIXADYENDVRSQ-UHFFFAOYSA-N n-[1-(benzenesulfonyl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=CC=C1 XAIXADYENDVRSQ-UHFFFAOYSA-N 0.000 description 1
- AOTIOZSNQFPNJH-UHFFFAOYSA-N n-[1-(benzenesulfonylmethyl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CS(=O)(=O)C1=CC=CC=C1 AOTIOZSNQFPNJH-UHFFFAOYSA-N 0.000 description 1
- VELIIHPOYAKKHA-UHFFFAOYSA-N n-[1-(cyclohexylmethyl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1CCCCC1 VELIIHPOYAKKHA-UHFFFAOYSA-N 0.000 description 1
- RNLIKTXBRLXGPY-UHFFFAOYSA-N n-[1-(furan-2-ylmethyl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CO1 RNLIKTXBRLXGPY-UHFFFAOYSA-N 0.000 description 1
- KUMDRRYTRPBDNI-UHFFFAOYSA-N n-[1-[(1-hydroxy-2h-pyridin-4-yl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CCN(O)C=C1 KUMDRRYTRPBDNI-UHFFFAOYSA-N 0.000 description 1
- AVRPPQPEZXXZIO-UHFFFAOYSA-N n-[1-[(2,3-difluorophenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CC(F)=C1F AVRPPQPEZXXZIO-UHFFFAOYSA-N 0.000 description 1
- XWIXMEMJUUUXDV-UHFFFAOYSA-N n-[1-[(2,6-difluorophenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=C(F)C=CC=C1F XWIXMEMJUUUXDV-UHFFFAOYSA-N 0.000 description 1
- WOZXKPUHXAGNNA-UHFFFAOYSA-N n-[1-[(3,4-difluorophenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=C(F)C(F)=C1 WOZXKPUHXAGNNA-UHFFFAOYSA-N 0.000 description 1
- KYWZBXXHWMAJGM-UHFFFAOYSA-N n-[1-[(3,5-dichlorophenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC(Cl)=CC(Cl)=C1 KYWZBXXHWMAJGM-UHFFFAOYSA-N 0.000 description 1
- DJNKXFFWPIEPST-UHFFFAOYSA-N n-[1-[(3-fluorophenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CC(F)=C1 DJNKXFFWPIEPST-UHFFFAOYSA-N 0.000 description 1
- XENGQHJCGXVHPS-UHFFFAOYSA-N n-[1-[(3-methoxyphenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC(CN2CC(C(C)CC2)N(C)C=2C=3C=CNC=3N=CN=2)=C1 XENGQHJCGXVHPS-UHFFFAOYSA-N 0.000 description 1
- MBYGQCLMIWYJKG-UHFFFAOYSA-N n-[1-[(4-fluorophenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=C(F)C=C1 MBYGQCLMIWYJKG-UHFFFAOYSA-N 0.000 description 1
- OHXSTMVQELSZED-UHFFFAOYSA-N n-[1-[(4-methoxyphenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1CN1CC(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CC1 OHXSTMVQELSZED-UHFFFAOYSA-N 0.000 description 1
- LOLJQNSXOMKFMT-UHFFFAOYSA-N n-[1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl]ethylidene]hydroxylamine Chemical compound CC1CCC(C(C)=NO)CC1N(C)C1=NC=NC2=C1C=CN2 LOLJQNSXOMKFMT-UHFFFAOYSA-N 0.000 description 1
- IQKOFVVNSXCJSN-UHFFFAOYSA-N n-[1-[6-(benzylamino)pyrimidin-4-yl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(N=CN=1)=CC=1NCC1=CC=CC=C1 IQKOFVVNSXCJSN-UHFFFAOYSA-N 0.000 description 1
- AQHVRSUYNGNXOZ-UHFFFAOYSA-N n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]benzamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1=CC=CC=C1 AQHVRSUYNGNXOZ-UHFFFAOYSA-N 0.000 description 1
- JRFILNRCZMZHQZ-UHFFFAOYSA-N n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]cyclopentanecarboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1CCCC1 JRFILNRCZMZHQZ-UHFFFAOYSA-N 0.000 description 1
- SDZGEYOYAHZILJ-UHFFFAOYSA-N n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]cyclopropanecarboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1CC1 SDZGEYOYAHZILJ-UHFFFAOYSA-N 0.000 description 1
- VKODGQHCYLJNPG-UHFFFAOYSA-N n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]methanesulfonamide Chemical compound CC1CCN(S(=O)(=O)CCNS(C)(=O)=O)CC1N(C)C1=NC=NC2=C1C=CN2 VKODGQHCYLJNPG-UHFFFAOYSA-N 0.000 description 1
- BWODOSRHYYFYAL-UHFFFAOYSA-N n-[4-(acetylsulfamoyl)phenyl]-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(S(=O)(=O)NC(C)=O)C=C1 BWODOSRHYYFYAL-UHFFFAOYSA-N 0.000 description 1
- UEMXCVXXCWBSQO-UHFFFAOYSA-N n-[4-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-4-oxobutyl]methanesulfonamide Chemical compound CC1CCN(C(=O)CCCNS(C)(=O)=O)CC1N(C)C1=NC=NC2=C1C=CN2 UEMXCVXXCWBSQO-UHFFFAOYSA-N 0.000 description 1
- BGQHZISOZGIZCV-UHFFFAOYSA-N n-benzyl-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NCC1=CC=CC=C1 BGQHZISOZGIZCV-UHFFFAOYSA-N 0.000 description 1
- NNKPHNTWNILINE-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 NNKPHNTWNILINE-UHFFFAOYSA-N 0.000 description 1
- JGDAYRXXBGXXGG-UHFFFAOYSA-N n-methyl-2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-oxoacetamide Chemical compound C1N(C(=O)C(=O)NC)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 JGDAYRXXBGXXGG-UHFFFAOYSA-N 0.000 description 1
- RBOKEUPEGKRTPI-UHFFFAOYSA-N n-methyl-3-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]propanamide Chemical compound C1N(CCC(=O)NC)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 RBOKEUPEGKRTPI-UHFFFAOYSA-N 0.000 description 1
- SVGSLFSBCLPFBM-UHFFFAOYSA-N n-methyl-n-(4-methyl-1-morpholin-4-ylsulfonylpiperidin-3-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)N1CCOCC1 SVGSLFSBCLPFBM-UHFFFAOYSA-N 0.000 description 1
- GPVKWABLWSUDQE-UHFFFAOYSA-N n-methyl-n-(4-methyl-1-piperidin-1-ylsulfonylpiperidin-3-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)N1CCCCC1 GPVKWABLWSUDQE-UHFFFAOYSA-N 0.000 description 1
- MUFDJXPYGHSTCL-UHFFFAOYSA-N n-methyl-n-(4-methyl-1-pyrrolidin-1-ylsulfonylpiperidin-3-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)N1CCCC1 MUFDJXPYGHSTCL-UHFFFAOYSA-N 0.000 description 1
- LQWYMRBEANETJH-UHFFFAOYSA-N n-methyl-n-(4-methyl-1-quinolin-2-ylpiperidin-3-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC=CC2=NC(N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=CC=C21 LQWYMRBEANETJH-UHFFFAOYSA-N 0.000 description 1
- MVCSSSGKQCMNFQ-UHFFFAOYSA-N n-methyl-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]cyclohexanecarboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCN(C)C(=O)C1CCCCC1 MVCSSSGKQCMNFQ-UHFFFAOYSA-N 0.000 description 1
- FMUOXQFHWFUZQB-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(1,3-thiazol-2-yl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=NC=CS1 FMUOXQFHWFUZQB-UHFFFAOYSA-N 0.000 description 1
- AHXCJQMWLAFGPB-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(1,3-thiazol-2-ylmethyl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=NC=CS1 AHXCJQMWLAFGPB-UHFFFAOYSA-N 0.000 description 1
- VJVUKGGLJWGDIL-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(3-methylphenyl)sulfonylpiperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=CC(C)=C1 VJVUKGGLJWGDIL-UHFFFAOYSA-N 0.000 description 1
- RIQIAXUQTZSGMI-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(3-nitrophenyl)sulfonylpiperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 RIQIAXUQTZSGMI-UHFFFAOYSA-N 0.000 description 1
- PWIHTXDCVXJBCH-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(4-methyl-1,3-benzoxazol-2-yl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC=C2OC(N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=NC2=C1C PWIHTXDCVXJBCH-UHFFFAOYSA-N 0.000 description 1
- DNWGYMDGFSUKID-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(5-methyl-1,3-benzoxazol-2-yl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CC1=CC=C2OC(N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=NC2=C1 DNWGYMDGFSUKID-UHFFFAOYSA-N 0.000 description 1
- QYRPJQSAIQUHHS-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(5-nitro-1,3-benzoxazol-2-yl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound [O-][N+](=O)C1=CC=C2OC(N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=NC2=C1 QYRPJQSAIQUHHS-UHFFFAOYSA-N 0.000 description 1
- SRXRYNIPRVJWPC-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(5-pyrrolidin-1-ylsulfonylpyridin-2-yl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(N=C1)=CC=C1S(=O)(=O)N1CCCC1 SRXRYNIPRVJWPC-UHFFFAOYSA-N 0.000 description 1
- OAELPESROREARW-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(6-methyl-1,3-benzoxazol-2-yl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=C(C)C=C2OC(N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=NC2=C1 OAELPESROREARW-UHFFFAOYSA-N 0.000 description 1
- RCBQBSSVDGCIAQ-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(6-methylpyridazin-3-yl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=CC=C(C)N=N1 RCBQBSSVDGCIAQ-UHFFFAOYSA-N 0.000 description 1
- WXYYHGAYLYQELZ-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(pyridin-2-ylmethyl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CC=N1 WXYYHGAYLYQELZ-UHFFFAOYSA-N 0.000 description 1
- BXXSVSHTKLNQHF-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(pyridin-3-ylmethyl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CN=C1 BXXSVSHTKLNQHF-UHFFFAOYSA-N 0.000 description 1
- ZHXWETHAYBXKEL-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-[(1-methylimidazol-2-yl)methyl]piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=NC=CN1C ZHXWETHAYBXKEL-UHFFFAOYSA-N 0.000 description 1
- ICFLHUVCGKHWBW-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-[(4-methylsulfonylphenyl)methyl]piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=C(S(C)(=O)=O)C=C1 ICFLHUVCGKHWBW-UHFFFAOYSA-N 0.000 description 1
- CWIUUIXHTNTBDN-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-[(4-piperidin-1-ylsulfonylphenyl)methyl]piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC(C=C1)=CC=C1S(=O)(=O)N1CCCCC1 CWIUUIXHTNTBDN-UHFFFAOYSA-N 0.000 description 1
- KUAVAVVWIAXBJK-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-[2-(methylamino)pyrimidin-4-yl]piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CNC1=NC=CC(N2CC(C(C)CC2)N(C)C=2C=3C=CNC=3N=CN=2)=N1 KUAVAVVWIAXBJK-UHFFFAOYSA-N 0.000 description 1
- CKUHWFYIKOTOGY-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-[4-(trifluoromethyl)phenyl]sulfonylpiperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 CKUHWFYIKOTOGY-UHFFFAOYSA-N 0.000 description 1
- ZJJZIPPIZVRPDK-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound FC(F)(F)C1=CC=C2SC(N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=NC2=C1 ZJJZIPPIZVRPDK-UHFFFAOYSA-N 0.000 description 1
- XHEHEYSNUXNFKG-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-[6-(methylamino)pyrimidin-4-yl]piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=NC(NC)=CC(N2CC(C(C)CC2)N(C)C=2C=3C=CNC=3N=CN=2)=N1 XHEHEYSNUXNFKG-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- ZAHJXIZFAHUPFW-UHFFFAOYSA-N oxolan-3-yl 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylate Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)OC1CCOC1 ZAHJXIZFAHUPFW-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001184 polypeptide Chemical group 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Chemical group 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- MAFFVYBHTVKZMC-UHFFFAOYSA-N propan-2-yl 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)C)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 MAFFVYBHTVKZMC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- MNUYILMTXWFWMH-UHFFFAOYSA-N tert-butyl 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylate Chemical compound CC1CCN(C(=O)OC(C)(C)C)CC1N(C)C1=NC=NC2=C1C=CN2 MNUYILMTXWFWMH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Pozadina izuma
Ovaj izum se odnosi na pirolo[2,3-d]pirimidinske spojeve koji su inhibitori protein-kinaza, kao što je enzim Janus kinaza 3 (u daljem tekstu označavan i kao JAK3), a ti spojevi kao takvi mogu se koristiti u terapijske svrhe kao imunosupresivna sredstva prilikom presađivanja organa, kod ksenogenog presatka, lupusa, multiple skleroze, reumatoidnog artritisa, psorijaze, dijabetesa tipa I i komplikacija nastalih kao posljedica dijabetesa, raka, astme, atopičnog dermatitisa, autoimunih poremećaja štitnjače, ulceroznog kolitisa, Crohnove bolesti, Alzheimerove bolesti, leukemije i drugih indikacija kod kojih bi imunosupresija bila poželjna.
Ovaj izum se također odnosi na postupak upotrebe takvih spojeva prilikom liječenja gore navedenih indikacija kod sisavaca, naročito ljudi, kao i njihovih pogodnih farmaceutskih pripravaka.
JAK3 je član porodice Janus protein-kinaza. Iako ostali članove ove porodice eksprimiraju uglavnom sva tkiva, JAK3 ekspresija ograničena je samo na hematopoetske stanice. Ovo je u skladu sa njegovom bitnom ulogom u signaliziranju preko receptora za IL-2, IL-4, IL-7, IL-9 i IL-15 pomoću nekovalentnih asocijacija JAK3 sa gama lancem koji je zajednički tim višelančanim receptorima. Za populaciju pacijenata s XSCID-om opaženo je jako sniženje razine JAK3 proteina ili genetski defekti zajedničkog gama lanca, što ukazuje da bi imunosupresija trebala rezultirati iz blokade signalizacije preko JAK3 puta. Istraživanja na životinjama pokazala su da JAK3 ne samo da igra kritičnu ulogu u sazrijevanju B i T limfocita, već i da je JAK3 konstitutivno potrebna za održavanje funkcija T stanice. Modulacija imunosne aktivnosti preko ovog novog mehanizma može se pokazati korisnom u liječenju poremećaja proliferacije T stanica, kao što su odbacivanje presadaka i autoimune bolesti.
Bit izuma
Izum se odnosi na spoj formule
[image] ,
ili njegovu farmaceutski prihvatljivu sol; gdje
R1 je grupa formule
[image] ,
gdje y je 0, 1 ili 2;
R4 je izabran iz grupe koju čine vodik, (C1-C6)alkil, (C1-C6)alkilsulfonil, (C2-C6)alkenil, (C2-C6)alkinil, pri čemu su alkilne, alkenilne i alkinilne grupe izborno supstituirane s deuterijem, hidroksi, amino, trifluormetilom, (C1-C4)alkoksi, (C1-C6)aciloksi, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, cijano, nitro, (C2-C6)alkenil, (C2-C6)alkinil ili (C1-C6)acilamino; ili R4 je (C3-C10)cikloalkil, pri čemu je cikloalkilna grupa izborno supstituirana s deuterijem, hidroksi, amino, trifluormetilom, (C1-C6)aciloksi, (C1-C6)acilamino, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, cijano, cijano(C1-C6)alkil, trifluormetil(C1-C6)alkil, nitro, nitro(C1-C6)alkil ili (C1-C6)acilamino;
R5 je (C2-C9)heterocikloalkil, pri čemu heterocikloalkilne grupe moraju biti supstituirane s jednom do pet grupa koje čine karboksi, cijano, amino, deuterij, hidroksi, (C1-C6)alkil, (C1-C6)alkoksi, halo, (C1-C6)acil, (C1-C6)alkilamino, amio(C1-C6)alkil, (C1-C6)alkoksi-CO-NH, (C1-C6)alkilamino-CO-, (C2-C6)alkenil, (C2-C6)alkinil, (C1-C6)alkilamino, amino(C1-C6)alkil, hidroksi(C1-C6)alkil, (C1-C6)alkoksi(C1-C6)alkil, (C1-C6)aciloksi(C1-C6)alkil, nitro, cijano(C1-C6)alkil, halo(C1-C6)alkil, nitro(C1-C6)alkil, trifluormetil, trifluormetil(C1-C6)alkil, (C1-C6)acilamino, (C1-C6)acilamino(C1-C6)alkil, (C1-C6)alkoksi(C1-C6)acilamino, amino(C1-C6)acil, amino(C1-C6)acil(C1-C6)alkil, (C1-C6)alkilamino(C1-C6)acil, ((C1-C6)alkil)2amino(C1-C6)acil, R15R16N-CO-O-, R15R16N-CO-(C1-C6)alkil, (C1-C6)alkil-S(O)m, R15R16NS(O)m, R15R16NS(O)m(C1-C6)alkil, R15S(O)mR16N, R15S(O)mR16N(C1-C6)alkil, gdje m je 0, 1 ili 2, a R15 i R16 su svaki nezavisno izabrani od vodika ili (C1-C6)alkila; i grupa formule
[image] ,
gdje a je 0, 1, 2, 3 ili 4;
b, c, e, f i g su svaki nezavisno 0 ili 1;
d je 0, 1, 2, ili 3;
X je S(O)n, gdje n je 0, 1 ili 2; kisik, karbonil ili -C(=N-cijano)-;
Y je S(O)n, gdje n je 0, 1 ili 2; ili karbonil; i
Z je karbonil, C(O)O-, C(O)NR-, gdje R je vodik ili (C1-C6)alkil; ili Z je S(O)n, gdje n je 0, 1 ili 2;
R6, R7, R8, R9, R10 i R11 su svaki nezavisno izabrani iz grupe koju čine vodik ili (C1-C6)alkil izborno supstituiran s deuterijem, hidroksi, amino, trifluormetilom, (C1-C6)aciloksi, (C1-C6)acilamino, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, cijano, cijano(C1-C6)alkil, trifluormetil(C1-C6)alkil, nitro, nitro(C1-C6)alkil ili (C1-C6)acilamino;
R12 je (C6-C10)aril, (C2-C9)heteroaril, (C3-C10)cikloalkil ili (C2-C9)heterocikloalkil, pri čemu su arilne, heteroarilne, cikloalkilne i heterocikloalkilne grupe izborno supstituirane s jednom do četiri grupe koje čine vodik, deuterij, amino, halo, okso, hidroksi, nitro, karboksi, (C2-C6)alkenil, (C2-C6)alkinil, trifluormetil, trifluormetoksi, (C1-C6)alkil, (C1-C6)alkoski, (C3-C10)cikloalkil, (C1-C6)alkil-CO-NH-, (C1-C6)alkoksi-CO-NH-, (C1-C6)alkil-CO-NH-(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-(C1-C6)alkoksi, karboksi, karboksi(C1-C6)alkil, karboksi(C1-C6)alkoksi, benziloksikarbonil(C1-C6)alkoksi, (C1-C6)alkoksikarbonil(C1-C6)alkoksi, (C6-C10)aril, amino, amino(C1-C6)alkil, (C1-C6)alkoksikarbonilamino, (C6-C10)aril(C1-C6)alkoksikarbonilamino, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, (C1-C6)alkilamino(C1-C6)alkil, ((C1-C6)alkil)2amino(C1-C6)alkil, hidroksi, (C1-C6)alkoksi, karboksi, karboksi(C1-C6)alkil, (C1-C6)alkoksikarbonil, (C1-C6)alkoksikarbonil(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-, (C1-C6)alkil-CO-NH-, cijano, (C5-C9)heterocikloalkil, amino-CO-NH-, (C1-C6)alkilamino-CO-NH-, ((C1-C6)alkil)2amino-CO-NH-, (C6-C10)arilamino-CO-NH-, (C5-C9)heteroarilamino-CO-NH-, (C1-C6)alkilamino-CO-NH-(C1-C6)alkil, ((C1-C6)alkil)2amino-CO-NH-(C1-C6)alkil, (C6-C10)arilamino-CO-NH-(C1-C6)alkil, (C5-C9)heteroarilamino-CO-NH-(C1-C6)alkil, (C1-C6)alkilcijano, (C1-C6)alkilkarboksi(C1-C6)alkoksi, (C1-C6)alkilkarboksi, sulfonilamino, aminosulfonil, sulfonilamino(C1-C6)alkil, sulfonilaminokarboksi(C1-C6)alkil, (C1-C6)alkilsulfonil, (C1-C6)alkilsulfonilamino, (C1-C6)alkilsulfonilamino(C1-C6)alkil, (C6-C10)arilsulfonil, (C6-C10)arilsulfonilamino, (C6-C10)arilsulfonilamino(C1-C6)alkil, (C1-C6)alkilsulfonilamino, (C1-C6)alkilsulfonilamino(C1-C6)alkil, (C3-C10)cikloalkil, (C3-C10)cikloalkoksi, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, (C6-C10)arilamino, (C1-C6)alkiltio, (C6-C10)ariltio, (C1-C6)alkilsulfinil, (C6-C10)arilsulfinil, (C1-C6)alkilsulfonil, (C6-C10)arilsulfonil, (C1-C6)acil, (C1-C6)alkoksi-CO-NH-, (C1-C6)alkilamino-CO-, (C5-C9)heteroaril, (C2-C9)heterocikloalkil ili (C6-C10)aril, pri čemu heteroarilne, heterocikloalkilne i arilne grupe koje su izborno supstituirane na R12 mogu biti dalje supstituirane s jednom do tri grupe koje čine halo, (C1-C6)alkil, (C1-C6)alkil-CO-NH-, (C1-C6)alkoksi-CO-NH-, (C1-C6)alkil-CO-NH-(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-(C1-C6)alkoksi, karboksi, karboksi(C1-C6)alkil, karboksi(C1-C6)alkoksi, benziloksikarbonil(C1-C6)alkoksi, (C1-C6)alkoksikarbonil(C1-C6)alkoksi, (C6-C10)aril, amino, amino(C1-C6)alkil, (C1-C6)alkoksikarbonilamino, (C6-C10)aril(C1-C6)alkoksikarbonilamino, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, (C1-C6)alkilamino(C1-C6)alkil, ((C1-C6)alkil)2amino(C1-C6)alkil, hidroksi, (C1-C6)alkoksi, karboksi, karboksi(C1-C6)alkil, (C1-C6)alkoksikarbonil, (C1-C6)alkoksikarbonil(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-, (C1-C6)alkil-CO-NH-, cijano, (C5-C9)heterocikloalkil, amino-CO-NH-, (C1-C6)alkilamino-CO-NH-, ((C1-C6)alkil)2amino-CO-NH-, (C6-C10)arilamino-CO-NH-, (C5-C9)heteroarilamino-CO-NH-, (C1-C6)alkilamino-CO-NH-(C1-C6)alkil, ((C1-C6)alkil)2amino-CO-NH-(C1-C6)alkil, (C6-C10)arilamino-CO-NH-(C1-C6)alkil, (C5-C9)heteroarilamino-CO-NH-(C1-C6)alkil, (C1-C6)alkilsulfonil, (C1-C6)alkilsulfonilamino, (C1-C6)alkilsulfonilamino(C1-C6)alkil, (C6-C10)arilsulfonil, (C6-C10)arilsulfonilamino, (C6-C10)arilsulfonilamino(C1-C6)alkil, (C1-C6)alkilsulfonilamino, (C1-C6)alkilsulfonilamino(C1-C6)alkil, (C5-C9)heteroaril i (C2-C9)heterocikloalkil;
R2 i R3 su svaki nezavisno izabrani iz grupe koju čine vodik, deuterij, amino, halo, hidroksi, nitro, karboksi, (C2-C6)alkenil, (C2-C6)alkinil, trifluormetil, trifluormetoksi, (C1-C6)alkil, (C1-C6)alkoksi, (C3-C10)cikloalkil, pri čemu su alkilne, alkoksi ili cikloalkilne grupe izborno supstituirane s jednom do tri grupe izabrane od halo, hidroksi, karboksi, amino(C1-C6)alkiltio, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, (C5-C9)heteroaril, (C2-C9)heterocikloalkil, (C3-C9)cikloalkil ili (C6-C10)aril; ili R2 i R3 su svaki nezavisno (C3-C10)cikloalkil, (C3-C10)cikloalkoksi, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, (C6-C10)arilamino, (C1-C6)alkiltio, (C6-C10)ariltio, (C1-C6)alkilsulfinil, (C6-C10)arilsulfinil, (C1-C6)alkilsulfonil, (C6-C10)arilsulfonil, (C1-C6)acil, (C1-C6)alkoksi-CO-NH-, (C1-C6)alkilamino-CO-, (C5-C9)heteroaril, (C2-C9)heterocikloalkil ili (C6-C10)aril, pri čemu su heteroarilne, heterocikloalkilne i arilne grupe izborno supstituirane s jednim do tri od halo, (C1-C6)alkil, (C1-C6)alkil-CO-NH-, (C1-C6)alkoksi-CO-NH-, (C1-C6)alkil-CO-NH-(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-(C1-C6)alkoksi, karboksi, karboksi(C1-C6)alkil, karboksi(C1-C6)alkoksi, benziloksikarbonil(C1-C6)alkoksi, (C1-C6)alkoksikarbonil(C1-C6)alkoksi, (C6-C10)aril, amino, amino(C1-C6)alkil, (C1-C6)alkoksikarbonilamino, (C6-C10)aril(C1-C6)alkoksikarbonilamino, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, (C1-C6)alkilamino(C1-C6)alkil, ((C1-C6)alkil)2amino(C1-C6)alkil, hidroksi, (C1-C6)alkoksi, karboksi, karboksi(C1-C6)alkil, (C1-C6)alkoksikarbonil, (C1-C6)alkoksikarbonil(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-, (C1-C6)alkil-CO-NH-, cijano, (C5-C9)heterocikloalkil, amino-CO-NH-, (C1-C6)alkilamino-CO-NH-, ((C1-C6)alkil)2amino-CO-NH-, (C6-C10)arilamino-CO-NH-, (C5-C9)heteroarilamino-CO-NH-, (C1-C6)alkilamino-CO-NH-(C1-C6)alkil, ((C1-C6)alkil)2amino-CO-NH-(C1-C6)alkil, (C6-C10)arilamino-CO-NH-(C1-C6)alkil, (C5-C9)heteroarilamino-CO-NH-(C1-C6)alkil, (C1-C6)alkilsulfonil, (C1-C6)alkilsulfonilamino, (C1-C6)alkilsulfonilamino(C1-C6)alkil, (C6-C10)arilsulfonil, (C6-C10)arilsulfonilamino, (C6-C10)arilsulfonilamino(C1-C6)alkil, (C1-C6)alkilsulfonilamino, (C1-C6)alkilsulfonilamino(C1-C6)alkil, (C5-C9)heteroaril ili (C2-C9)heterocikloalkil;
uz uvjet da R5 mora biti supstituiran s grupom formule II.
Ovaj izum se također odnosi na farmaceutski prihvatljive kisele adicijske soli spojeva formule I. Kiseline koje su korištene za pripremanje farmaceutski prihvatljivih kiselih adicijskih soli gore spomenutih bazičnih spojeva ovog izuma su one koje tvore netoksične kisele adicijske soli, tj. soli koje sadrže farmakološki prihvatljive anione, kao što su soli hidroklorida, hidrobromida, hidrojodida, nitrata, sulfata, bisulfata, fosfata, kiselog fosfata, acetata, laktata, citrata, kiselog citrata, tartarata, bitartarata, sukcinata, maletata, fumarata, glukonata, saharata, benzoata, metansulfonata, etansulfonata, benzensulfonata, p-toluensulfonata i pamoata [tj. 1,1'-metilen-bis-(2-hidroksi-3-naftoata)].
Izum se također odnosi na bazične adicijske soli formule I. Kemijske baze koje se može koristiti kao regense za pripremanje farmaceutski prihvatljivih bazičnih soli onih spojeva formule I koji su kisele prirode, su one koje tvore netoksične bazične soli sa takvim spojevima. Takve netoksične bazične soli uključuju, ali nisu ograničene na one izvedene od takvih farmakološki prihvatljivih kationa kao što su kationi alkalnih metala (npr. kalij i natrij) i kationi zemnoalkalnih metala (npr. kalcij i magnezij), amonijeve soli ili aminske adicijske soli koje su topljive u vodi kao što je N-metilglukamin-(meglumin), te soli nižih alkanolamonija i druge bazične soli ili farmaceutski prihvatljivi organski amini.
Pojam "Oxone®" je naziv monopersulfatnog spoja korištenog u ovom izumu, formule 2KHSO5 • KHSO4 • K2SO4, koji prodaje Aldrich Chemical Company, P.O. Box 2060, Milwaukee, WI 53201, SAD.
Izraz "alkil" kako se ovdje koristi, ukoliko drugačije nije istaknuto, uključuje zasićene monovalentne radikale ugljikovodika koji imaju nerazgranate ili razgranate ostatke ili njihove kombinacije.
Izraz "alkoksi" kako se ovdje koristi, uključuje O-alkil grupe, gdje "alkil" je definiran prethodno.
Izraz "halo" kako se ovdje koristi, ukoliko nije drugačije istaknuto, uključuje fluor, klor, brom ili jod.
Spojevi ovog izuma mogu sadržavati dvostruke veze. Kada su ovakve veze prisutne, spojevi ovog izuma dolaze u cis i trans konfiguracijama, i kao njihove smjese.
Ukoliko nije istaknuto drugačije, alkilne i alkenilne grupe koje se ovdje spominju, kao i alkilni ostaci i ostale grupe koje se ovdje spominju (npr. alkoksi), mogu biti nerazgranate ili razgranate, a također mogu biti i cikličke (npr. ciklopropil, ciklobutil, ciklopentil, cikloheksil ili cikloheptil), ili mogu biti nerazgranate ili razgranate i mogu sadržati cikličke ostatke. Ukoliko nije istaknuto drugačije, halogen uključuje fluor, klor, brom i jod.
(C2-C9)heterocikloalkil kada se ovdje koristi odnosi se na pirolidinil, tetrahidrofuranil, dihidrofuranil, tetrahidropiranil, piranil, tiopiranil, aziridinil, oksiranil, metilendioksil, kromenil, izoksazolidinil, 1,3-oksazolidin-3-il, izotiazolidinil, 1,3-tiazolidin-3-il, 1,2-pirazolidin-2-il, 1,3-pirazolidin-1-il, piperidinil, tiomorfolinil, 1,2-tetrahidrotiazin-2-il, 1,3-tetrahidrotiazin-3-il, tetrahidrotiadiazinil, morfolinil, 1,2-tetrahidrodiazin-2-il, 1,3-tetrahidrodiazin-1-il, tetrahidroazepinil, piperazinil, kromanil, itd. Stručnjaku u ovom području tehnike biti će jasno da su spomenuti (C2-C9)heterocikloalkilni prsteni povezani preko atoma ugljika ili sp3 hibridiziranog dušika kao heteroatoma.
(C2-C9)heteroaril kada se ovdje koristi odnosi se na furil, tienil, tiazolil, pirazolil, izotiazolil, oksazolil, izoksazolil, pirolil, triazolil, tetrazolil, imidazolil, 1,3,5-oksadiazolil, 1,2,4-oksadiazolil, 1,2,3-oksadiazolil, 1,3,5-tiadiazolil, 1,2,3-tiadiazolil, 1,2,4-tiadiazolil, piridil, pirimidil, pirazinil, piridazinil, 1,2,4-triazinil, 1,2,3-triazinil, 1,3,5-triazinil, pirazolo[3,4-b]piridinil, cinolinil, pteridinil, purinil, 6,7-dihidro-5H-[1]piridinil, benzo[b]tiofenil, 5,6,7,8-tetrahidro-kinolin-3-il, benzoksazolil, benzotiazolil, benzizotiazolil, benzizoksazolil, benzimidazolil, tianaftenil, izotianaftenil, benzofuranil, izobenzofuranil, izoindolil, indolil, indolizinil, indazolil, izokinolil, kinolil, ftalazinil, kinoksalinil, kinazolinil, benzoksazinil, itd. Stručnjaku u ovom području tehnike biti će jasno da su spomenuti (C2-C9)heteroalkilni prsteni povezani preko atoma ugljika ili sp3 hibridiziranog dušika kao heteroatoma.
(C6-C10)aril kada se ovdje koristi odnosi se na fenil ili naftil.
Spojevi formule (I) mogu se primjenjivati u farmaceutski prihvatljivom obliku bilo samostalno, ili u kombinaciji s jednim ili više dodatnih sredstava koja moduliraju imunosni sustav sisavaca ili s antiinflamatornim sredstvima. Ova sredstva mogu uključivati, ali nisu ograničena na ciklosporin A (npr. Sandimmune® ili Neoral®, rapamicin, FK-506 (Takrolimus), leflunomid, deoksispergvalin, mikofenolat (npr. Cellcept®), azatioprin (npr. Imuran®), daklizumab (npr. Zenapax®), OKT3 (npr. Orthoclone®), AtGam, aspirin, acetaminofen, ibuprofen, naproksen, piroksikam i antiinflamatorni steroidi (npr. prednizolon ili deksametazon). Ta sredstva se mogu davati kao dio istih ili različitih oblika doziranja, pomoću istih ili različitih načina primjene, te po istim ili različitim rasporedima primjene, u skladu sa standardnom farmaceutskom praksom.
Spojevi ovog izuma uključuju sve konformacijske izomere (npr. cis i trans izomere). Spojevi ovog izuma imaju asimetrične centre, i prema tome postoje u različitim enantiomernim i diastereomernim oblicima. Izum se odnosi na upotrebu svih optičkih izomera i stereoizomera spojeva ovog izuma i njihovih smjesa, i na sve farmaceutske pripravke i postupke liječenja u kojima se mogu upotrijebiti ili koji ih mogu sadržati. U skladu sa time, izum uključuje i E i Z konfiguracije. Spojevi formule I također mogu postojati i kao tautomeri. Ovaj izum se odnosi na upotrebu svih ovakvih tautomera i njihovih smjesa.
Ovaj izum također uključuje farmaceutske pripravke koji sadrže predlijekove spojeva formule I. Ovaj izum također uključuje postupke liječenja ili sprječavanja poremećaja koji se mogu liječiti ili spriječiti inhibicijom protein-kinaza, kao što je enzim Janus kinaza 3, koji uključuju primjenu predlijekova spojeva formule I. Spojevi formule I koji imaju slobodne amino, amido, hidroksi ili karboksilne grupe se mogu prevesti u predlijekove. Predlijekovi uključuju spojeve kod kojih se aminokiselinski ostatak, ili polipeptidni lanac od dva ili više (npr. dva, tri ili četiri) aminokiselinska ostataka koji su kovalentno vezani preko peptidnih veza, vežu za slobodne amino, hidroksi ili karboksilne grupe spojeva formule I. Aminokiselinski ostaci obuhvaćaju 20 aminokiselina koje se javljaju u prirodi, a koje se obično označavaju troslovnim oznakama, a također uključuju i 4-hidroksiprolin, hidroksilizin, demozin, izodemozin, 3-metilhistidin, norvlin, beta-alanin, gama-aminomaslačna kiselina, citrulin, homocistein, homoserin, ornitin i metionin-sulfon. Predlijekovi također uključuju i spojeve kod kojih su karbonati, karbamati, amidi i alkilni esteri kovalenno vezani za gore navedene supstituente formule I preko karbonila u ugljičnom bočnom lancu predlijeka.
Poželjni spojevi formule I uključuju one kod kojih R5 je (C2-C9)heterocikloalkil izborno supstituiran s jednom do tri grupe izabrane od deuterija, hidroksi, (C1-C6)alkil, halo, (C1-C6)alkoksi i grupe formule II.
Drugi poželjni spojevi formule I uključuju one kod kojih a je 0; b je 1; X je karbonil; c je 0; d je 0; e je 0; f je 0; i g je 0.
Drugi poželjni spojevi formule I uključuju one kod kojih a je 0; b je 1; X je karbonil; c je 0; d je 1; e je 0; f je 0; i g je 0.
Drugi poželjni spojevi formule I uključuju one kod kojih a je 0; b je 1; X je karbonil; c je 1; d je 0; e je 0; f je 0; i g je 0.
Drugi poželjni spojevi formule I uključuju one kod kojih a je 0; b je 1; X je -C(=N=cijano)-; c je 1; d je 0; e je 0; f je 0; i g je 0.
Drugi poželjni spojevi formule I uključuju one kod kojih a je 0; b je 0; c je 0; d je 0; e je 0; f je 0; g je 1; i Z je -C(O)-O-.
Drugi poželjni spojevi formule I uključuju one kod kojih a je 0; b je 1; X je S(O)n; n je 2; c je 0; d je 0; e je 0; f je 0; i g je 0.
Drugi poželjni spojevi formule I uključuju one kod kojih a je 0; b je 1; X je S(O)n; n je 2; c je 0; d je 2; e je 0; f je 1; g je 1; i Z je karbonil.
Drugi poželjni spojevi formule I uključuju one kod kojih a je 0; b je 1; X je S(O)n; n je 2; c je 0; d je 2; e je 0; f je 1; i g je 0.
Drugi poželjni spojevi formule I uključuju one kod kojih a je 0; b je 1; X je karbonil; c je 1; d je 0; e je 1; Y je S(O)n; n je 2; f je 0; i g je 0.
Drugi poželjni spojevi formule I uključuju one kod kojih a je 0; b je 1; X je S(O)n; n je 2; c je 1; d je 0; e je 0; f je 0; i g je 0.
Drugi poželjni spojevi formule I uključuju one kod kojih je a 1; b je 1; X je karbonil; c je 1; d je 0; e je 0; f je 0; i g je 0.
Drugi poželjni spojevi formule I uključuju one kod kojih a je 0; b je 1; X je S(O)n; c je 0; d je 1; e je 1; Y je S(O)n; n je 2; f je 0; i g je 0.
Drugi poželjni spojevi formule I uključuju one kod kojih a je 0; b je 1; X je S(O)n; c je 0; d je 1; e je 1; Y je S(O)n; n je 2; f je 1; i g je 0.
Drugi poželjni spojevi formule I uključuju one kod kojih a je 0; b je 1; X je kisik; c je 0; d je 1; e je 1; Y je S(O)n; n je 2; f je 1; i g je 0.
Drugi poželjni spojevi formule I uključuju one kod kojih a je 0; b je 1; X je kisik; c je 0; d je 1; e je 1; Y je S(O)n; n je 2; f je 0; i g je 0.
Drugi poželjni spojevi formule I uključuju one kod kojih a je 0; b je 1; X je karbonil; c je 1; d je 1; e je 1; Y je S(O)n; f je 0; i g je 0.
Drugi poželjni spojevi formule I uključuju one kod kojih a je 0; b je 1; X je karbonil; c je 1; d je 1; e je 1; Y je S(O)n; n je 2; f je 1; i g je 0.
Drugi poželjni spojevi formule I uključuju one kod kojih R12 je (C6-C10)aril ili (C2-C9)heteroaril, pri čemu je arilna ili heteroarilna grupa izborno supstituirana s jednom do četiri grupe koje čine vodik, halo, hidroksi, karboksi, trifluormetil, (C1-C6)alkil, (C1-C6)alkoksi, (C1-C6)alkil-CO-NH-, amino, amino(C1-C6)alkil, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, cijano, amino-CO-NH-, (C1-C6)alkilamino-CO-NH-, ((C1-C6)alkil)2-CO-NH-, (C5-C9)heteroarilamino-CO-NH-, (C1-C6)alkilsulfonil, (C1-C6)alkilsulfonilamino, (C6-C10)arilsulfonilamino, (C1-C6)alkilsulfonilamino i (C1-C6)alkoksi-CO-NH-.
Specifično poželjni spojevi formule I uključuju one gdje spomenuti je spoj izabran iz grupe koja se sastoji od:
4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-ilmetil}-benzensulfonamid;
(4-sulfamoil-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
(4-nitro-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-tetrazol-1-il-etanon;
(4-metilsulfamoil-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
(3-hidroksi-pirolidin-1-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon;
[2-({4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-amino)-tiazol-4-il]-octena kiselina;
Metil-(4-metil-5'-nitro-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-3-il)-(7H-pirolo[2,3-d]pirimidin-4-il)-amin;
5-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-okso-etil)-tiazolidin-2,4-dion;
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-tiazolidin-3-il-metanon;
Metil-[4-metil-1-(5-nitro-tiazol-2-il)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin;
Etilni ester [2-({4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-amino)-tiazol-4-il]-octene kiseline;
(4-metansulfonil-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
Tiazol-2-ilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
(4-cijano-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-pirolidin-1-il-metanon;
(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-amid furan-2-karboksilne kiseline;
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il} (tetrahidro-furan-3-il)-metanon;
Izoksazol-3-ilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
(6-cijano-piridin-3-il)amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-5'-karbonitril;
(4-metil-tiazol-2-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne grupe;
2-ciklopropil-1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-etanon;
Ciklopentil-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon;
(3-metil-izoksazol-4-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
[4-({4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-amino)-fenil]-octena kiselina;
[1-(5-amino-tiazol-2-il)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin;
(3-metil-izotiazol-5-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
3-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-ciklopentanon;
Benzil-metil-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline; i
Dimetilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
Ovaj izum također se odnosi i na farmaceutski pripravak za (a) liječenje ili sprječavanje poremećaja ili stanja izabranih od odbacivanja organskog presatka, ksenogenog presadka, lupusa, multiple skleroze, reumatoidnog artritisa, psorijaze, dijabetesa Tipa I i komplikacija nastalih kao posljedica dijabetesa, raka, astme, atopičnog dermatitisa, autoimunih poremećaja štitnjače, ulceroznog kolitisa, Crohnove bolesti, Alzheimerove bolesti, leukemije i drugih autoimunih poremećaja, ili (b) inhibiciju protein-kinaza ili Janus kinaze 3 (JAK3), kod sisavca, uključujući i čovjeka, koji pripravak sadrži količinu spoja formule I ili njegove farmaceutski prihvatljive soli, koja je djelotvorna kod takvih poremećaja ili stanja, i farmaceutski prihvatljivu podlogu.
Ovaj izum se također odnosi na i postupak inhibicije proteinske tirozin-kinaza ili Janus kinaze 3 (JAK3), kod sisavca, uključujući i čovjeka, koji postupak se sastoji u primjeni na spomenutom sisavcu djelotvorne količine spoja formule I ili njegove farmaceutski prihvatljive soli.
Ovaj izum se također odnosi i na postupak liječenja ili sprječavanja poremećaja ili stanja izabranih od odbacivanja organskog presatka, ksenogenog presadka, lupusa, multiple skleroze, reumatoidnog artritisa, psorijaze, dijabetesa Tipa I i komplikacija nastalih kao posljedica dijabetesa, raka, astme, atopičnog dermatitisa, autoimunih poremećaja štitnjače, ulceroznog kolitisa, Crohnove bolesti, Alzheimerove bolesti, leukemije i drugih autoimunih poremećaja, kod sisavca, uključujući i čovjeka, koji postupak se sastoji u primjeni na spomenutom sisavcu količine spoja formule I ili njegove farmaceutski prihvatljive soli, koja je djelotvorna u liječenju takvih stanja.
Detaljni opis izuma
Reakcijske sheme koje slijede ilustriraju dobivanje spojeva ovog izuma. R2, R3, R4 i R5 u reakcijskim shemama i u diskusiji koja slijedi, ukoliko nije istaknuto drugačije, definirano su kao u prethodnom tekstu.
Postupak dobivanja A
[image]
Postupak dobivanja B
[image]
Postupak dobivanja C
[image]
Shema 1
[image]
Shema 2
[image]
Shema 3
[image]
U reakciji 1 Postupka dobivanja A, 4-klorpirolo[2,3-d]pirimidinski spoj formule XXI, gdje R je vodik ili zaštitna grupa kao što je benzensulfonil ili benzil, prevodi se u 4-klor-5-halopirolo[2,3-d]pirimidinski spoj formule XX, gdje Y je klor, brom ili jod, reakcijom spoja XXI sa N-klorsukcinimidom, N-bromsukcinimidom ili N-jodsukcinimidom. Reakcijska smjesa zagrijava se na refluksu, u kloroformu, tijekom vremenskog perioda od oko 1 sata do oko 3 sata, poželjno oko 1 sata. Alternativno, u reakciji 1 Postupka dobivanja A, 4-klorpirolo[2,3-d]pirimidinski formule XXI, gdje R je vodik, prevodi se u odgovarajući 4-klor-5-nitropirolo[2,3-d]pirimidinski formule XX, gdje Y je nitro, reakcijom spoja XXI sa dušičnom kiselinom u sumpornoj kiselini na temperaturi od oko -10 °C do oko 10 °C, poželjno oko 0 °C, tijekom vremenskog perioda od oko 5 minuta do oko 15 minuta, poželjno oko10 minuta. Spoj formule XXI, gdje Y je nitro, prevodi se u odgovarajući 4-klor-5-aminopirolo[2,3-d]pirimidinski formule XX, gdje Y je amino, reakcijom spoja XXI pod različitim uvjetima dobro poznatim stručnjacima u ovom području tehnike, kao što su hidrogenoliza uz paladij ili kositar(IV)klorid i klorovodična kiselina.
U reakciji 2 Postupka dobivanja A, 4-klor-5-halopirolo[2,3-d]pirimidinski spoj formule XX, gdje R je vodik, prevodi se u odgovarajući spoj formule XIX, gdje R2 je (C1-C6)alkil ili benzil, obradom spoja XX sa N-butillitijem, na temperaturi od oko -78 °C, i reakcijom tako dobivenog dianionskog međuprodukta sa alkil-halogenidom ili benzil-halogenidom na temperaturi od oko -78 °C do sobne temperature, poželjno na sobnoj temperaturi. Alternativno, tako dobiveni dianion reagira sa molekulskim kisikom kako bi se formirao odgovarajući 4-klor-5-hidroksipirolo[2,3-d]pirimidinski spoj formule XIX, gdje R2 je hidroksi. Spoj formule XX, gdje Y je brom ili jod i R je benzensulfonat, prevodi se u spoj formule XIX, gdje R2 je (C6-C12)aril ili vinil, obradom spoja XX sa N-butillitijem, na temperaturi od oko -78 °C, nakon čega slijedi dodavanje cink-klorida, na temperaturi od oko -78 °C. Odgovarajući tako dobiveni organo-cinkov međuprodukt nakon toga reagira sa aril-jodidom ili vinil-jodidom u prisustvu katalitičke količine paladija. Reakcijska smjesa miješa se na temperaturi od oko 50 °C do oko 80 °C, poželjno oko 70 °C, tijekom vremenskog perioda od oko 1 sata do 3 sata, poželjno oko 1 sata.
U reakciji 3 Postupka dobivanja A, spoj formule XIX prevodi se u odgovarajući spoj formule XVI, obradom spoja XIX sa N-butillitijem, litij-diizopropilaminom ili natrij-hidridom, na temperaturi od oko -78 °C, u prisustvu polarnog neprotonskog otapala, kao što je tetrahidrofuran. Tako dobiveni anionski međuprodukt dalje reagira sa (a) alkil-halogenidom ili benzil-halogenidom, na temperaturi od oko -78 °C do sobne temperature, poželjno -78 °C, u slučaju kada R3 je alkil ili benzil; (b) aldehidom ili ketonom, na temperaturi od oko -78 °C do sobne temperature, poželjno -78 °C, u slučaju kada R3 je alkoksi; i (c) sa cink-kloridom, na temperaturi od oko -78 °C do sobne temperature, poželjno -78 °C, a odgovarajući tako dobiveni organo-cinkov međuprodukt nakon toga reagira sa aril-jodidom ili vinil-jodidom u prisustvu katalitičke količine paladija. Dobivena reakcijska smjesa miješa se na temperaturi od oko 50 °C do oko 80 °C, poželjno oko 70 °C, tijekom vremenskog perioda od oko 1 sata do 3 sata, poželjno oko 1 sata. Alternativno, tako dobiveni anion reagira sa molekulskim kisikom kako bi se formirao odgovarajući 4-klor-6-hidroksipirolo[2,3-d]pirimidinski spoj formule XVI, gdje R3 je hidroksi.
U reakciji 1 Postupka dobivanja B, 4-klorpirolo[2,3-d]pirimidinski spoj formule XXI prevodi se u odgovarajući spoj formule XXII, prema postupku analognom onom opisanom prethodno u reakciji 3 Postupka dobivanja A.
U reakciji 2 Postupka dobivanja B, spoj formule XXII prevodi se u odgovarajući spoj formule XVI, prema postupcima analognim onima opisanim prethodno u reakcijama 1 i 2 Postupka dobivanja A.
U reakciji 1 Postupka dobivanja C, 4-metilpiridinski spoj formule XXXI prevodi se u odgovarajući spoj formule XXX prvo alkiliranjem spoja XXXI sa benzil-kloridom u prisustvu polarnog neprotonskog otapala, kao što je aceton. Reakcijska smjesa miješa se na temperaturi od oko 40 °C do oko 80 °C tijekom vremenskog perioda od oko 4 sata do oko 24 sata. Tako dobiveni piridinijski međuprodukt se zatim reducira pomoću redukcijskog sredstva kao što je natrij-bor-hidrid, u prisustvu polarnog protonskog otapala kao što je metanol, etanol, voda i njihove smjese. Reakcija se miješa na temperaturi od oko 0 °C do oko sobne temperature, tijekom vremenskog perioda od oko 18 sati do 24 sata.
U reakciji 2 Postupka dobivanja C, spoj formule XXX prevodi se u odgovarajući spoj formule XXIX, obradom spoja XXX sa bor-trifluorid eteratom u prisustvu redukcijskog sredstva i neprotonskog otapala, kao što je tetrahidrofuran. Reakcijska smjesa miješa se na temperaturi od oko 0 °C do sobne temperature, tijekom vremenskog perioda od oko 1 sata do oko 3 sata. Tako dobiveni međuproduktni kompleks se zatim zaluži pomoću vodene otopine natrij-hidroksida, nakon čega se obradi sa oksidansom kao što je vodik-peroksid ili Oxone®, na temperaturi od oko 0 °C do sobne temperature, tijekom vremenskog perioda od oko 12 sati do oko 24 sata.
U reakciji 3 Postupka dobivanja C, spoj formule XXIX obradi se sa oksidansom, kao što je krom-oksid ili dimetil-sulfoksid, oksalil-klorid ili SO3-piridinski kompleks, tijekom vremenskog perioda od oko 1 sata do 3 sata, na sobnoj temperaturi. Tako dobiveni međuproduktni keton se zatim obradi sa aminom (R4-NH2) u prisustvu kiseline, kao što je octena kiselina, na sobnoj temperaturi, tijekom vremenskog perioda od oko 2 do oko 24 sata, u organskom otapalu kao što je metanol, etanol ili tetrahidrofuran. Tako dobiveni odgovarajući iminski međuprodukt se nakon toga obradi sa redukcijskim sredstvom, kao što je natrij-bor-hidrid ili natrij-cijanobor-hidrid ili natrij-triacetoksibor-hidrid, na sobnoj temperaturi, tijekom vremenskog perioda od oko 2 sata do oko 24 sata.
U reakciji 1 Sheme 1, 4-klorpirolo[2,3-d]pirimidinski spoj formule XVII prevodi se u odgovarajući spoj formule XVI, gdje R je benzensulfonil ili benzil, obradom spoja XVII sa benzensulfonil-kloridom, benzil-kloridom ili benzil-bromidom, u prisustvu baze kao što je natrij-hidrid ili kalij-karbonat, i u prisustvu polarnog neprotonskog otapala kao što je dimetilformamid ili tetrahidrofuran. Reakcijska smjesa miješa se na temperaturi od oko 0 °C do oko 70 °C, poželjno oko 30 °C, tijekom vremenskog perioda od oko 1 sata do oko 3 sata, poželjno oko 2 sata.
U reakciji 2 Sheme 1, 4-klorpirolo[2,3-d]pirimidinski spoj formule XVI prevodi se u odgovarajući 4-aminopirolo[2,3-d]pirimidinski spoj formule XV, kondenzacijom spoja XVI sa aminom formule NHR4R5. Reakcija se izvodi u alkoholnom otapalu kao što su tert-butanol, metanol ili etanol, ili neko drugo organsko otapalo visokog vrelišta kao što je dimetilformamid, trietilamin, 1,4-dioksan ili 1,2-dikloretan, na temperaturi od oko 60 °C do oko 120 °C, poželjno oko 80 °C. Tipična reakcijska vremena su oko 2 sata do oko 48 sati, poželjno oko 16 sati. Kada R5 je heterocikloalkilna grupa koja sadrži dušik, svaki dušik mora biti zaštićen zaštitnom grupom, kao što je benzil. Uklanjanje R5 zaštitne grupe izvodi se pod uvjetima koji odgovaraju toj korištenoj određenoj zaštitnoj grupi i koji neće utjecati na R zaštitnu grupu na pirolo[2,3-d]pirimidinskom prstenu. Uklanjanje R5 zaštitne grupe kada je to benzil, izvodi se u alkoholnom otapalu kao što je etanol, u prisustvu vodika, i katalizatora kao što je paladij-hidroksid na ugljiku. Tako formirana R5 heterociklička grupa koja sadrži dušik može dalje reagirati sa velikim brojem različitih elektrofila formule II. Za formiranje uree, elektrofili formule II kao što su izocijanati, karbamati i karbamoil-kloridi reagiraju sa R5 dušikom heteroalkilne grupe u otapalu kao što je acetonitril ili dimetilformamid, u prisustvu baze kao što je natrij-karbonat ili kalij-karbonat, na temperaturi od oko 20 °C do oko 100 °C, tijekom vremenskog perioda od oko 24 sata do oko 72 sata. Za formiranje amida i sulfonamida, elektrofili formule II kao što su acil-kloridi i sulfonil-kloridi, reagiraju sa R5 dušikom heteroalkilne grupe u otapalu kao što je metilen-klorid, u prisustvu baze kao što je piridin, na sobnoj temperaturi tijekom vremenskog perioda od oko 12 sati do oko 24 sata. Formiranje amida također se može izvesti i reakcijom karboksilne kiseline sa heteroalkilnom grupom u prisustvu karbodiimida kao što je 1-(3-dimetilaminopropil)-3-etilkarbodiimid, u otapalu kao što je metilen-klorid na temperaturi okoline, tijekom 12-24 sata. Za formiranje alkila, elektrofili formule II kao što su �,�-nezasićeni amidi, kiseline, nitrili, esteri i �-halo amidi, reagiraju sa R5 dušikom heteroalkilne grupe, u otapalu kao što je metanol na sobnoj temperaturi, tijekom vremenskog perioda od oko 12 sati do oko 18 sati. Formiranje alkila također se može izvesti i reakcijom aldehida sa hetroalkilnom grupom, u prisustvu redukcijskog sredstva kao što je natrij-cijanobor-hidrid, u otapalu kao što je metanol na temperaturi okoline, tijekom vremenskog perioda od oko 12 sati do oko 18 sati.
U reakciji 3 Sheme 1, uklanjanje zaštitne grupe iz spoja formule XV gdje R je benzensulfonil, kako bi se dobilo odgovarajući spoj formule I, izvodi se obradom spoja XV sa alkalnom bazom, kao što je natrij-hidroksid ili kalij-hidroksid, u alkoholnom otapalu kao što je metanol ili etanol, ili u smjesi otapala kao što su alkohol/tetrahidrofuran ili alkohol/voda. Reakcija se izvodi na sobnoj temperaturi, tijekom vremenskog perioda od oko 15 minuta do oko 1 sata, poželjno 30 minuta. Uklanjanje zaštitne grupe sa spoja formule XV, gdje R je benzil, izvodi se obradom spoja XV sa natrijem, u amonijaku na temperaturi od oko -78 °C, tijekom vremenskog perioda od oko 15 minuta do oko 1 sata.
U reakciji 1 Sheme 2, 4-klorpirolo[2,3-d]pirimidinski spoj formule XX prevodi se u odgovarajući 4-aminopirolo[2,3-d]pirimidinski spoj formule XXIV, prema postupku analognom onom opisanom prethodno u reakciji 2 Sheme 1.
U reakciji 2 Sheme 2, 4-amino-5-halopirolo[2,3-d]pirimidinski spoj formule XXIV, gdje R je benzensulfonat i Z je brom ili jod, prevodi se u odgovarajući spoj formule XXIII reakcijom spoja XXIV sa: (a) arilbornom kiselinom, u slučaju kada R2 je aril, u neprotonskom otapalu, kao što je tetrahidrofuran ili dioksan, u prisustvu katalitičke količine paladija(0), na temperaturi od oko 50 °C do oko 100 °C, poželjno oko 70 °C, tijekom vremenskog perioda od oko 2 sata do oko 48 sati, poželjno oko 12 sati; (b) alkinima, u slučaju kada R2 je alkinil, u prisustvu katalitičke količine bakar(I)-jodida i paladija(0), i polarnog otapala kao što je dimetilformamid, na sobnoj temperaturi, tijekom vremenskog perioda od oko 1 sata do oko 5 sati, poželjno oko 3 sata; i (c) alkenima ili stirenima, u slučaju kada R2 je vinil ili stirenil, u prisustvu katalitičke količine paladija u dimetilformamidu, dioksanu ili tetrahidrofuranu, na temperaturi od oko 2 sata do oko 48 sati, poželjno oko 48 sati.
U reakciji 3 Sheme 2, spoj formule XXIII prevodi se u odgovarajući spoj formule XV, prema postupku analognom onom opisanom prethodno u reakciji 3 Postupka dobivanja A.
U reakciji 1 Sheme 3, spoj formule XVII prevodi se u odgovarajući spoj formule I, prema postupku analognom onom opisanom prethodno u reakciji 2 Sheme 1.
Spojevi ovog izuma koji su bazične prirode mogu tvoriti mnoštvo soli sa različitim neorganskim i organskim kiselinama. Iako takve soli moraju biti farmaceutski prihvatljive za primjenu na životinjama, u praksi je često poželjno prvo izolirati spoj ovog izuma iz reakcijske smjese kao farmaceutski neprihvatljivu sol, koju se zatim obradom sa alkalnim reagensom jednostavno prevede nazad do slobodne baze spoja, koju se na kraju prevodi u farmaceutski prihvatljivu kiselu sol. Kisele soli bazičnih spojeva ovog izuma može se lako pripremiti, obradom bazičnog spoja sa suštinski istom količinom izabrane mineralne ili organske kiseline, u vodenom otapalu ili u pogodnom organskom otapalu, kao što je metanol ili etanol. Pažljivim uparavanjem otapala lako se dobiva željena kruta sol. Željena kisela sol također se može istaložiti iz otopine slobodne baze u organskom otapalu, dodavanjem otopini odgovarajuće mineralne ili organske kiseline.
Spojevi ovog izuma koji su kisele prirode, sposobni su da tvoriti bazične soli sa različitim farmakološki prihvatljivim kationima. Primjeri takvih soli uključuju soli alkalnih i zemnoalkalnih metala, a naročito soli natrija i kalija. Sve ove soli pripremaju se korištenjem konvencionalnih tehnika. Kemijske baze koje se koriste kao reagensi za pripremanje farmaceutski prihvatljivih bazničnih soli ovog izuma su one koje tvore netoksične bazične soli sa kiselim spojevima ovog izuma. Takve netoksične bazične soli uključuju one dobivene od farmakološki prihvatljivih kationa takvih kao što su natrij, kalij, kalcij i magnezij, itd. Ove soli mogu se lako pripremiti obradom odgovarajućih kiselih spojeva sa vodenom otopinom koja sadrži željene farmakološki prihvatljive katione, nakon čega slijedi uparavanje dobivene otopine do suhog, poželjno pod sniženim tlakom. Alternativno, one se također mogu pripremiti miješanjem otopina kiselih spojeva u nižim alkanolima s alkoksidom željenog alkalnog metala, nakon čega slijedi uparavanje dobivene otopine do suhog, na isti način kao prethodno. U svim slučajevima poželjno je koristiti stehiometrijske količine reagenasa, kako bi se osigurala kompletnost reakcije i maksimizirao prinos željenog konačnog produkta.
Pripravci ovog izuma mogu se formulirati na konvencionalan način korištenjem jedne ili više farmaceutski prihvatljive podloge. U skladu sa time, aktivni spojevi ovog izuma mogu se formulirati za oralnu, intranazalnu, parenteralnu (npr., intravenoznu, intramuskularnu ili subkutanu) ili rektalnu primjenu, ili u obliku koji pogodan za primjenu inhalacijom ili insuflacijom. Aktivni spojevi izuma također se mogu formulirati i za produženu isporuku.
Farmaceutski pripravci namijenjeni oralnoj primjeni mogu biti u obliku, na primjer, tableta ili kapsula, koje se pripremaju konvencionalnim načinom sa farmaceutski prihvatljivim pomoćnim sredstvima kao što su vezivna sredstva (npr. preželatinizirani kukuruzni škrob, polivinilpirolidon ili hidroksipropil-metilceluloza); sredstva za punjenje (npr. laktoza, mikrokristalna celuloza ili kalcij-fosfat); sredstva za podmazivanje (npr. magnezij-stearat, talk ili silicij-dioksid); sredstva za raspadanje (npr. krumpirov škrob ili natrijev škrob glikolat); ili sredstva za vlaženje (npr., natrij-lauril-sulfat). Tablete mogu biti obložene, korištenjem postupaka dobro poznatih u tehnici. Tekući pripravci namijenjeni oralnoj primjeni mogu imati oblik, na primjer, otopina, sirupa ili suspenzija, ili mogu biti suhi produkti koji se prije upotrebe konstituiraju s vodom ili s nekim drugim pogodnim vehikulumom. Takvi tekući pripravci mogu se pripremiti na konvencionalan način sa farmaceutski prihvatljivim aditivima kao što su suspendirajuća sredstva (npr. sorbitol sirup, metil-celuloza ili hidrogenizirane jestive masti); emulgirajuća sredstva (npr. lecitin ili arapska guma); nevodeni vehikulumi (npr. bademovo ulje, uljni esteri ili etil alkohol); i konzervansi (npr., metil ili propil p-hidroksibenzoati ili sorbinska kiselina).
Pripravci namijenjeni bukalnoj primjeni mogu biti u obliku tableta ili lozengi formuliranih na konvencionalan način.
Aktivni spojevi izuma mogu se formulirati za parenteralnu primjenu putem injekcija, uključujući upotrebu konvencionalnih tehnika kateterizacije ili infuzije. Formulacije za injekcije mogu se pripremiti u obliku pojedinačnih doza, npr. u ampulama ili višedoznim spremnicima, uz dodatak konzervansa. Takvi pripravci mogu biti u oblicima kao što su suspenzije, otopine ili emulzije u uljastim ili vodenim nosačima, a mogu sadržati i formulacijska sredstva kao što su suspendirajuća, stabilizujuća i/ili disperzirajuća sredstva. Alternativno, aktivni sastojak može biti u obliku praška koji se prije upotrebe rekonstituira sa pogodnim nosačem, npr. sterilnom vodom u kojoj nema pirogena.
Aktivni spojevi izuma također se mogu formulirati u rektalne pripravke kao što su supozitorije ili retencijske klizme, npr. tako do sadrže konvencionalne supozitorijske podloge kao što su kakao maslac ili drugi gliceridi.
Za intranazalnu primjenu ili primjenu inhalacijom, aktivni spojevi izuma se prikladno isporučuju u obliku otopina ili suspenzija iz spremnika s raspršivačkom pumpicom koju pacijent stiska ili pumpa, ili predajom aerosolnog spreja iz spremnika pod tlakom ili iz nebulizatora, uz upotrebu pogodnog pogonskog plina, npr. diklordifluormetana, triklorfluormetana, diklortetrafluoretana, ugljičnog dioksida ili nekog drugog prikladnog plina. U slučaju aerosola pod tlakom, oblik doziranja se može opremiti ventilom koji će ispuštati odmjerenu količinu. Spremnik pod tlakom ili nebulizator mogu sadržati otopinu ili suspenziju aktivnog spoja. Kapsule i ulošci (izrađeni, na primjer, od želatine) za upotrebu u inhalatoru ili insuflatoru mogu se formulirati tako da sadrže praškastu smjesu spoja izuma s pogodnom praškastom podlogom, kao što je laktoza ili škrob.
Predložena doza aktivnih spojeva izuma za oralnu, parenteralnu ili bukalnu primjenu namijenjena liječenju prethodno navedenih stanja (npr. reumatoidni artritis) kod prosječnog odraslog čovjeka iznosi 0,1 do 1.000 mg aktivnog sastojka po jediničnoj dozi koja se može primijeniti, na primjer, 1 do 4 puta dnevno.
Formulacije aerosola namijenjene liječenju prethodno navedenih stanja (npr. astme) kod prosječnog odraslog čovjeka poželjno su pripremljene tako da svaka odmjerena doza ili "dašak" aerosola sadrži 20 µg do 1.000 µg spoja izuma. Ukupna dnevna doza aerosola biti će u rasponu od 0,1 mg do 1000 mg. Primjena može biti nekoliko puta na dan, na primjer, 2, 3, 4 ili 8 puta, dajući primjerice 1, 2 ili 3 doze svaki put.
Spojevi formule (I) primjenjuju se u farmaceutski prihvatljivom obliku bilo samostalno, ili u kombinaciji sa jednim ili više dodatnih sredstava koja moduliraju imunosni sustav sisavaca, ili sa antiinflamatornim sredstvima, i ta sredstva mogu uključivati, ali nisu ograničena na ciklosporin A (npr. Sandimmune® ili Neoral®, rapamicin, FK-506 (Takrolimus), leflunomid, deoksispergvalin, mikofenolat (npr. Callcept®, azatioprin (npr. Imuran®), daklizumab (npr. Zenapax®), OKT3 (npr. Orthocolone®), AtGam, aspirin, aktaminofen, ibuprofen, naproksen, piroksikam i antiinflamatorni steroidi (npr. prednizolon ili deksametazon); a takva sredstva se mogu davati kao dio istih ili različitih oblika doziranja, pomoću istih ili različitih načina primjene, te po istim ili različitim rasporedima primjene, u skladu sa standardnom farmaceutskom praksom.
FK506 (Tacrolimus) daje se oralno u dozi od 0,10-0,15 mg/kg tjelesne težine, svakih 12 sati, unutar prvih 48 sati postoperativno. Doza se prati preko razine Tacrolimus-a u serumu.
Ciklosporin A (Sandimmune oralna ili intravenozna formulacija, ili Neoral® oralna otopina ili kapsule) daje se oralno u dozi od 5 mg/kg tjelesne težine, svakih 12 sati, unutar 48 sati postoperativno. Doza se provjerava preko razine Ciklosporina A u krvi.
Aktivna sredstva mogu se formulirati za produženu isporuku korištenjem postupaka koji su dobro poznati stručnjacima u ovom području tehnike. Primjeri takvih formulacija mogu se naći u US patentima 3,538,214; 4,060,598; 4,173,626; 3,119,742 i 3,492,397.
Sposobnost spojeva formule I ili njihovih farmaceutski prihvatljivih soli da inhibiraju Janus kinazu 3, i da prema tome pokažu svoju djelotvornost u liječenju poremećaja ili stanja za koje je karakteristična Janus kinaza 3 prikazana je slijedećim in vitro analizama.
Biološka analiza
Enzimatska analiza JAK3 (JH1:GST)
Analiza JAK3 kinaze koristi protein koji je eksprimiran u SF9 stanicama inficiranim bakulovirusom (fuzijski protein GST i katalitički domena humanog JAK3), koji je pročišćen afinitetnom kromatografijom na glutation-sepaharozi. Substrat za reakciju je poli-glutaminska kiselina-tirozin (PGT (4:1), Sigma, kataloški broj P0275). Njime su obložene Nunc Maxi Sorp pločice u koncentraciji od 100 µg/ml tijekom noći na 37 °C. Jutro poslije oblaganja, pločice su ispirane tri puta, a JAK3 je dodat u jažice koje sadrže 100 µl pufera za kinazu (50 mM HEPES, pH 7,3, 125 mM NaCl, 24 mM MgCl2) + 0,2 uM ATP + 1 mM Na ortovanadata.) Reakcija je trajala 30 minuta na sobnoj temperaturi, nakon čega su pločice ispirane još tri puta. Razina fosforiliranog tirozina u nekoj jažici određivana je standardnom ELISA analizom korištenjem anti-fosfotirozin protutijela (ICN PY20, kataloški broj 69-151-1).
Inhibicija proliferacije humanih T-limfoblasta ovisne o IL-2
Ovaj test mjeri inhibitorni efekt spojeva na proliferaciju T-limfoblasta ovisnu o IL-2 in vitro. Budući da prenošenje signala peko IL-2 receptora zahtjeva JAK3, aktivni stanični inhibitori JAK-3 trebali bi inhibirati proliferaciju T-limfoblasta ovisnu o IL-2.
Stanice za ovu analizu izolirane su iz svježe ljudske krvi. Poslije odvajanja mononuklearnih stanica korištenjem Accuspin System-Histopaque-1077 (Sigma, kataloški broj A7054), primarne humane T-stanice su izolirane negativnom selekcijom korištenjem Lympho-Kwik T (One Lambda, Inc., kataloški broj LK-50T). T-stanice su uzgojene na 1-2 × 106/ml u mediji (RPMI + 10 % fetalni teleći serum inaktiviran toplinom (Hyclone, kataloški broj A-1111-L) + 1 % penicilin/streptomicin (Gibco)), i pobuđene na proliferaciju dodavanjem 10 ug/ml PHA (Murex Diagnosis, kataloški broj HA 16). Poslije 3 dana na 37 °C u 5 % CO2, stanice su tri puta ispirane u mediji, resuspendirane do gustoće od 1-2 × 106 stanica/ml u mediji uz dodatak 100 jedinica/ml humanog rekombinantnog IL-2 (R&D Systems, kataloški broj202-IL). Poslije 1 tjedna stanice ovise o IL-2, a mogu se održavati do 3 tjedna hranjenjem dva puta tjedno sa istim volumenima medije + 100 jedinica/ml IL-2.
Da bi analizirali sposobnost testiranih spojeva da inhibiraju proliferaciju T-stanica ovisnu o IL-2, stanice ovisne o IL-2 ispirane su tri puta, resuspendirane u mediju i zatim stavljene (50,000 stanica/jažica/0,1 ml) u mikrotitarsku ploču s 96-jažica ravnog dna (Falcon, kataloški broj 353075). Iz 10 mM matične otopine testiranog spoja u DMSO, serijske dvostruke otopine spoja dodate su u triplikatu u jažice počevši od 10 uM. Poslije 1 sata, svakoj testiranoj jažici dodaje se 10 jedinica/ml IL-2. Pločice su zatim inkubirane na 37 °C, 5 % CO2 tijekom 72 sata. Nakon toga pločice se obilježava sa 3H-timidinom (0,5 uCi/jažica) (NEN, kataloški broj NET-027A) i inkubira još 18 sati. Kulture s ploča su zatim prikupljene pomoću uređajem za prikupljanje s ploča od 96-jažica, nakon čega je određena količina 3H-timidina ugrađenog u proliferirajuće stanice brojanjem na Packard Top Count scincilacijskom brojaču. Podaci su analizirani pomoću grafičkog prikaza % infibicije proliferacije u ovisnosti o koncentraciji testiranog spoja. Iz ovog grafikona određena je vrijednost IC50 (uM).
Primjeri koji slijede ilustriraju dobivanje spojeva ovog izuma, pri čemu izum nije ograničen na tamo date detalje. Korišteni su komercijalni reagensi bez dodatnog pročišćavanja. THF se odnosi na tetrahidrofuran. DMF se odnosi na N,N-dimetilformamid. Spektri masa niske rezolucije LRMS (Low Resolution Mass Spectra) snimljeni su, bilo pomoću Hewlett Packard 5989® korištenjem kemijske ionizacije (amonij), ili pomoću Fisons (ili Micro Mass) Atmospheric Pressure Chemical Ionization (APCI) platformi koja koristi 50/50 smjesu acetonitrila/vode uz 0,1 % mravlje kiseline kao ionizacijskog sredstva. Sobna temperatura odnosi se na 20-25 °C.
Primjer 1
Furan-2-il-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
Postupak A 1-benzil-4-metil-piridinijklorid
U miješanu otopinu 4-metilpiridina (26 ml/0,268 mola) u 70 ml acetona dodaje se 31 ml (0,268 mola) benzil-klorida. Dobivena smjesa miješa se na 50 °C 18 sati. Poslije hlađenja na sobnoj temperaturi, reakcija se filtrira, ispire acetonom i suši pod sniženim tlakom, dajući 38 g naslovljenog spoja. Fltrat se koncentrira pod sniženim tlakom, dajući dodatnih 5,6 grama naslovljenog spoja (ukupni prinos od 74 %).
LRMS: 184.
Postupak B 1-benzil-4-metil-1,2,3,6-tetrahidro-piridin
U miješanu otopinu produkta iz Postupka A (38 grama/0,171 mola) koja je otopljena u 140 ml 10:1 etanola/vode na 0 °C dodaje se 16 grama (0,427 mola) natrij-bor-hidrida u obrocima tijekom 25 minuta. Dobivena smjesa miješa se 18 sati na sobnoj temperaturi, nakon čega se reakcija ugasi dodavanjem 100 ml vode. Reakcijska smjesa se filtrira, filterski kolač ispire se vodom i etil-acetatom, a zajedno prikupljeni filtrati koncentriraju se pod sniženim tlakom kako bi se uklonile organske tvari. Ostatak se razblaži vodom (100 ml) i ekstrahira tri puta s 150 ml etil-acetata. Spojeni etil-acetatni ekstrakti suše se preko Na2SO4 i koncentriraju do suhog in vacuo, dajući 32 grama (100 %) naslovljenog spoja u obliku žutog ulja.
LRMS: 188 (M+1).
Postupak C 1-benzil-4-metil-piperidin-3-ol
U otopinu produkta iz Postupka B (72,45 grama/0,387 mola) koja je otopljena u 240 ml THF dodaje se 21,4 grama NaBH4 i smjesa se ohladi do 0 °C. Nakon toga u kapima se dodaje otopina bor-nitrifluorid eterata (109,4 ml otopljenih u 200 ml THF) tijekom 1,5 sata. Reakcijska smjesa se zatim zagrijava do sobne temperature i miješa 2 sata. Reakcija se ponovo ohladi do 0 °C, nakon čega se u kapima dodaje 29,3 ml vode tijekom 15 minuta, a zatim se u kapima dodaje 2N natrij-hidroksid (97,5 ml) tijekom 20 minuta. Dobivena smjesa miješa se na 0 °C tijekom 40 minuta, nakon čega se zagrijava do sobne temperature. Reakcijskoj smjesi dodaje se vodik-peroksid (30 %) (97,5 ml) u kapima tako da temperatura ne pređe 50 °C (približno 30 minuta). Kada se završi sa dodavanjem, reakcijska smjesa se miješan 10 minuta i zatim ohladi do 0 °C. Dodaje se koncentrirana klorovodična kiselina (97,5 ml) tijekom 5 minuta, nakon čega se reakcijska smjesa reducira do jedne trećine njenog volumena u vakuumu, a pH se podesi na 9-10 pomoću 6N natrij-hidroksida (vodena otopina). Dobivena smjesa tri puta se ekstrahira eterom, a zajedno prikupljeni eterski slojevi suše se preko MgSO4 i uparuju do suhog in vacuo, dajući 65,32 grama (79 %) naslovljenog spoja u obliku žutog ulja.
LRMS: 206,1 (M+1).
Alternativan postupak: U otopinu produkta iz Postupka B (18,7 grama/0,1 mola) u THF (150 ml) dodaje se NaBH4 (6,5 grama/0,170 mola) na sobnoj temperaturi pod atmosferom N2. Talog se ohladi do 0 °C, nakon čega se polako dodaje BF3 • OEt2 (15 ml, 16,8 grama/0,118 mola) u THF (25 ml) preko lijevka za dodavanje. Dodavanje mora biti dovoljno sporo kako bi se temperatura reakcijske smjese zadržala ispod 0 °C. Nakon završetka dodavanja reakcijska smjesa se miješa na 0 °C tijekom 1 sata, a poslije toga na sobnoj temperaturi tijekom 1,5 sata. Reakcija se ponovo ohladi do 0 °C, nakon čega se sporo dodaje voda (50 ml) kako bi se uništio višak bora. Reakcijska smjesa miješa se na sobnoj temperaturi tijekom 2 sata, poslije čega slijedi dodavanje Oxone® (110 grama/0,343 mola) u vodi (500 ml) na 0 °C. Reakcijska smjesa se ostavi da se zagrije do sobne temperature, nakon čega se miješa tijekom noći. Reakcija se gasi dodavanjem krutog NaHSO3 sve dok se ne uništi višak oksidansa (KI/škrobni testni papir). pH reakcijske smjese iznosi 1-2. Reakcijska smjesa se zatim tri puta ekstrahira sa 50 ml etil-acetata, a vodeni sloj se dovodi do pH 12 dodatkom 6N natrij-hidroksida, nakon čega se ekstrahira etil-acetatom (četiri puta sa 100 ml). Organski sloj ispire se slanom vodom, suši preko Na2SO4 i koncentrira u vakuumu, dajući 19,0 grama (92 %) naslovljenog spoja u obliku ulja.
LRMS: 206,1 (M+1).
Postupak D Sol 1-benzil-4-metil-piperidin-3-ol-toluen-4-sulfonska kiseline
U miješanu otopinu produkta iz Postupka C (65,32 grama/0,318 mola) koja je otopljena u 175 ml acetona i ohlađena do 0 °C dodaje se otopina monohidrat paratoluensulfonske kiseline u 350 ml acetona (u kapima) tijekom 2 sata, a dobivena smjesa miješa se na 0 °C tijekom 1,5 sat. Talog se filtrira, a filterski kolač ispire se s 90 ml diizopropil-etera. Kruti produkt se zatim osuši u vakuumu, dajući 58,55 grama (100 %) naslovljenog spoja u obliku bijele krutine.
LRMS: 378,5 (M+1).
Postupak E 1-benzil-4-metil-piperidin-3-on
U otopinu produkta iz Postupka D (9,8 grama/0,026 mola) i 31,7 ml diizopropiletilamina otopljenog u 250 ml diklormetana i ohlađenog do 0 °C, dodaje se (u kapima) 12,4 grama SO3-piridinskog kompleksa otopljenog u 153 ml dimetilsulfoksida tijekom 40 minuta. Reakcija se zatim miješa 1,5 sat na sobnoj temperaturi, nakon čega se ugasi dodavanjem 200 ml zasićenog NaHCO3 (vodena otopina). Diklormetan se uklanja u vakuumu, a preostali vodeni ostatak četiri puta se ekstrahira diizopropiletrom (150 ml). Zajedno prikupljeni eterski slojevi ispiru se četiri puta vodom (100 ml), suše preko Na2SO4 i koncentriraju do suhog u vakuumu, dajući 3,81 grama (72,97 %) naslovljenog spoja u obliku žutog ulja.
LRMS: 204 (M+1).
Postupak F (1-benzil-4-metil-piperidin-3-il)-metil-amin
U miješanu otopinu produkta iz Postupka E (3,81 grama/0,019 mola) i 38 ml 2,0 M metilamina u THF dodaje se 2,2 ml octene kiseline, a dobivena smjesa miješa se na sobnoj temperaturi 1,5 sat. Dodaje se natrij-triacetoksi-borhidrid (NaB(OAc)3H) (7,94 grama/0,038 mola) kao krutina, a dobivena smjesa miješa se na sobnoj temperaturi tijekom 18 sati. Reakcija se ugasi dodatkom 2N klorovodične kiseline i pH se podesi do 1. Reakcijska smjesa dva puta se ispire eterom, nakon čega se vodenom sloju podesi pH na 12 dodatkom 6N natrij-hidroksida (vodena otopina) i ekstrahira se tri puta diklormetanom. Zajedno prikupljeni diklormetanski slojevi suše se preko Na2SO4, filtriraju i uparuju do suhog u vakuumu, dajući 3,51 grama (87,75 %) naslovljenog spoja u obliku tamnožutog ulja.
LRMS: 219,1 (M+1).
Postupak G (1-benzil-4-metil-piperidin-3-il)-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
Smjesa 4-klorpirolo[2,3-d]pirimidina (2,4 grama, 15,9 mmola) pripremljenog prema postupku koji je opisao Davoll u "J. Am. Chem. Soc.", 82, 131, (1960.), produkta iz Postupka F (1,7 grama, 7,95 mmola) i 10 ml trietilamina zagrijava se u zatvorenoj cijevi na 100 °C tijekom 4 dana. Poslije hlađenja do sobne temperature i koncentriranja pod sniženim tlakom, ostatak se pročišćava flash-kromatografijom (silicij dioksid; 3 % metanol u diklormetanu), dajući 1,0 gram (38 %) naslovljenog spoja u obliku bezbojnog ulja.
LRMS: 336,1 (M+1).
Postupak H Metil-(4-metil-piperidin-3-il)-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
Produktu iz Postupka G (0,7 grama, 2,19 mmola) koji je otopljen u 15 ml etanola dodano je 0,5 grama 20 % paladij-hidroksida na ugljiku (50 % vode) (Aldrich), a dobivenu smjesu se trese (Parr-ova tresilica) pod atmosferom vodika (50 psi) na sobnoj temperaturi tijekom 2 dana. Reakcijska smjesa filtrira se kroz Celit i koncentrira u vakuumu do suhog, a ostatak se pročišćava flash-kromatografijom (silicij dioksid; 5 % metanol u diklormetanu), dajući 0,48 grama (90 %) naslovljenog spoja.
LRMS: 246,1 (M+1).
Postupak I [1-(4-metoksi-benzensulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
U miješanu otopinu 1 ml piridina i 9 ml diklormetana dodaje se 40 mg (0,163 mmola) produkta iz Postupka H i 20 l 4-metoksi-benzensulfonil-klorida, a dobivenu smjesu se miješa na sobnoj temperaturi tijekom 18 sati. Reakcija se ugasi dodavanjem zasićenog NaHCO3 (vodena otopina), nakon čega se uklanja organski sloj, a vodeni sloj se ekstrahira diklormetanom. Diklormetanski sloj suši se preko Na2SO4 i koncentrira u vakuumu. Ostatak se pročišćava pomoću PTLC (silicij dioksid; 10:1 diklormetan/metanol), dajući 22 mg (32 %) naslovljenog spoja u obliku svjetložutog ulja. LRMS: 416,5 (M+1).
Naslovljeni spojevi za primjere 2-297 dobivaju se pomoću postupka analognom onom opisanom u Primjeru 1.
Primjer 2
[1-(4-metoksi-benzensulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 416.
Primjer 3
(1-benzensulfonil-4-metil-piperidin-3-il)-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 386.
Primjer 4
2-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-izoindol-1,3-dion
LRMS: 483.
Primjer 5
2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-amid cikloheksankarboksilne kiseline
LRMS: 463.
Primjer 6
2-klor-N-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-ilamino]-piperidin-1-sulfonil}-etil)-benzamid
LRMS: 492.
Primjer 7
4-klor-N-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-benzamid
LRMS: 492.
Primjer 8
(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-amid furan-2-karboksilne kiseline
LRMS: 447.
Primjer 9
3-metoksi-N-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-benzamid
LRMS: 487.
Primjer 10
(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-amid izoksazol-5-karboksilne kiseline
LRMS: 448.
Primjer 11
2,4-difluor-N-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-benzamid
LRMS: 493.
Primjer 12
3-klor-N-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-benzamid
LRMS: 492.
Primjer 13
3-fluor-N-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-benzamid
LRMS: 475.
Primjer 14
2-fluor-N-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-benzamid
LRMS: 475.
Primjer 15
4-fluor-N-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-benzamid
LRMS: 475.
Primjer 16
N-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-benzamid
LRMS: 457.
Primjer 17
(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-amid ciklopropankarboksilne kiseline
LRMS: 421.
Primjer 18
(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-amid ciklopentankarboksilne kiseline
LRMS: 449.
Primjer 19
Cikoopentil-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 342.
Primjer 20
(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-amid tetrahidro-furan-2-karboksilne kiseline
LRMS: 451.
Primjer 21
(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-amid tetrahidro-furan-3-karboksilne kiseline
LRMS: 451.
Primjer 22
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-(tetrahidro-furan-2-il)-metanon
LRMS: 344.
Primjer 23
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-(tetrahidro-furan-3-il)-metanon
LRMS: 344.
Primjer 24
(3-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-3-okso-propil)-amid
LRMS: 427.
Primjer 25
2-ciklopropil-1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-etanon
LRMS: 328.
Primjer 26
tert-butilni ester 2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-pirolidin-1-karboksilne kiseline
LRMS: 443.
Primjer 27
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-pirolidin-2-il-metanon
LRMS: 343.
Primjer 28
1-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-pirolidin-1-il)-etanon hidroklorid
LRMS: 385.
Primjer 29
Furan-3-il-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 340.
Primjer 30
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-piridin-2-il-metanon
LRMS: 351.
Primjer 31
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-fenil-metanon
LRMS: 350.
Primjer 32
1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-fenil-etanon
LRMS: 364.
Primjer 33
2-ciklopropil-1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-etanon hidroklorid
LRMS: 364.
Primjer 34
tert-butilni ester 2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-pirolidin-1-karboksilne kiseline
LRMS: 443.
Primjer 35
Benzilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 379.
Primjer 36
Fenilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 365.
Primjer 37
Tetrahidro-furan-3-ilni ester 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 360.
Primjer 38
1-(4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-piperidin-1-il)-etanon
LRMS: 399.
Primjer 39
2-ciklopentil-1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-etanon
LRMS: 356.
Primjer 40
Cikloheksamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 371.
Primjer 41
Azetidin-3-il-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon trifluoracetat
LRMS: 443.
Primjer 42
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-pirolidin-1-il-metanon
LRMS: 343.
Primjer 43
Metil-fenil-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 379.
Primjer 44
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-morfolin-4-il-metanon
LRMS: 359.
Primjer 45
Metil-(4-metil-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-3-il)-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 323.
Primjer 46
Metil-(4-metil-1-tiazol-2-il-piperidin-3-il)-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 329.
Primjer 47
Piridin-3-ilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 366.
Primjer 48
(4-fluor-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 383.
Primjer 49
(4-nitro-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 410.
Primjer 50
(4-metoksi-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 395.
Primjer 51
Etilni ester 4-({4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-amino)-benzojeve kiseline
LRMS: 437.
Primjer 52
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-piperidin-1-il-metanon
LRMS: 357.
Primjer 53
Metil-(4-metil-5'-nitro-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-3-il)-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 368.
Primjer 54
(3-fluor-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 383.
Primjer 55
(2,4-difluor-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 401.
Primjer 56
Metil-[4-metil-1-(pirolidin-1-sulfonil)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 379.
Primjer 57
(3-metoksi-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 395.
Primjer 58
(3-nitro-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 410.
Primjer 59
Metilni ester 1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-pirolidin-2-karboksilne kiseline
LRMS: 401.
Primjer 60
Metil-[4-metil-1-(5-nitro-tiazol-2-il)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 374.
Primjer 61
Metilni ester 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-5'-karboksilne kiseline
LRMS: 381.
Primjer 62
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-5'-il}-metanol
LRMS: 353.
Primjer 63
Metil-[4-metil-1-(piperidin-1-sulfonil)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 393.
Primjer 64
(3-cijano-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 390.
Primjer 65
(3,4-difluor-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 401.
Primjer 66
Metil-[4-metil-1-(morfolin-4-sulfonil)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 395.
Primjer 67
(4-klor-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 399.
Primjer 68
Metil-[4-metil-1-(6-metil-piridazin-3-il)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 338.
Primjer 69
(4-cijano-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 390.
Primjer 70
Bifenil-4-ilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 441.
Primjer 71
(4-trifluormetil-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 433.
Primjer 72
Benzilni ester metil-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-karbaminske kiseline
LRMS: 501.
Primjer 73
Ciklopropil-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 314.
Primjer 74
Ciklobutil-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 328.
Primjer 75
Metil-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-amid tetrahidro-furan-3-karboksilne kiseline
LRMS: 465.
Primjer 76
Metil-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-amid cikloheksankarboksilne kiseline
LRMS: 477.
Primjer 77
(5,7-diklor-1H-indol-2-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 458.
Primjer 78
4-({4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-amino)-benzojeva kiselina
LRMS: 409.
Primjer 79
(1-benzooksazol-2-il-4-metil-piperidin-3-il)-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 363.
Primjer 80
(1H-indol-2-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 389.
Primjer 81
(5-fluor-1H-indol-2-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 407.
Primjer 82
(5-metoksi-3-metil-benzofuran-2-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 434.
Primjer 83
(5-klor-benzofuran-2-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 424.
Primjer 84
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-(5-nitro-benzofuran-2-il)-metanon
LRMS: 435.
Primjer 85
(5-klor-2,3-dihidro-benzofuran-2-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 426.
Primjer 86
(4-hidroksi-piperidin-1-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 373.
Primjer 87
1-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-benzofuran-5-il)-etanon
LRMS: 432.
Primjer 88
1-(3-metil-2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-1H-indol-5-il)-etanon
LRMS: 445.
Primjer 89
[1-(5-klor-benzotiazol-2-il)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 413.
Primjer 90
tert-butilni ester (3-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-3-aza-biciklo[3.1.0]heks-6-il)karbaminske kiseline
LRMS: 470.
Primjer 91
3-(4-klor-fenoksi)-1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-propan-1-on
LRMS: 428.
Primjer 92
Piridin-2-ilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 366.
Primjer 93
Amid hidroklorid 1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-piperidin-4-karboksilne kiseline
LRMS: 436.
Primjer 94
(5-klor-piridin-2-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 400.
Primjer 95
3-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-ciklopentanon
LRMS: 356.
Primjer 96
(3-hidroksi-ciklopentil)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 358.
Primjer 97
4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-cikloheksanon
LRMS: 370.
Primjer 98
3-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-cikloheksanon
LRMS: 370.
Primjer 99
(5-nitro-piridin-2-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 413.
Primjer 100
[4-({4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-amino)-fenil]-octena kiselina
LRMS: 423.
Primjer 101
(4-amino-piperidin-1-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon hidroklorid
LRMS: 408.
Primjer 102
(6-metil-piridin-2-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 380.
Primjer 103
1-metil-4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-pirolidin-2-on
LRMS: 371.
Primjer 104
1-benzil-3-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-pirolidin-2-on
LRMS: 447.
Primjer 105
(5-trifluormetil-piridin-2-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 434.
Primjer 106
(4-cijano-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-cikloheksankarboksilne kiseline
LRMS: 389.
Primjer 107
(4-karbamoil-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 408.
Primjer 108
(4-sulfamoil-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 444.
Primjer 109
(5-metil-tiazol-2-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 386.
Primjer 110
(5,6-diklor-benzotiazol-2-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 491.
Primjer 111
(4-metil-tiazol-2-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 386.
Primjer 112
Azetidin-1-il-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon hidroklorid
LRMS: 365.
Primjer 113
Etilni ester [2-({4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-amino)-tiazol-4-il]-octene kiseline
LRMS: 458.
Primjer 114
(4,5-dimetil-tiazol-2-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 400.
Primjer 115
[2-({4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-amino)-tiazol-4-il]-octena kiselina
LRMS: 430.
Primjer 116
Benzotiazol-2-ilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 422.
Primjer 117
Tiazol-2-ilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 372.
Primjer 118
[6-(2-dimetilamino-etilamino)-piridin-3-il]-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 452.
Primjer 119
N-(4-klor-fenil)-2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-acetamid
LRMS: 413.
Primjer 120
N,N-dimetil-2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-acetamid
LRMS: 331.
Primjer 121
[6-(2-pirolidin-1-il-etilamino)-piridin-3-il]-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 478.
Primjer 122
tert-butilni ester {2-[5-({4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-amino)-piridin-2-iloksi]-etil}-karbaminske kiseline
LRMS: 525.
Primjer 123
[6-(2-amino-etoksi)-piridin-3-il]-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 425.
Primjer 124
(4-metilsulfamoil-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 458.
Primjer 125
(4-metansulfonil-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 443.
Primjer 126
(5-metil-[1,3,4]tiadiazol-2-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 387.
Primjer 127
(4-metilsulfamoil-fenil)-amid hidroklorid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 495.
Primjer 128
Metil-[4-metil-1-(1-fenil-etil)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 350.
Primjer 129
(3-hidroksi-pirolidin-1-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 359.
Primjer 130
tert-butilni ester 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 346.
Primjer 131
[4-(2-dimetilamino-etil)-tiazol-2-il]-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 443.
Primjer 132
4-metansulfonil-benzilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 457.
Primjer 133
(4-acetilsulfamoil-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 486.
Primjer 134
1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-fenil-etan-1,2-dion
LRMS: 378.
Primjer 135
Metil-[4-metil-1-(6-metilamino-pirimidin-4-il)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 353.
Primjer 136
Metil-[4-metil-1-(6-pirolidin-1-il-pirimidin-4-il)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 393.
Primjer 137
[1-(6-benzilamino-pirimidin-4-il)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 429.
Primjer 138
N,N-dimetil-N'-(6-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-pirimidin-4-il)-etan-1,2-diamin
LRMS: 410.
Primjer 139
[1-(6-klor-pirimidin-4-il)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 358.
Primjer 140
[1-(2-fluor-benzil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 354.
Primjer 141
[1-(2-klor-pirimidin-4-il)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 359.
Primjer 142
[1-(4-klor-pirimidin-2-il)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 359.
Primjer 143
Metil-[4-metil-1-(2-metilamino-pirimidin-4-il)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 353.
Primjer 144
Metil-[4-metil-1-(4-pirolidin-1-il-pirimidin-2-il)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 353.
Primjer 145
(3-metil-izoksazol-5-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 370.
Primjer 146
(3-metil-izoksazol-4-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kisleine
LRMS: 370.
Primjer 147
(5-metil-izoksazol-3-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 370.
Primjer 148
(5-tert-butil-izoksazol-3-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 412.
Primjer 149
Izoksazol-3-ilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 356.
Primjer 150
N-metil-3-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-propionamid
LRMS: 331.
Primjer 151
1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-propan-2-on
LRMS: 302.
Primjer 152
Metilni ester {4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-okso-octene kiseline
LRMS: 332.
Primjer 153
(1-cikloheksilmetil-4-metil-piperidin-3-il)-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 342.
Primjer 154
[1-(5-amino-tiazol-2-il)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 344.
Primjer 155
Metil-(4-metil-piperidin-3-il)-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 246.
Primjer 156
Metilni ester 3-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-3-okso-propionske kiseline
LRMS: 346.
Primjer 157
(1-benzensulfonilmetil-4-metil-piperidin-3-il)-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 400.
Primjer 158
(3-hidroksi-pirolidin-1-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 359.
Primjer 159
1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-propan-1,2-dion
LRMS: 316.
Primjer 160
(6-sulfamoil-piridin-3-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 445.
Primjer 161
(6-acetilamino-piridin-3-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 423.
Primjer 162
[4-(2-dimetilamino-etilsulfamoil)-fenil]-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 515.
Primjer 163
(6-cijano-piridin-3-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 391.
Primjer 164
Piridin-2-ilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-5'-sulfo kiseline
LRMS: 479.
Primjer 165
[6-(Pirolidin-1-karbonil)-piridin-3-il]-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 463.
Primjer 166
2-imidazol-1-il-1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-etanon
LRMS: 354.
Primjer 167
Metilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-5'-karboksilne kiseline
LRMS: 380.
Primjer 168
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-5'-il}-morfolin-4-il-metanon
LRMS: 436.
Primjer 169
Propilamid 5-({4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-amino)-piridin-2-karboksilne kiseline
LRMS: 451.
Primjer 170
Amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-5'-karboksilne kiseline
LRMS: 366.
Primjer 171
4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-5'-karbonitril
LRMS: 348.
Primjer 172
[4-(pirolidin-1-sulfonil)-fenil]-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 498.
Primjer 173
[4-(morfolin-4-sulfonil)-fenil]-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 514.
Primjer 174
(3-hidroksi-pirolidin-1-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 359.
Primjer 175
[6-(morfolin-4-karbonil)-piridin-3-il]-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 479.
Primjer 176
[6-(morfolin-4-karbonil)-piridin-3-il]-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 479.
Primjer 177
2-imidazol-1-il-1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-etanon
LRMS: 354.
Primjer 178
Izoksazol-3-ilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 356.
Primjer 179
(2,5-dimetil-2H-pirazol-3-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 383.
Primjer 180
(5-ciklopropil-2-metil-2H-pirazol-3-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 409.
Primjer 181
(3-metil-izotiazol-5-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 386.
Primjer 182
4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-ilmetil}-benzojeva kiselina
LRMS: 380.
Primjer 183
Metil-[4-metil-5'-(pirolidin-1-sulfonil)-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 456.
Primjer 184
Metilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-5'-sulfo kiseline
LRMS: 416.
Primjer 185
4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-ilmetil}-benzensulfonamid
LRMS: 415.
Primjer 186
N-tert-butil-4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-ilmetil}-benzensulfonamid
LRMS: 472.
Primjer 187
1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-pirazol-1-il-etanon
LRMS: 354.
Primjer 188
Metil-[4-metil-1-(5-nitro-benzooksazol-2-il)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 408.
Primjer 189
(2-hidroksi-etil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-5'-sulfo kiselina
LRMS: 446.
Primjer 190
N-tert-butil-4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-ilmetil}-benzensulfonamid
LRMS: 471.
Primjer 191
N-metil-2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-okso-acetamid
LRMS: 331.
Primjer 192
[1-(5-etansulfonil-benzooksazol-2-il)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 455.
Primjer 193
Metil-[4-metil-1-(5-metil-benzooksazol-2-il)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 377.
Primjer 194
(6-klor-piridin-3-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 400.
Primjer 195
Metil-(4-metil-1-kinolin-2-il-piperidin-3-il)-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 373.
Primjer 196
Amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-5'-sulfo kiseline
LRMS: 402.
Primjer 197
1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-pirolidin-1-il-etan-1,2-dion
LRMS: 371.
Primjer 198
Metil-[4-metil-1-(4-metil-benzooksazol-2-il)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 377.
Primjer 199
1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-morfolin-4-il-etan-1,2-dion
LRMS: 387.
Primjer 200
(6-metansulfonil-piridin-3-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 444.
Primjer 201
(6-metansulfonil-piridin-3-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 444.
Primjer 202
Metil-[4-metil-1-(6-nitro-benzooksazol-2-il)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 408.
Primjer 203
(6-metansulfonil-piridin-3-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 444.
Primjer 204
(6-metansulfonil-piridin-3-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 444.
Primjer 205
Metil-[4-metil-1-(6-nitro-benzooksazol-2-il)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 408.
Primjer 206
Metil-[4-metil-1-(toluen-3-sulfonil)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 400.
Primjer 207
Metil-[4-metil-1-(4-trifluormetil-benzensulfonil)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 454.
Primjer 208
(1-benzotiazol-2-il-4-metil-piperidin-3-il)-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino
LRMS: 379.
Primjer 209
[1-(5,7-dimetil-benzooksazol-2-il)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 391.
Primjer 210
Metilni ester 2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-benzooksazol-6-karboksilne kiseline
LRMS: 421.
Primjer 211
Metil-[4-metil-1-(6-metil-benzooksazol-2-il)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 377.
Primjer 212
[1-(6-metoksi-benzooksazol-2-il)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 393.
Primjer 213
Metil-[4-metil-1-(5-trifluormetil-benzotiazol-2-il)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 447.
Primjer 214
[1-(5,7-diklor-benzooksazol-2-il)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 432.
Primjer 215
[1-(6-klor-piridin-3-sulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 422.
Primjer 216
[1-(4-klor-benzensulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 421.
Primjer 217
[1-(4-fluor-benzensulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 404.
Primjer 218
4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-benzonitril
LRMS: 411.
Primjer 219
4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-benzensulfonil fluorid
LRMS: 468.
Primjer 220
2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-benzonitril
LRMS: 411.
Primjer 221
1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-tetrazol-1-il-etanon
LRMS: 356.
Primjer 222
Metil-[4-metil-1-(2,2,2-trifluor-etansulfonil)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 392.
Primjer 223
[1-(2,6-difluor-benzensulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 422.
Primjer 224
[1-(4-tert-butil-benzensulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 442.
Primjer 225
[1-(2,4-difluor-benzensulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 422.
Primjer 226
Metil-[4-metil-1-(2-trifluormetil-benzensulfonil)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 454.
Primjer 227
[1-(3,5-bis-trifluormetil-benzensulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 522.
Primjer 228
[1-(3,5-diklor-benzensulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 455.
Primjer 229
4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-benzojeva kiselina
LRMS: 431.
Primjer 230
[1-(6-klor-piridin-3-sulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 422.
Primjer 231
[1-(4-klor-benzensulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 421.
Primjer 232
[1-(4-fluor-benzensulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 404.
Primjer 233
4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-benzonitril
LRMS: 411.
Primjer 234
4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-benzensulfonil fluorid
LRMS: 468.
Primjer 235
2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-benzonitril
LRMS: 411.
Primjer 236
1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-tetrazol-1-il-etanon
LRMS: 356.
Primjer 237
Metil-[4-metil-1-(2,2,2-trifluor-etansulfonil)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 392.
Primjer 238
[1-(2,6-difluor-benzensulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 422.
Primjer 239
[1-(4-tert-butil-benzensulfonill)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 442.
Primjer 240
[1-(2,4-difluor-benzensulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 422.
Primjer 241
Metil-[4-metil-1-(2-trifluormetil-benzensulfonil)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 454.
Primjer 242
[1-(3,5-bis-trifluormetil-benzensulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 522.
Primjer 243
[1-(3,5-diklor-benzensulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 455.
Primjer 244
4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-benzojeva kiselina
LRMS: 431.
Primjer 245
(3-fluor-fenil)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 368.
Primjer 246
Izotiazol-4-il-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 357.
Primjer 247
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-tiofen-3-il-metanon
LRMS: 356.
Primjer 248
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-(5-metil-1H-pirazol-3-il)-metanon
LRMS: 354.
Primjer 249
(5-metil-izoksazol-3-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 355.
Primjer 250
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-(5-metil-tiofen-2-il)-metanon
LRMS: 371.
Primjer 251
(4-fluor-fenil)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 368.
Primjer 252
Metil-[4-metil-1-(3-nitro-benzensulfonil)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 431.
Primjer 253
[1-(3-fluor-benzensulfonil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 404.
Primjer 254
(2-fluor-fenil)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 368.
Primjer 255
(1,5-dimetil-1H-pirazol-3-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 368.
Primjer 256
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-(2-metil-tiazol-4-il)-metanon
LRMS: 371.
Primjer 257
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-tiazol-4-il-metanon
LRMS: 357.
Primjer 258
(4-metil-izotiazol-5-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 371.
Primjer 259
2,2-dimetil-5-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-okso-etil)-[1,3]dioksolan-4-on
LRMS: 403.
Primjer 260
2-ciklopropil-N-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-acetamid
LRMS: 436.
Primjer 261
N-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-metansulfonamid
LRMS: 432.
Primjer 262
(3-hidroksi-pirolidin-1-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 359.
Primjer 263
4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-ilmetil}-benzonitril
LRMS: 362.
Primjer 264
3-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-benzensulfonil fluorid
LRMS: 469.
Primjer 265
2,2-dimetil-5-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-okso-etil-[1,3]dioksolan-4-on
LRMS: 402.
Primjer 266
Benzilni ester 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 381.
Primjer 267
4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-ilmetil}-benzensulfonamid
LRMS: 416.
Primjer 268
[1-(1H-imidazol-2-ilmetil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 326.
Primjer 269
2-klor-benzilni ester 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 415.
Primjer 270
Metil-[4-metil-1-(1-metil-1H-imidazol-2-ilmetil)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 340.
Primjer 271
1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-fenoski-etanon
LRMS: 380.
Primjer 272
2-(4-fluor-fenoski)-1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-etanon
LRMS: 381.
Primjer 273
2,2,2-triklor-etilni ester 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 420.
Primjer 274
2-(2-klor-fenoksi)-1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-etanon
LRMS: 415.
Primjer 275
2-(3-klor-fenoksi)-1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-etanon
LRMS: 415.
Primjer 276
2-metansulfonil-1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-etanon
LRMS: 367.
Primjer 277
2-(1,1-diokso-tetrahidro-1$I%6&-tiofen-3-il)-1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-etanon
LRMS: 407.
Primjer 278
Metil-[4-metil-1-(1-fenil-etil)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 351.
Primjer 279
1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-(toluen-4-sulfonil)-etanon
LRMS: 443.
Primjer 280
4-hidroksi-1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-etanon
LRMS: 304.
Primjer 281
1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-3-nitro-propan-1-on
LRMS: 347.
Primjer 282
5-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-okso-etil)-tiazolidin-2,4-dion
LRMS: 404.
Primjer 283
3-hidroksi-1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-propan-1-on
LRMS: 318.
Primjer 284
N-(4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-4-okso-butil)-metansulfonamid
LRMS: 410.
Primjer 285
2,2-dimetil-propilni ester 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 360.
Primjer 286
1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-(tiazolidin-3-sulfonil)-etanon
LRMS: 440.
Primjer 287
(3,4-dihidroksi-pirolidin-1-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon
LRMS: 376.
Primjer 288
4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-tiazolidin-2-on
LRMS: 376.
Primjer 289
Prop-2-inilni ester 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 328.
Primjer 290
(2-cijano-etil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 342.
Primjer 291
(2-cijano-etil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 342.
Primjer 292
1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-cikloheksil}-etanon oksim
LRMS: 302.
Primjer 293
Cijanometil-metil-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 342.
Primjer 294
Izopropilni ester 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 332.
Primjer 295
(2-cijano-etil)-metil-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline
LRMS: 356.
Primjer 296
4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-ilmetil}-piridin-1-ol
LRMS: 355.
Primjer 297
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-acetonitril
LRMS: 285.
Primjer 298
[1-(2-fluor-benzil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
Postupak J
U otopinu produkta iz Postupka H (50 mg, mmola?) otopljenog u 5 ml metanola dodaje se 154 ul (mmola?) 2-fluor-benzaldehida. Dobivena smjesa miješa se na sobnoj temperaturi 4 sata, nakon čega se dodaje x mg (y mmola) natrij-cijanobor-hidrida, a dobivena smjesa se miješa na sobnoj temperaturi tijekom 18 sati. Reakcija se ugasi dodavanjem 2 kapi 1N NaOH (vodena otopina), a smjesa se koncentrirana pod sniženim tlakom kako bi se uklonio metanol. Ostatak se otopi u kloroformu i ispire vodom. Vodeni sloj se ponovo ispire tri puta s kloroformom, nakon čega se zajedno prikupljeni organski ekstrakti suše preko MgSO4 i koncentriraju do suhog u vakuumu. Sirovi produkt se zatim pročišćava flash-kromatografijom (silicij dioksid; 2,5 % metanol u kloroformu), dajući 36 mg (47,5 %) naslovljenog spoja u obliku bijele krutine.
LRMS: 372,4 (M+1).
Naslovljeni spojevi za primjere 299-324 dobivaju su pomoću postupka analognom onom opisanom u Primjeru 298.
Primjer 299
(1-benzil-4-metil-piperidin-3-il)-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 336.
Primjer 300
(1-furan-2-ilmetil-4-metil-piperidin-3-il)-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 326.
Primjer 301
[1-(4-metoksi-benzil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 366.
Primjer 302
[1-(4-fluor-benzil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 354.
Primjer 303
Metil-(4-metil-1-piridin-3-ilmetil-piperidin-3-il)-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 337.
Primjer 304
Metil-(4-metil-1-tiazol-2-ilmetil-piperidin-3-il)-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 343.
Primjer 305
Metil-(4-metil-1-piridin-2-ilmetil-piperidin-3-il)-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 337.
Primjer 306
Metil-[4-metil-1-(1-fenil-etil)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 350.
Primjer 307
(1-benzil-4-metil-piperidin-3-il)-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 336.
Primjer 308
(1-benzil-4-metil-piperidin-3-il)-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 336.
Primjer 309
3-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-ilmetil}-benzonitril
LRMS: 361.
Primjer 310
[1-(3-fluor-benzil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 354.
Primjer 311
[1-(3-metoksi-benzil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 366.
Primjer 312
3-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-ilmetil}-benzojeva kiselina
LRMS: 380.
Primjer 313
[1-(2-fluor-benzil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 354.
Primjer 314
[1-(2,6-difluor-benzil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 372.
Primjer 315
Metil-(4-metil-1-fenetil-piperidin-3-il)-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 350.
Primjer 316
[1-(2,3-difluor-benzil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 372.
Primjer 317
[1-(3,4-difluor-benzil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 372.
Primjer 318
[1-(4-metansulfonil-benzil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 414.
Primjer 319
Metil-{4-metil-1-[4-(piperidin-1-sulfonil)-benzil]-piperidin-3-il}-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 483.
Primjer 320
[1-(3,5-difluor-benzil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 372.
Primjer 321
[1-(3-klor-benzil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 371.
Primjer 322
[1-(3,5-difluor-benzil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 372.
Primjer 323
[1-(3-klor-benzil)-4-metil-pipridin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 371.
Primjer 324
[1-(3,5-diklor-benzil)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin
LRMS: 405.
Claims (27)
1. Spoj formule
[image]
,
ili njegova farmaceutski prihvatljiva sol; naznačen time što
R1 je grupa formule
[image]
,
gdje y je 0, 1 ili 2;
R4 je izabran iz grupe koju čine vodik, (C1-C6)alkil, (C1-C6)alkilsulfonil, (C2-C6)alkenil, (C2-C6)alkinil, pri čemu su alkilne, alkenilne i alkinilne grupe izborno supstituirane s deuterijem, hidroksi, amino, trifluormetilom, (C1-C4)alkoksi, (C1-C6)aciloksi, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, cijano, nitro, (C2-C6)alkenil, (C2-C6)alkinil ili (C1-C6)acilamino; ili R4 je (C3-C10)cikloalkil, pri čemu je cikloalkilna grupa izborno supstituirana s deuterijem, hidroksi, amino, trifluormetilom, (C1-C6)aciloksi, (C1-C6)acilamino, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, cijano, cijano(C1-C6)alkil, trifluormetil(C1-C6)alkil, nitro, nitro(C1-C6)alkil ili (C1-C6)acilamino;
R5 je (C2-C9)heterocikloalkil, pri čemu heterocikloalkilne grupe moraju biti supstituirane s jednom do pet grupa koje čine karboksi, cijano, amino, deuterij, hidroksi, (C1-C6)alkil, (C1-C6)alkoksi, halo, (C1-C6)acil, (C1-C6)alkilamino, amio(C1-C6)alkil, (C1-C6)alkoksi-CO-NH, (C1-C6)alkilamino-CO-, (C2-C6)alkenil, (C2-C6)alkinil, (C1-C6)alkilamino, amino(C1-C6)alkil, hidroksi(C1-C6)alkil, (C1-C6)alkoksi(C1-C6)alkil, (C1-C6)aciloksi(C1-C6)alkil, nitro, cijano(C1-C6)alkil, halo(C1-C6)alkil, nitro(C1-C6)alkil, trifluormetil, trifluormetil(C1-C6)alkil, (C1-C6)acilamino, (C1-C6)acilamino(C1-C6)alkil, (C1-C6)alkoksi(C1-C6)acilamino, amino(C1-C6)acil, amino(C1-C6)acil(C1-C6)alkil, (C1-C6)alkilamino(C1-C6)acil, ((C1-C6)alkil)2amino(C1-C6)acil, R15R16N-CO-O-, R15R16N-CO-(C1-C6)alkil, (C1-C6)alkil-S(O)m, R15R16NS(O)m, R15R16NS(O)m(C1-C6)alkil, R15S(O)mR16N, R15S(O)mR16N(C1-C6)alkil, gdje m je 0, 1 ili 2, a R15 i R16 su svaki nezavisno izabrani od vodika ili (C1-C6)alkila; i grupa formule
[image]
,
gdje a je 0, 1, 2, 3 ili 4;
b, c, e, f i g su svaki nezavisno 0 ili 1;
d je 0, 1, 2, ili 3;
X je S(O)n, gdje n je 0, 1 ili 2; kisik, karbonil ili -C(=N-cijano)-;
Y je S(O)n, gdje n je 0, 1 ili 2; ili karbonil; i
Z je karbonil, C(O)O-, C(O)NR-, gdje R je vodik ili (C1-C6)alkil; ili Z je S(O)n, gdje n je 0, 1 ili 2;
R6, R7, R8, R9, R10 i R11 su svaki nezavisno izabrani iz grupe koju čine vodik ili (C1-C6)alkil izborno supstituiran s deuterijem, hidroksi, amino, trifluormetilom, (C1-C6)aciloksi, (C1-C6)acilamino, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, cijano, cijano(C1-C6)alkil, trifluormetil(C1-C6)alkil, nitro, nitro(C1-C6)alkil ili (C1-C6)acilamino;
R12 je (C6-C10)aril, (C2-C9)heteroaril, (C3-C10)cikloalkil ili (C2-C9)heterocikloalkil, pri čemu su arilne, heteroarilne, cikloalkilne i heterocikloalkilne grupe izborno supstituirane s jednom do četiri grupe koje čine vodik, deuterij, amino, halo, okso, hidroksi, nitro, karboksi, (C2-C6)alkenil, (C2-C6)alkinil, trifluormetil, trifluormetoksi, (C1-C6)alkil, (C1-C6)alkoski, (C3-C10)cikloalkil, (C1-C6)alkil-CO-NH-, (C1-C6)alkoksi-CO-NH-, (C1-C6)alkil-CO-NH-(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-(C1-C6)alkoksi, karboksi, karboksi(C1-C6)alkil, karboksi(C1-C6)alkoksi, benziloksikarbonil(C1-C6)alkoksi, (C1-C6)alkoksikarbonil(C1-C6)alkoksi, (C6-C10)aril, amino, amino(C1-C6)alkil, (C1-C6)alkoksikarbonilamino, (C6-C10)aril(C1-C6)alkoksikarbonilamino, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, (C1-C6)alkilamino(C1-C6)alkil, ((C1-C6)alkil)2amino(C1-C6)alkil, hidroksi, (C1-C6)alkoksi, karboksi, karboksi(C1-C6)alkil, (C1-C6)alkoksikarbonil, (C1-C6)alkoksikarbonil(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-, (C1-C6)alkil-CO-NH-, cijano, (C5-C9)heterocikloalkil, amino-CO-NH-, (C1-C6)alkilamino-CO-NH-, ((C1-C6)alkil)2amino-CO-NH-, (C6-C10)arilamino-CO-NH-, (C5-C9)heteroarilamino-CO-NH-, (C1-C6)alkilamino-CO-NH-(C1-C6)alkil, ((C1-C6)alkil)2amino-CO-NH-(C1-C6)alkil, (C6-C10)arilamino-CO-NH-(C1-C6)alkil, (C5-C9)heteroarilamino-CO-NH-(C1-C6)alkil, (C1-C6)alkilcijano, (C1-C6)alkilkarboksi(C1-C6)alkoksi, (C1-C6)alkilkarboksi, sulfonilamino, aminosulfonil, sulfonilamino(C1-C6)alkil, sulfonilaminokarboksi(C1-C6)alkil, (C1-C6)alkilsulfonil, (C1-C6)alkilsulfonilamino, (C1-C6)alkilsulfonilamino(C1-C6)alkil, (C6-C10)arilsulfonil, (C6-C10)arilsulfonilamino, (C6-C10)arilsulfonilamino(C1-C6)alkil, (C1-C6)alkilsulfonilamino, (C1-C6)alkilsulfonilamino(C1-C6)alkil, (C3-C10)cikloalkil, (C3-C10)cikloalkoksi, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, (C6-C10)arilamino, (C1-C6)alkiltio, (C6-C10)ariltio, (C1-C6)alkilsulfinil, (C6-C10)arilsulfinil, (C1-C6)alkilsulfonil, (C6-C10)arilsulfonil, (C1-C6)acil, (C1-C6)alkoksi-CO-NH-, (C1-C6)alkilamino-CO-, (C5-C9)heteroaril, (C2-C9)heterocikloalkil ili (C6-C10)aril, pri čemu heteroarilne, heterocikloalkilne i arilne grupe koje su izborno supstituirane na R12 mogu biti dalje supstituirane s jednom do tri grupe koje čine halo, (C1-C6)alkil, (C1-C6)alkil-CO-NH-, (C1-C6)alkoksi-CO-NH-, (C1-C6)alkil-CO-NH-(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-(C1-C6)alkoksi, karboksi, karboksi(C1-C6)alkil, karboksi(C1-C6)alkoksi, benziloksikarbonil(C1-C6)alkoksi, (C1-C6)alkoksikarbonil(C1-C6)alkoksi, (C6-C10)aril, amino, amino(C1-C6)alkil, (C1-C6)alkoksikarbonilamino, (C6-C10)aril(C1-C6)alkoksikarbonilamino, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, (C1-C6)alkilamino(C1-C6)alkil, ((C1-C6)alkil)2amino(C1-C6)alkil, hidroksi, (C1-C6)alkoksi, karboksi, karboksi(C1-C6)alkil, (C1-C6)alkoksikarbonil, (C1-C6)alkoksikarbonil(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-, (C1-C6)alkil-CO-NH-, cijano, (C5-C9)heterocikloalkil, amino-CO-NH-, (C1-C6)alkilamino-CO-NH-, ((C1-C6)alkil)2amino-CO-NH-, (C6-C10)arilamino-CO-NH-, (C5-C9)heteroarilamino-CO-NH-, (C1-C6)alkilamino-CO-NH-(C1-C6)alkil, ((C1-C6)alkil)2amino-CO-NH-(C1-C6)alkil, (C6-C10)arilamino-CO-NH-(C1-C6)alkil, (C5-C9)heteroarilamino-CO-NH-(C1-C6)alkil, (C1-C6)alkilsulfonil, (C1-C6)alkilsulfonilamino, (C1-C6)alkilsulfonilamino(C1-C6)alkil, (C6-C10)arilsulfonil, (C6-C10)arilsulfonilamino, (C6-C10)arilsulfonilamino(C1-C6)alkil, (C1-C6)alkilsulfonilamino, (C1-C6)alkilsulfonilamino(C1-C6)alkil, (C5-C9)heteroaril i (C2-C9)heterocikloalkil;
R2 i R3 su svaki nezavisno izabrani iz grupe koju čine vodik, deuterij, amino, halo, hidroksi, nitro, karboksi, (C2-C6)alkenil, (C2-C6)alkinil, trifluormetil, trifluormetoksi, (C1-C6)alkil, (C1-C6)alkoksi, (C3-C10)cikloalkil, pri čemu su alkilne, alkoksi ili cikloalkilne grupe izborno supstituirane s jednom do tri grupe izabrane od halo, hidroksi, karboksi, amino(C1-C6)alkiltio, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, (C5-C9)heteroaril, (C2-C9)heterocikloalkil, (C3-C9)cikloalkil ili (C6-C10)aril; ili R2 i R3 su svaki nezavisno (C3-C10)cikloalkil, (C3-C10)cikloalkoksi, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, (C6-C10)arilamino, (C1-C6)alkiltio, (C6-C10)ariltio, (C1-C6)alkilsulfinil, (C6-C10)arilsulfinil, (C1-C6)alkilsulfonil, (C6-C10)arilsulfonil, (C1-C6)acil, (C1-C6)alkoksi-CO-NH-, (C1-C6)alkilamino-CO-, (C5-C9)heteroaril, (C2-C9)heterocikloalkil ili (C6-C10)aril, pri čemu su heteroarilne, heterocikloalkilne i arilne grupe izborno supstituirane s jednim do tri od halo, (C1-C6)alkil, (C1-C6)alkil-CO-NH-, (C1-C6)alkoksi-CO-NH-, (C1-C6)alkil-CO-NH-(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-(C1-C6)alkoksi, karboksi, karboksi(C1-C6)alkil, karboksi(C1-C6)alkoksi, benziloksikarbonil(C1-C6)alkoksi, (C1-C6)alkoksikarbonil(C1-C6)alkoksi, (C6-C10)aril, amino, amino(C1-C6)alkil, (C1-C6)alkoksikarbonilamino, (C6-C10)aril(C1-C6)alkoksikarbonilamino, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, (C1-C6)alkilamino(C1-C6)alkil, ((C1-C6)alkil)2amino(C1-C6)alkil, hidroksi, (C1-C6)alkoksi, karboksi, karboksi(C1-C6)alkil, (C1-C6)alkoksikarbonil, (C1-C6)alkoksikarbonil(C1-C6)alkil, (C1-C6)alkoksi-CO-NH-, (C1-C6)alkil-CO-NH-, cijano, (C5-C9)heterocikloalkil, amino-CO-NH-, (C1-C6)alkilamino-CO-NH-, ((C1-C6)alkil)2amino-CO-NH-, (C6-C10)arilamino-CO-NH-, (C5-C9)heteroarilamino-CO-NH-, (C1-C6)alkilamino-CO-NH-(C1-C6)alkil, ((C1-C6)alkil)2amino-CO-NH-(C1-C6)alkil, (C6-C10)arilamino-CO-NH-(C1-C6)alkil, (C5-C9)heteroarilamino-CO-NH-(C1-C6)alkil, (C1-C6)alkilsulfonil, (C1-C6)alkilsulfonilamino, (C1-C6)alkilsulfonilamino(C1-C6)alkil, (C6-C10)arilsulfonil, (C6-C10)arilsulfonilamino, (C6-C10)arilsulfonilamino(C1-C6)alkil, (C1-C6)alkilsulfonilamino, (C1-C6)alkilsulfonilamino(C1-C6)alkil, (C5-C9)heteroaril ili (C2-C9)heterocikloalkil;
uz uvjet da R5 mora biti supstituiran s grupom formule II.
2. Spoj prema patentnom zahtjevu 1, naznačen time što R5 je (C2-C9)heterocikloalkil izborno supstituiran s jednom do tri grupe izabrane od deuterija, hidroksi, (C1-C6)alkil, halo, (C1-C6)alkoksi i grupe formule II.
3. Spoj prema patentnom zahtjevu 1, naznačen time što a je 0; b je 1; X je karbonil; c je 0; d je 0; e je 0; f je 0; i g je 0.
4. Spoj prema patentnom zahtjevu 1, naznačen time što a je 0; b je 1; X je karbonil; c je 0; d je 1; e je 0; f je 0; i g je 0.
5. Spoj prema patentnom zahtjevu 1, naznačen time što a je 0; b je 1; X je karbonil; c je 1; d je 0; e je 0; f je 0; i g je 0.
6. Spoj prema patentnom zahtjevu 1, naznačen time što a je 0; b je 1; X je -C(=N=cijano)-; c je 1; d je 0; e je 0; f je 0; i g je 0.
7. Spoj prema patentnom zahtjevu 1, naznačen time što a je 0; b je 0; c je 0; d je 0; e je 0; f je 0; g je 1; i Z je -C(O)-O-.
8. Spoj prema patentnom zahtjevu 1, naznačen time što a je 0; b je 1; X je S(O)n; n je 2; c je 0; d je 0; e je 0; f je 0; i g je 0.
9. Spoj prema patentnom zahtjevu 1, naznačen time što a je 0; b je 1; X je S(O)n; n je 2; c je 0; d je 2; e je 0; f je 1; g je 1; i Z je karbonil.
10. Spoj prema patentnom zahtjevu 1, naznačen time što a je 0; b je 1; X je S(O)n; n je 2; c je 0; d je 2; e je 0; f je 1; i g je 0.
11. Spoj prema patentnom zahtjevu 1, naznačen time što a je 0; b je 1; X je karbonil; c je 1; d je 0; e je 1; Y je S(O)n; n je 2; f je 0; i g je 0.
12. Spoj prema patentnom zahtjevu 1, naznačen time što a je 0; b je 1; X je S(O)n; n je 2; c je 1; d je 0; e je 0; f je 0; i g je 0.
13. Spoj prema patentnom zahtjevu 1, naznačen time što je a 1; b je 1; X je karbonil; c je 1; d je 0; e je 0; f je 0; i g je 0.
14. Spoj prema patentnom zahtjevu 1, naznačen time što a je 0; b je 1; X je S(O)n; c je 0; d je 1; e je 1; Y je S(O)n; n je 2; f je 0; i g je 0.
15. Spoj prema patentnom zahtjevu 1, naznačen time što a je 0; b je 1; X je S(O)n; c je 0; d je 2, 3 ili 4; e je 1; Y je S(O)n; n je 2; f je 1; i g je 0.
16. Spoj prema patentnom zahtjevu 1, naznačen time što a je 0; b je 1; X je kisik; c je 0; d je 2, 3 ili 4; e je 1; Y je S(O)n; n je 2; f je 1; i g je 0.
17. Spoj prema patentnom zahtjevu 1, naznačen time što a je 0; b je 1; X je kisik; c je 0; d je 2, 3 ili 4; e je 1; Y je S(O)n; n je 2; f je 0; i g je 0.
18. Spoj prema patentnom zahtjevu 1, naznačen time što a je 0; b je 1; X je karbonil; c je 1; d je 2, 3 ili 4; e je 1; Y je S(O)n; f je 0; i g je 0.
19. Spoj prema patentnom zahtjevu 1, naznačen time što a je 0; b je 1; X je karbonil; c je 1; d je 2, 3 ili 4; e je 1; Y je S(O)n; n je 2; f je 1; i g je 0.
20. Spoj prema patentnom zahtjevu 1, naznačen time što R12 je (C6-C10)aril ili (C2-C9)heteroaril, pri čemu je arilna ili heteroarilna grupa izborno supstituirana s jednom do četiri grupe koje čine vodik, halo, hidroksi, karboksi, trifluormetil, (C1-C6)alkil, (C1-C6)alkoksi, (C1-C6)alkil-CO-NH-, amino, amino(C1-C6)alkil, (C1-C6)alkilamino, ((C1-C6)alkil)2amino, cijano, amino-CO-NH-, (C1-C6)alkilamino-CO-NH-, ((C1-C6)alkil)2-CO-NH-, (C5-C9)heteroarilamino-CO-NH-, (C1-C6)alkilsulfonil, (C1-C6)alkilsulfonilamino, (C6-C10)arilsulfonilamino, (C1-C6)alkilsulfonilamino i (C1-C6)alkoksi-CO-NH-.
21. Spoj prema patentnom zahtjevu 1, naznačen time što spomenuti spoj je izabran iz grupe koja se sastoji od:
4-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-ilmetil}-benzensulfonamid;
(4-sulfamoil-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
(4-nitro-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-tetrazol-1-il-etanon;
(4-metilsulfamoil-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
(3-hidroksi-pirolidin-1-il)-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon;
[2-({4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-amino)-tiazol-4-il]-octena kiselina;
Metil-(4-metil-5'-nitro-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-3-il)-(7H-pirolo[2,3-d]pirimidin-4-il)-amin;
5-(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-2-okso-etil)-tiazolidin-2,4-dion;
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-tiazolidin-3-il-metanon;
Metil-[4-metil-1-(5-nitro-tiazol-2-il)-piperidin-3-il]-(7H-pirolo[2,3-d]pirimidin-4-il)-amin;
Etilni ester [2-({4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-amino)-tiazol-4-il]-octene kiseline;
(4-metansulfonil-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
Tiazol-2-ilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
(4-cijano-fenil)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-pirolidin-1-il-metanon;
(2-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-sulfonil}-etil)-amid furan-2-karboksilne kiseline;
{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il} (tetrahidro-furan-3-il)-metanon;
Izoksazol-3-ilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
(6-cijano-piridin-3-il)amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-3,4,5,6-tetrahidro-2H-[1,2']bipiridinil-5'-karbonitril;
(4-metil-tiazol-2-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne grupe;
2-ciklopropil-1-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-etanon;
Ciklopentil-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-il}-metanon;
(3-metil-izoksazol-4-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
[4-({4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-amino)-fenil]-octena kiselina;
[1-(5-amino-tiazol-2-il)-4-metil-piperidin-3-il]-metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amin;
(3-metil-izotiazol-5-il)-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
3-{4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karbonil}-ciklopentanon;
Benzil-metil-amid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline; i
Dimetilamid 4-metil-3-[metil-(7H-pirolo[2,3-d]pirimidin-4-il)-amino]-piperidin-1-karboksilne kiseline;
22. Farmaceutski pripravak za (a) liječenje ili sprječavanje poremećaja ili stanja izabranih od odbacivanja organskog presatka, ksenogenog presadka, lupusa, multiple skleroze, reumatoidnog artritisa, psorijaze, dijabetesa Tipa I i komplikacija nastalih kao posljedica dijabetesa, raka, astme, atopičnog dermatitisa, autoimunih poremećaja štitnjače, ulceroznog kolitisa, Crohnove bolesti, Alzheimerove bolesti, leukemije i drugih autoimunih poremećaja, ili (b) inhibiciju protein-kinaza ili Janus kinaze 3 (JAK3), kod sisavca, uključujući i čovjeka, naznačen time što sadrži količinu spoja prema patentnom zahtjevu 1 ili njegove farmaceutski prihvatljive soli, koja je djelotvorna kod takvih poremećaja ili stanja, i farmaceutski prihvatljivu podlogu.
23. Farmaceutski pripravak za (a) liječenje ili sprječavanje poremećaja ili stanja izabranih od odbacivanja organskog presatka, ksenogenog presadka, lupusa, multiple skleroze, reumatoidnog artritisa, psorijaze, dijabetesa Tipa I i komplikacija nastalih kao posljedica dijabetesa, raka, astme, atopičnog dermatitisa, autoimunih poremećaja štitnjače, ulceroznog kolitisa, Crohnove bolesti, Alzheimerove bolesti, leukemije i drugih autoimunih poremećaja, ili (b) inhibiciju protein-kinaza ili Janus kinaze 3 (JAK3), kod sisavca, uključujući i čovjeka, naznačen time što sadrži količinu spoja prema patentnom zahtjevu 1 ili njegove farmaceutski prihvatljive soli, samu ili u kombinaciji sa jednim ili više dodatnih sredstava koja moduliraju imunosni sustav sisavaca ili sa antiinflamatornim sredstvima, koja je djelotvorna kod takvih poremećaja ili stanja, i farmaceustki prihvatljivu podlogu.
24. Postupak inhibicije protein-kinaza ili Janus kinaze 3 (JAK3), kod sisavca, uključujući i čovjeka, naznačen time što se sastoji u primjeni na spomenutom sisavcu djelotvorne količine spoja prema patentnom zahtjevu 1 ili njegove farmaceutski prihvatljive soli.
25. Postupak liječenja ili sprječavanja poremećaja ili stanja izabranih od odbacivanja organskog presatka, ksenogenog presadka, lupusa, multiple skleroze, reumatoidnog artritisa, psorijaze, dijabetesa Tipa I i komplikacija nastalih kao posljedica dijabetesa, raka, astme, atopičnog dermatitisa, autoimunih poremećaja štitnjače, ulceroznog kolitisa, Crohnove bolesti, Alzheimerove bolesti, leukemije i drugih autoimunih poremećaja, kod sisavca, uključujući i čovjeka, naznačen time što se sastoji u primjeni na spomenutom sisavcu količine spoja prema patentnom zahtjevu 1 ili njegove farmaceutski prihvatljive soli, koja je djelotvorna u liječenju takvih stanja.
26. Postupak inhibicije protein-kinaza ili Janus kinaze 3 (JAK3), kod sisavca, uključujući i čovjeka, naznačen time što se sastoji u primjeni na spomenutom sisavcu djelotvorne količine spoja prema patentnom zahtjevu 1 ili njegove farmaceutski prihvatljive soli, same ili u kombinaciji sa jednim ili više dodatnih sredstava koja moduliraju imunosni sustav sisavaca ili sa antiinflamatornim sredstvima.
27. Postupak liječenja ili sprječavanja poremećaja ili stanja izabranih od odbacivanja organskog presatka, ksenogenog presadka, lupusa, multiple skleroze, reumatoidnog artritisa, psorijaze, dijabetesa Tipa I i komplikacija nastalih kao posljedica dijabetesa, raka, astme, atopičnog dermatitisa, autoimunih poremećaja štitnjače, ulceroznog kolitisa, Crohnove bolesti, Alzheimerove bolesti, leukemije i drugih autoimunih poremećaja, kod sisavca, uključujući i čovjeka, naznačen time što se sastoji u primjeni na spomenutom sisavcu djelotvorne količine spoja prema patentnom zahtjevu 1 ili njegove farmaceutski prihvatljive soli, same ili u kombinaciji sa jednim ili više dodatnih sredstava koja moduliraju imunosni sustav sisavaca ili sa antiinflamatornim sredstvima.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21428700P | 2000-06-26 | 2000-06-26 | |
PCT/IB2001/000975 WO2002000661A1 (en) | 2000-06-26 | 2001-06-05 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20021000A2 true HRP20021000A2 (en) | 2005-02-28 |
Family
ID=22798508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20021000A HRP20021000A2 (en) | 2000-06-26 | 2002-12-12 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
Country Status (48)
Families Citing this family (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
TR200003719T2 (tr) * | 1998-06-19 | 2001-03-21 | Pfizer Products Inc. | Pirolo[2,3-d]Pirimidin bileşikleri |
EP1147214B1 (en) | 1999-01-13 | 2011-01-05 | The Research Foundation Of State University Of New York | A novel method for designing protein kinase inhibitors |
PL218519B1 (pl) | 1999-12-10 | 2014-12-31 | Pfizer Prod Inc | Związki pirolo [2,3-d] pirymidynowe, środek farmaceutyczny zawierający te związki oraz ich zastosowanie |
US7301023B2 (en) * | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
WO2003035621A1 (en) * | 2001-10-22 | 2003-05-01 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them |
US7005445B2 (en) | 2001-10-22 | 2006-02-28 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors and methods for designing them |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
EP1388541A1 (en) | 2002-08-09 | 2004-02-11 | Centre National De La Recherche Scientifique (Cnrs) | Pyrrolopyrazines as kinase inhibitors |
EP1572213A1 (en) | 2002-11-26 | 2005-09-14 | Pfizer Products Inc. | Method of treatment of transplant rejection |
SE0300457D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
SE0300458D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
SE0300456D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
CN100516041C (zh) * | 2003-07-15 | 2009-07-22 | 大日本住友制药株式会社 | 新型杂芳基衍生物 |
US8178671B2 (en) | 2003-07-30 | 2012-05-15 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds |
CA2545192A1 (en) * | 2003-11-25 | 2005-06-09 | Pfizer Products Inc. | Method of treatment of atherosclerosis |
JP2007531744A (ja) * | 2004-04-05 | 2007-11-08 | 武田薬品工業株式会社 | 6−アザインドール化合物 |
CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
MXPA06015237A (es) | 2004-06-29 | 2007-12-10 | Amgen Inc | Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck. |
ES2401138T3 (es) * | 2004-08-13 | 2013-04-17 | Genentech, Inc. | Inhibidores basados en tiazol de enzimas que usan ATP |
AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
US7662824B2 (en) | 2005-03-18 | 2010-02-16 | Janssen Pharmaceutica Nv | Acylhydrazones as kinase modulators |
RU2411242C2 (ru) | 2005-05-13 | 2011-02-10 | Айрм, Ллк. | Соединения и композиции в качестве ингибиторов протеинкиназ |
WO2007046867A2 (en) * | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their uses as therapeutic agents |
EP1904457B1 (en) | 2005-06-08 | 2017-09-06 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
KR20080026654A (ko) | 2005-07-14 | 2008-03-25 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로시클릭 야누스 키나제 3 억제제 |
EP2270014A1 (en) | 2005-09-22 | 2011-01-05 | Incyte Corporation | Azepine inhibitors of janus kinases |
LT2474545T (lt) * | 2005-12-13 | 2017-02-27 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
GB0605691D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
US7838542B2 (en) | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
WO2008029237A2 (en) * | 2006-09-05 | 2008-03-13 | Pfizer Products Inc. | Combination therapies for rheumatoid arthritis |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
ES2415863T3 (es) | 2006-12-22 | 2013-07-29 | Incyte Corporation | Heterociclos sustituidos como inhibidores de Janus Quinasas |
KR20090106604A (ko) | 2007-01-12 | 2009-10-09 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 피리딘 화합물 |
LT3070090T (lt) | 2007-06-13 | 2019-06-25 | Incyte Holdings Corporation | Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
NZ585261A (en) | 2007-10-11 | 2011-10-28 | Astrazeneca Ab | Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
CA2715658C (en) | 2008-02-15 | 2016-07-19 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
DK2288610T3 (en) | 2008-03-11 | 2016-11-28 | Incyte Holdings Corp | Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
BRPI0910921B1 (pt) | 2008-04-16 | 2022-06-21 | Portola Pharmaceuticals, Inc | Inibidores de proteína syk quinase, composição farmacêutica, kit e usos dos referidos inibidores |
JP2011518219A (ja) | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ, インコーポレイテッド | タンパク質キナーゼの阻害剤 |
CA2732628A1 (en) * | 2008-08-01 | 2010-02-04 | Biocryst Pharmaceuticals, Inc. | Therapeutic agents |
PT2384326E (pt) * | 2008-08-20 | 2014-06-09 | Zoetis Llc | Compostos de pirrolo[2,3-d]pirimidina |
US8385364B2 (en) * | 2008-09-24 | 2013-02-26 | Nec Laboratories America, Inc. | Distributed message-passing based resource allocation in wireless systems |
EP2396004A4 (en) * | 2009-02-11 | 2012-07-25 | Reaction Biology Corp | SELECTIVE KINASE HEMMER |
ES2552386T3 (es) | 2009-04-03 | 2015-11-27 | F. Hoffmann-La Roche Ag | Composiciones de {3-[5-(4-cloro-fenil)-1H-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico y usos de las mismas |
JP5709276B2 (ja) | 2009-04-20 | 2015-04-30 | オースペックス ファーマシューティカルズ,エルエルシー | ヤヌスキナーゼ3のピペリジンインヒビター |
JP5775070B2 (ja) | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションIncyte Corporation | ヤヌスキナーゼ阻害剤としてのピラゾール−4−イル−ピロロ[2,3−d]ピリミジンおよびピロール−3−イル−ピロロ[2,3−d]ピリミジンのN−(ヘテロ)アリール−ピロリジン誘導体 |
MY161416A (en) | 2009-05-22 | 2017-04-14 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors |
TW201111385A (en) * | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
WO2011029046A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Bruton's tyrosine kinase inhibitors |
EP2485589A4 (en) * | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYARY INHIBITORS OF BTK |
WO2011044481A1 (en) | 2009-10-09 | 2011-04-14 | Incyte Corporation | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
JP5629324B2 (ja) * | 2009-10-15 | 2014-11-19 | ファイザー・インク | ピロロ[2,3−d]ピリミジン化合物 |
JP2013510166A (ja) | 2009-11-06 | 2013-03-21 | プレキシコン インコーポレーテッド | キナーゼ調節のための化合物、方法およびその適用 |
JP5739446B2 (ja) * | 2009-12-18 | 2015-06-24 | ファイザー・インク | ピロロ[2,3−d]ピリミジン化合物 |
US20120309776A1 (en) * | 2010-02-05 | 2012-12-06 | Pfitzer Inc. | Pyrrolo[2,3-d]pyrimidine urea compounds as jak inhibitors |
CA2788659C (en) * | 2010-02-24 | 2015-05-05 | Pfizer Inc. | Veterinary compositions |
AR081315A1 (es) | 2010-03-10 | 2012-08-08 | Incyte Corp | Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t |
TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
ME02445B (me) | 2010-05-21 | 2016-09-20 | Incyte Holdings Corp | Topikalna formulacija za inhibiciju jak-a |
SG187742A1 (en) | 2010-08-20 | 2013-03-28 | Hutchison Medipharma Ltd | Pyrrolopyrimidine compounds and uses thereof |
US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
EP2635557A2 (en) | 2010-11-01 | 2013-09-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
AU2012214762B2 (en) | 2011-02-07 | 2015-08-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
EP2675451B9 (en) | 2011-02-18 | 2017-07-26 | Novartis Pharma AG | mTOR/JAK INHIBITOR COMBINATION THERAPY |
WO2012127506A1 (en) | 2011-03-22 | 2012-09-27 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
BR112013025410A2 (pt) | 2011-04-01 | 2016-12-20 | Astrazeneca Ab | tratamento terapêutico |
PE20140832A1 (es) | 2011-06-20 | 2014-07-14 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
JP2014521725A (ja) | 2011-08-10 | 2014-08-28 | ノバルティス・ファルマ・アクチェンゲゼルシャフト | JAKPI3K/mTOR併用療法 |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
CA2856301C (en) | 2011-11-23 | 2020-10-06 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
CN104185420B (zh) | 2011-11-30 | 2017-06-09 | 埃默里大学 | 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂 |
PT2785349T (pt) | 2011-11-30 | 2019-12-11 | Astrazeneca Ab | Tratamento combinado de cancro |
BR112014014325B1 (pt) * | 2011-12-21 | 2022-06-07 | Jiangsu Hengrui Medicine Co.,Ltd. | Derivados de pirrol do tipo anel heteroarílico de seis membros, seus usos e seus processos de preparação, e composição farmacêutica |
CA2868966C (en) | 2012-03-29 | 2021-01-26 | Francis Xavier Tavares | Lactam kinase inhibitors |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
WO2014045305A1 (en) | 2012-09-21 | 2014-03-27 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
EP2903970A4 (en) | 2012-10-08 | 2016-11-30 | Portola Pharm Inc | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS |
CA3178452A1 (en) | 2012-11-15 | 2014-05-22 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
US9481679B2 (en) | 2012-12-17 | 2016-11-01 | Sun Pharmaceutical Industries Limited | Process for the preparation of tofacitinib and intermediates thereof |
JP6145179B2 (ja) | 2013-02-22 | 2017-06-07 | ファイザー・インク | ヤヌス関連キナーゼ(JAK)の阻害剤としてのピロロ[2,3−d]ピリミジン誘導体 |
LT3489239T (lt) | 2013-03-06 | 2022-03-10 | Incyte Holdings Corporation | Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai |
RS59790B1 (sr) | 2013-03-15 | 2020-02-28 | G1 Therapeutics Inc | Privremena zaštita normalnih ćelija tokom hemoterapije |
JP6435315B2 (ja) | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 高活性抗新生物薬及び抗増殖剤 |
WO2014194741A1 (zh) * | 2013-06-07 | 2014-12-11 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐及其制备方法 |
MY195091A (en) | 2013-08-07 | 2023-01-10 | Incyte Corp | Sustained Release Dosage Forms for a JAK1 Inhibitor |
WO2015027090A1 (en) * | 2013-08-22 | 2015-02-26 | Genentech, Inc. | Intermediates and processes for preparing compounds |
CA2921956C (en) * | 2013-08-22 | 2021-10-19 | Genentech, Inc. | Process for preparing (r)-5-bromo-4-(3-amino)piperidin-1-yl)-3-(cyclopropanecarboxamido)-1h-pyrrolo[2,3-b]pyridine |
JP6192839B2 (ja) * | 2013-12-05 | 2017-09-06 | ファイザー・インク | ピロロ[2,3−d]ピリミジニル、ピロロ[2,3−b]ピラジニル、およびピロロ[2,3−d]ピリジニルアクリルアミド |
US20150297606A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
WO2015179414A1 (en) * | 2014-05-19 | 2015-11-26 | Merial, Inc. | Anthelmintic compounds |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
JP6585158B2 (ja) | 2014-08-12 | 2019-10-02 | ファイザー・インク | ヤヌスキナーゼの阻害に有用なピロロ[2,3−d]ピリミジン誘導体 |
KR101710127B1 (ko) * | 2014-08-29 | 2017-02-27 | 한화제약주식회사 | 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민 |
EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
CN105566327A (zh) * | 2014-10-09 | 2016-05-11 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法 |
DK3216790T3 (da) * | 2014-11-05 | 2019-11-25 | Jiangsu Hengrui Medicine Co | Krystallinsk form af jak-kinasehæmmer-bisulfat og en fremgangsmåde til fremstilling deraf |
JP6742323B2 (ja) * | 2015-01-20 | 2020-08-19 | 无▲錫▼福祈制▲薬▼有限公司Wuxi Fortune Pharmaceutical Co.,Ltd | Jak阻害剤 |
ES2928757T3 (es) | 2015-05-01 | 2022-11-22 | Pfizer | Acrilamidas de pirrolo[2,3-b]pirazinilo y epóxidos de las mismas como inhibidores de la Janus Quinasa |
KR101771219B1 (ko) * | 2015-08-21 | 2017-09-05 | 양지화학 주식회사 | 야누스 키나제 1 선택적 억제제 및 그 의약 용도 |
US10045981B2 (en) | 2015-11-24 | 2018-08-14 | Jakpharm, Llc | Selective kinase inhibitors |
CN107098908B (zh) * | 2016-02-23 | 2021-01-08 | 欣凯医药科技(上海)有限公司 | 一种吡咯并嘧啶类化合物的制备方法和应用 |
WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
WO2018017153A1 (en) | 2016-07-21 | 2018-01-25 | Biogen Ma Inc. | Succinate forms and compositions of bruton's tyrosine kinase inhibitors |
CN106120090A (zh) * | 2016-08-31 | 2016-11-16 | 飞佛特种纺织品(宁波)有限公司 | 一种防刮擦阳光面料的制备方法 |
EP3543241B8 (en) * | 2016-11-23 | 2022-10-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Preparation method for and intermediate of pyrrolo six-membered heteroaromatic ring derivative |
KR102576011B1 (ko) | 2017-01-06 | 2023-09-06 | 쥐원 쎄라퓨틱스, 인크. | 암의 치료를 위한 조합 요법 |
CN106831538B (zh) * | 2017-01-22 | 2019-06-25 | 苏州楚凯药业有限公司 | 托法替尼中间体的制备方法 |
US20200157092A1 (en) * | 2017-02-27 | 2020-05-21 | Janssen Pharmaceutlca NV | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
CN107337676A (zh) * | 2017-06-08 | 2017-11-10 | 江苏正大清江制药有限公司 | 一种托法替布起始原料的制备方法 |
RU2019142591A (ru) | 2017-06-29 | 2021-07-29 | Г1 Терапьютикс, Инк. | Морфологические формы g1t38 и способы их получения |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
WO2019152374A1 (en) | 2018-01-30 | 2019-08-08 | Incyte Corporation | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
MX2020010322A (es) | 2018-03-30 | 2022-11-30 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
SG11202101807SA (en) | 2018-08-24 | 2021-03-30 | G1 Therapeutics Inc | Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one |
WO2020198583A1 (en) | 2019-03-27 | 2020-10-01 | Insilico Medicine Ip Limited | Bicyclic jak inhibitors and uses thereof |
BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
EP4061367A1 (en) | 2019-11-22 | 2022-09-28 | Incyte Corporation | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
CN114591321A (zh) * | 2020-12-04 | 2022-06-07 | 广州费米子科技有限责任公司 | 氮杂并环化合物、其制备方法及其用途 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3670079A (en) * | 1970-10-06 | 1972-06-13 | Merck & Co Inc | Anabolic agents |
US4997936A (en) * | 1977-10-19 | 1991-03-05 | Merck & Co., Inc. | 2-carbamimidoyl-6-substituted-1-carbadethiapen-2-em-3-carboxylic acids |
US4456464A (en) * | 1982-05-19 | 1984-06-26 | Zoecon Corporation | Phenoxy- and pyridyloxy-phenoxyalkyl phosphinates and related sulfur compounds for weed control |
US4526608A (en) * | 1982-07-14 | 1985-07-02 | Zoecon Corporation | Certain 2-pyridyloxyphenyl-oximino-ether-carboxylates, herbicidal compositions containing same and their herbicidal method of use |
US4590282A (en) * | 1984-09-24 | 1986-05-20 | Sandoz Ltd. | Pest control agents |
US4933339A (en) * | 1985-08-21 | 1990-06-12 | Rohm And Haas Company | (2-cyano-2-arylethyl)pyridine compounds useful in controlling fungicidal activity |
CA1328333C (en) * | 1988-03-04 | 1994-04-05 | Quirico Branca | Amino acid derivatives |
US4879309A (en) * | 1988-09-27 | 1989-11-07 | Schering Corporation | Mercapto-acylamino acids as antihypertensives |
US5356903A (en) * | 1993-04-22 | 1994-10-18 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolines |
US6136595A (en) | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
US5389509A (en) | 1993-10-04 | 1995-02-14 | Eastman Kodak Company | Ultrathin high chloride tabular grain emulsions |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
ES2109796T3 (es) | 1994-05-03 | 1998-01-16 | Ciba Geigy Ag | Derivados de pirrolopirimidilo con efecto antiproliferante. |
WO1996040142A1 (en) | 1995-06-07 | 1996-12-19 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
ES2167586T3 (es) | 1995-07-05 | 2002-05-16 | Du Pont | Pirimidinonas fungicidas. |
BR9609617B1 (pt) | 1995-07-06 | 2010-07-27 | derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica. | |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
DE69613211T2 (de) | 1995-11-14 | 2001-11-15 | Pharmacia & Upjohn Spa | Aryl- und heteroaryl- purin- und pyridopyrimidin- derivate |
EP0888349B1 (en) | 1996-01-23 | 2002-05-22 | Novartis AG | Pyrrolopyrimidines and processes for their preparation |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
GB9604361D0 (en) * | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
WO1997032879A1 (de) | 1996-03-06 | 1997-09-12 | Novartis Ag | 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINE |
WO1997049706A1 (en) | 1996-06-25 | 1997-12-31 | Novartis Ag | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF |
BR9710362A (pt) | 1996-07-13 | 1999-08-17 | Glaxo Group Ltd | Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
EP0938486B1 (en) | 1996-08-23 | 2008-01-16 | Novartis AG | Substituted pyrrolopyrimidines and processes for their preparation |
AU4718997A (en) | 1996-11-27 | 1998-06-22 | Pfizer Inc. | Fused bicyclic pyrimidine derivatives |
DE69839338T2 (de) | 1997-02-05 | 2008-07-10 | Warner-Lambert Company Llc | Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation |
AU6568398A (en) | 1997-03-24 | 1998-10-20 | Pharmacia & Upjohn Company | Method for identifying inhibitors of jak2/cytokine receptor binding |
JP2002510687A (ja) * | 1998-04-02 | 2002-04-09 | ニューロゲン コーポレイション | アミノアルキル置換ピロロ[2,3−b]ピリジンおよびピロロ[2,3−d]ピリミジン誘導体:crf1レセプタのモジュレータ |
MXPA00011773A (es) | 1998-05-28 | 2002-06-04 | Parker Hughes Inst | Quinazolinas para tratar tumores en el cerebro. |
TR200003719T2 (tr) * | 1998-06-19 | 2001-03-21 | Pfizer Products Inc. | Pirolo[2,3-d]Pirimidin bileşikleri |
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
WO2000000202A1 (en) | 1998-06-30 | 2000-01-06 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
DE69924500T2 (de) | 1998-08-21 | 2006-02-09 | Parker Hughes Institute, St. Paul | Chinazolinderivate |
BR9913887A (pt) * | 1998-09-18 | 2001-10-23 | Basf Ag | Composto, e, métodos de inibir a atividade de proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente |
CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
US6506762B1 (en) * | 1999-09-30 | 2003-01-14 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
PL218519B1 (pl) * | 1999-12-10 | 2014-12-31 | Pfizer Prod Inc | Związki pirolo [2,3-d] pirymidynowe, środek farmaceutyczny zawierający te związki oraz ich zastosowanie |
US7301023B2 (en) * | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
GB0119249D0 (en) * | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
US7253166B2 (en) * | 2003-04-22 | 2007-08-07 | Irm Llc | 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells |
EP1797054A2 (en) * | 2004-08-02 | 2007-06-20 | OSI Pharmaceuticals, Inc. | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
-
2001
- 2001-06-05 YU YU83302A patent/YU83302A/sh unknown
- 2001-06-05 HU HU0301114A patent/HUP0301114A3/hu unknown
- 2001-06-05 ES ES06007969T patent/ES2318605T3/es not_active Expired - Lifetime
- 2001-06-05 DE DE60118917T patent/DE60118917T2/de not_active Expired - Lifetime
- 2001-06-05 NZ NZ522364A patent/NZ522364A/en unknown
- 2001-06-05 PT PT01934243T patent/PT1294724E/pt unknown
- 2001-06-05 MX MXPA03000068A patent/MXPA03000068A/es active IP Right Grant
- 2001-06-05 EE EEP200200711A patent/EE200200711A/xx unknown
- 2001-06-05 WO PCT/IB2001/000975 patent/WO2002000661A1/en active IP Right Grant
- 2001-06-05 SI SI200130528T patent/SI1294724T1/sl unknown
- 2001-06-05 CN CNB018117929A patent/CN100351253C/zh not_active Expired - Fee Related
- 2001-06-05 IL IL15277101A patent/IL152771A0/xx unknown
- 2001-06-05 GE GE5008A patent/GEP20053541B/en unknown
- 2001-06-05 PL PL01359563A patent/PL359563A1/xx not_active Application Discontinuation
- 2001-06-05 AT AT01934243T patent/ATE323704T1/de not_active IP Right Cessation
- 2001-06-05 EA EA200201096A patent/EA006153B1/ru not_active IP Right Cessation
- 2001-06-05 SK SK1734-2002A patent/SK17342002A3/sk unknown
- 2001-06-05 UA UA2002118861A patent/UA74370C2/uk unknown
- 2001-06-05 AU AU60538/01A patent/AU784297C/en not_active Ceased
- 2001-06-05 OA OA1200200385A patent/OA12292A/en unknown
- 2001-06-05 DE DE60137734T patent/DE60137734D1/de not_active Expired - Lifetime
- 2001-06-05 BR BR0111561-8A patent/BR0111561A/pt not_active IP Right Cessation
- 2001-06-05 JP JP2002505785A patent/JP4068958B2/ja not_active Expired - Fee Related
- 2001-06-05 KR KR10-2002-7017610A patent/KR100516419B1/ko not_active IP Right Cessation
- 2001-06-05 DZ DZ013359A patent/DZ3359A1/fr active
- 2001-06-05 DK DK06007969T patent/DK1686130T3/da active
- 2001-06-05 AP APAP/P/2002/002695A patent/AP1911A/en active
- 2001-06-05 EP EP01934243A patent/EP1294724B1/en not_active Expired - Lifetime
- 2001-06-05 CZ CZ20023993A patent/CZ20023993A3/cs unknown
- 2001-06-05 CA CA002412560A patent/CA2412560C/en not_active Expired - Fee Related
- 2001-06-05 AT AT06007969T patent/ATE423120T1/de not_active IP Right Cessation
- 2001-06-05 DK DK01934243T patent/DK1294724T3/da active
- 2001-06-05 ES ES01934243T patent/ES2257410T3/es not_active Expired - Lifetime
- 2001-06-05 EP EP06007969A patent/EP1686130B1/en not_active Expired - Lifetime
- 2001-06-20 TW TW090115016A patent/TWI243820B/zh not_active IP Right Cessation
- 2001-06-21 GT GT200100117A patent/GT200100117A/es unknown
- 2001-06-25 PE PE2001000614A patent/PE20020381A1/es not_active Application Discontinuation
- 2001-06-25 US US09/891,028 patent/US6696567B2/en not_active Expired - Fee Related
- 2001-06-25 TN TNTNSN01095A patent/TNSN01095A1/fr unknown
- 2001-06-25 SV SV2001000506A patent/SV2002000506A/es not_active Application Discontinuation
- 2001-06-25 MY MYPI20012986 patent/MY127236A/en unknown
- 2001-06-25 AR ARP010103013A patent/AR029279A1/es active IP Right Grant
- 2001-06-26 DO DO2001000200A patent/DOP2001000200A/es unknown
- 2001-06-26 EC EC2001004105A patent/ECSP014105A/es unknown
- 2001-06-26 PA PA20018521101A patent/PA8521101A1/es unknown
-
2002
- 2002-10-31 IS IS6606A patent/IS2305B/is unknown
- 2002-10-31 BG BG107236A patent/BG107236A/bg unknown
- 2002-11-11 IL IL152771A patent/IL152771A/en not_active IP Right Cessation
- 2002-11-27 CU CU20020290A patent/CU23263B7/es not_active IP Right Cessation
- 2002-12-12 HR HR20021000A patent/HRP20021000A2/hr not_active Application Discontinuation
- 2002-12-16 NO NO20026030A patent/NO324934B1/no not_active IP Right Cessation
- 2002-12-19 ZA ZA200210275A patent/ZA200210275B/en unknown
- 2002-12-20 MA MA26969A patent/MA26917A1/fr unknown
-
2003
- 2003-06-16 US US10/463,724 patent/US6962993B2/en not_active Expired - Fee Related
- 2003-10-03 HK HK03107143A patent/HK1054930A1/xx not_active IP Right Cessation
-
2005
- 2005-04-21 US US11/112,307 patent/US7192963B2/en not_active Expired - Fee Related
-
2007
- 2007-02-22 US US11/710,164 patent/US20070161666A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6696567B2 (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
CA2393640C (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
WO2005051393A1 (en) | Method of treatment of atherosclerosis | |
KR20050086784A (ko) | 이식 거부반응의 치료 방법 | |
WO2005060972A2 (en) | Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection | |
SK14652003A3 (sk) | Spôsob optického rozlíšenia (1-benzyl-4-metylpiperidín-3-yl)- metylamínu a jeho použitie a prípravu derivátov pyrol[2,3-d]pyrimidínu, a ich použitie ako inhibítorov proteínkináz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20080529 Year of fee payment: 8 |
|
ODBC | Application rejected |